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SYNOPSIS 
Whilst pulmonary hypertension is a relatively uncommon condition, it is associated 
with a poor quality of life and poor survival. It is therefore important that we correctly 
identify patients who suffer from pulmonary hypertension, assess the underlying 
cause (an essential step for treatment) and seek those who are at risk of death. 
Current guidelines centre on right heart catheterisation as the recommended tool to 
answer these important clinical questions.  
Since it was first described in the mid-1950s, there have been significant 
improvements in the survival of patients with pulmonary hypertension, mainly due 
to the introduction of vasodilator therapies and surgical procedures. There have been 
parallel improvements in imaging technologies, the most tangible of which is cardiac 
MRI, allowing time resolved assessment of cardiac structure and function. Despite 
these improvements in non-invasive methodologies, there remains heavy reliance 
upon invasively measured pressures and flow for the diagnosis, phenotyping and 
assessment of risk in patients with pulmonary hypertension.  
The aim of this PhD thesis is to evaluate, and hopefully increase, the role of cardio 
pulmonary vascular MRI in the non-invasive assessment of pulmonary hypertension. 
I show that cardiac MRI metrics, particularly when combined in a regression model, 
are able to predict mean pulmonary arterial pressure. Such models are able to identify 
with reasonable accuracy the presence of pulmonary hypertension in patients 
referred to a tertiary referral centre. The role of cardio-pulmonary MRI in the 
assessment of the underlying group of pulmonary hypertension, such as chronic 
thrombo-embolic pulmonary hypertension and PH-left heart disease, is then explored 
as identification of patients who may respond to PH specific therapy is an important 
step. Finally, the role of MRI in the assessment of prognosis, concentrating specifically 
on patients with PH left heart disease and PH in patients with chronic obstructive 
pulmonary disease is assessed.  
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1 PULMONARY HYPERTENSION  
 
Pulmonary hypertension is a heterogenous collection of disorders that are 
characterised by elevated mean pulmonary arterial pressure (mPAP). Whilst 
considered to be relatively rare (in the UK the prevalence is 97 cases per million) (1), 
it is associated with a poor quality of life and survival: Median survival in untreated 
idiopathic pulmonary arterial hypertension is 2.8 years (2). The “abnormal 
muscularisation” of the pulmonary arterial wall was first described in 1957 by 
Sheffield pathologist Donald Heath (3) and medical interest in the condition grew in 
the 1970s due to an epidemic of “primary pulmonary hypertension” (now replaced 
by the term pulmonary arterial hypertension) due to Aminorex, an appetite 
suppressant (4,5). Since then, a number of therapies that reverse pulmonary arterial 
remodelling have significantly improved outcomes in certain forms of the disease; 
however, there remains poor survival and quality of life in selected patient groups. 
1.1 THE PULMONARY CIRCULATION 
The human cardiovascular system comprises two circuits in series: the systemic and 
pulmonary circulations. The main role of the pulmonary circulation is gas exchange; 
carrying oxygen absorbed by the lungs to the rest of the body and returning carbon 
dioxide to be expired.  
Figure 1.1: Diagrammatic representation of the cardiopulmonary circuit.  
SVC: Superior vena cava, RA: Right atrium, IVC: Inferior Vena Cava, RV: Right ventricle, PA: Pulmonary 
artery, PV: Pulmonary veins, Ao: Aorta, LA: Left atrium, LV: Left ventricle. 
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In health, the pulmonary circulation is a low pressure, low resistance, highly 
compliant system, with a normal mean pulmonary arterial pressure of 14±3mmHg 
(6). Pulmonary hypertension may be caused by increased pulmonary vascular 
resistance or high pulmonary venous pressures (pulmonary venous hypertension), 
which can be idiopathic or related to multiple cardiac, respiratory or systemic 
diseases. These increased pulmonary arterial pressures cause increased right 
ventricular afterload, leading to right ventricular dysfunction, remodelling, failure 
and eventual death.  
Right ventricular and pulmonary arterial pressures and flows are measured on right 
heart catheterisation, an invasive technique that uses a balloon tipped thermodilution 
catheter inserted into the jugular (or less commonly femoral) vein (7). The tip is then 
advanced into the pulmonary artery, pulmonary artery wedge position, right ventricle 
and right atrium (1). It has a 1.1% risk of morbidity and 0.06% risk of mortality (8).  
From the pulmonary arterial pressure waveform, the systolic pulmonary arterial 
pressure (sPAP) and diastolic pulmonary arterial pressure (dPAP) can be measured. 
The mean pulmonary arterial pressure (mPAP) is then defined as 𝑚𝑃𝐴𝑃 =
 
𝑠𝑃𝐴𝑃+2.𝑑𝑃𝐴𝑃
3
. The upper limit of normal is considered 20mmHg, but PH is defined as a 
resting mPAP ≥25mmHg. Interestingly, patients with mPAP 21-24mmHg are followed 
up closely due to a potential increase in mortality rates, although there is little 
evidence for how to treat these patients and the term “borderline pulmonary 
hypertension” is currently not used in guidelines (6).  
 
 
Figure 1.2: Diagrammatic representation of the PAWP measurement. 
 
Dr CS Johns  Cardio-Pulmonary MRI in PH   15 
 
Making assumptions that exclude compliance of the vasculature, Poiseuille’s law 
describes the relationship between resistance (R), length (L) and radius (r) of a 
cylinder and viscosity of the fluid (µ), in this case blood: 𝑅 ∝  
8𝜇𝐿
𝜋𝑟4
. Thus, small changes 
in vessel radius have a large impact on resistance. In the lung, this resistance can be 
characterised as the pulmonary vascular resistance 𝑃𝑉𝑅 (𝑊𝑈) =  
𝑚𝑃𝐴𝑃−𝐿𝐴𝑃
𝐶𝑂
. Where 
CO is cardiac output (L/min) and LAP is left atrial pressure (mmHg), estimated 
through measuring pulmonary arterial wedge pressure (PAWP). Left atrial pressure 
is estimated using PAWP, where a threshold of >15mmHg defines the presence of left 
heart disease.  
 
  
Figure 1.3: The typical pulmonary arterial and pulmonary arterial wedge pressure waveforms. 
Note the degree of variation with the respiratory cycle. Reproduced under creative commons license from 
Rosenkranz S, Preston IR. Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. 
Eur Respir Rev. 2015 Dec;24(138):642–52. 
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1.2 THE DIAGNOSIS OF PULMONARY HYPERTENSION  
Pulmonary hypertension (PH) is defined at right heart catheterisation as a mean 
pulmonary arterial pressure (mPAP) ≥25mmHg (1). It ranges from mild elevations of 
pulmonary artery pressure, frequently due to cardiac and respiratory disease, to often 
severe elevations of pressure in patients with a pulmonary arterial vasculopathy (9). 
Regardless of aetiology, it has a significant negative impact on both quality of life and 
survival. The current classification identifies 5 groups with similar clinical and 
pathological characteristics; Group 1: Pulmonary arterial hypertension (PAH), Group 
2: PH due to left heart disease (PH-LHD), Group 3: PH due to lung disease and/or 
hypoxia (PH-lung), Group 4: Chronic thrombo-embolic PH (CTEPH), and Group 5: PH 
with unclear/multifactorial mechanisms, which are outlined below (1). Key aspects 
of PH management include establishing the diagnosis, identifying the form of PH 
(which defines the optimal treatment strategy) and the serial assessment of disease 
severity.  
The diagnosis of PH is usually suggested by an echocardiogram performed in the 
breathless patient (9). However, the diagnosis is increasingly suggested following 
other imaging investigations, such as computerised tomography (CT) (10), which may 
identify a dilated pulmonary artery or right ventricle.  
Once a diagnosis of PH is suspected it is important to identify the cause as this defines 
the optimal treatment strategy (1). Forms of PH (PAH and CTEPH), for which 
therapies directed at the pulmonary vasculature have been proven effective are 
uncommon, whilst for commoner forms (PH-LHD and PH-resp), treatment is 
currently aimed at the underlying cardiac or lung disease.  
As the diagnosis is made using invasive methodologies, diagnostic strategies are 
dependent on the physician ensuring that further investigation is in the best interests 
of the patient. An important part of this strategy is an appreciation of factors that 
increase the pre-test probability of identifying forms of PH for which therapies 
directed at the pulmonary vasculature are likely to be beneficial. Features from the 
history are important; a previous history of thromboembolic disease raises the 
probability of CTEPH. Alternatively, features known to increase the likelihood of PAH, 
such as the presence of an underlying connective tissue disease (e.g. systemic 
sclerosis, with a prevalence of PAH 9% (11)), portal hypertension (prevalence of PAH 
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2-6%(12–14) ) and HIV (prevalence of PAH 0.5%(15)) should also be sought. In 
contrast, mild elevation of pulmonary artery pressures, in patients with severe 
respiratory or cardiac disease, may not require further investigation where there are 
no red flag features (such as, severe elevation of pulmonary artery pressures or 
severe impairment of right ventricular function). 
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1.3 THE CLASSIFICATION OF PULMONARY HYPERTENSION 
Pulmonary hypertension is classified in 5 groups based upon shared clinical features, 
pathological findings, haemodynamics, and management decisions (1,16,17).  
 
 Group 1: Pulmonary arterial hypertension (PAH)  
Group 1 pulmonary arterial hypertension (PAH) may be idiopathic (IPAH), heritable 
(such as BMPR2 mutation), associated with drugs/toxins or due to an underlying 
condition (connective tissues disease, HIV, portal hypertension, congenital heart 
disease or schistosomiasis) (1,16,17). These conditions are all characterised 
pathologically by remodelling of the precapillary arterioles, and respond to treatment 
with pulmonary vasodilator therapy (see treatment of PH section on page 26).   
 
 
 
 
Figure 1.4: Diagrammatic representation of the haemodynamic effects of group 1: PAH.  
Pre-capillary pulmonary arteriolar remodelling leads to increased pulmonary vascular resistance (PVR). This 
increases the load on the right ventricle and also reduces pulmonary venous flow to the left atrium, impairing 
LV filling. Inset, is a histopathology slide of a vessel with severe neo-intimal formation, there is thickening of the 
smooth muscle layer. Histology reproduced with permission from Wolters Kluwer Health. Rabinovitch et al, 
Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension Circulation Research, 115, 
2014. http://circres.ahajournals.org/content/115/1/165 
 
Dr CS Johns  Cardio-Pulmonary MRI in PH   19 
The underlying pathological mechanism of elevated pulmonary vascular resistance 
in patients with PAH is due to a number of pathological processes (Figure 1.5) (18): 
 Sustained pulmonary vasoconstriction 
 Obliteration of small and large arteries and arterioles 
 Formation of plexiform lesions 
 In situ thrombosis 
 Concentric thickening of arteriolar wall from 
o Smooth muscle proliferation (Medial hypertrophy) 
o Intimal fibrosis 
 
 
Figure 1.5: The pathophysiological changes of pulmonary vascular remodelling in PAH. 
Reproduced with permission from Wolters Kluwer Health. Rabinovitch et al, Inflammation and Immunity in the 
Pathogenesis of Pulmonary Arterial Hypertension Circulation Research, 115, 2014. 
http://circres.ahajournals.org/content/115/1/165 (19) 
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 Group 2: Pulmonary hypertension due to left heart disease (PH-LHD) 
Pulmonary hypertension is most commonly seen in patients with left heart disease 
(1,9,20,21), defined on right heart catheter by mPAP ≥25mmHg and a pulmonary 
arterial wedge pressure >15mmHg (22). It is being increasingly recognised (23), and 
is associated with a poor prognosis (24–27) and high levels of health care utilisation. 
Patients with left heart disease due to valvular disease, systolic, or most often diastolic 
dysfunction may develop pulmonary hypertension (28). This initially results from 
passive backward transmission of high left ventricular filling pressures through the 
pulmonary circulation, previously termed “passive” or “pulmonary venous” 
pulmonary hypertension (29). Where the pulmonary hypertension is solely due to 
passive backwards transmission of high left ventricular filling pressures, it is now 
termed isolated post capillary pulmonary hypertension (Ipc-PH). 
Some patients with post-capillary pulmonary hypertension may develop a degree of 
pre-capillary vascular remodelling. It is likely that this is due to prolonged elevation 
of pulmonary arterial pressures (22,30–37) causing stress related pulmonary 
capillary endothelial injury (38,39). Previously, the difference between mPAP and 
PAWP (the trans-pulmonary gradient, TPG) was used to identify patients with PH “out 
of proportion” to left heart disease. A study by Gerges et al identified the diastolic 
pulmonary pressure gradient (DPG = diastolic pulmonary artery pressure  -  mean 
PAWP) as a superior prognostic parameter in patients with post-capillary disease, as 
Figure 1.6: Isolated post capillary pulmonary hypertension (Ipc-PH). 
This results from the backward transmission of high left ventricular filling pressures. It is defined on right heart 
catheter as PAWP >15mmHg and a diastolic pulmonary gradient (DPG) ≥7mmHg or PVR ≥3WU.   
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it is not dependent upon cardiac output (30). The 5th world PH symposium, therefore, 
introduced the classification of combined pre and post capillary pulmonary 
hypertension (Cpc-PH), defined as mPAP ≥ 25mmHg, PAWP >15 mmHg,  DPG of ≥7 
and/or pulmonary vascular resistance (PVR) >3 WU (22).  
 
Patients with Cpc-PH are at greater risk of deterioration than those with isolated post-
capillary PH (Ipc-PH), but may benefit from PAH-specific therapy, especially in the 
context of randomized controlled trials (37,40,41) (also see ClinicalTrials.gov 
identifier: NCT02070991). It would be of clinical benefit to increase the role of non-
invasive identification and phenotyping of this patient group for identification of 
potential vasodilator responsive cases in randomised control trials.   
Figure 1.7: Combined pre and post-capillary pulmonary hypertension (Cpc-PH). 
This results from precapillary pulmonary vascular remodelling in the presence of high left ventricular filling 
pressures.  
Figure 1.8: Histology from a patient with Ipc-PH (left), Cpc-PH (middle) and IPAH (right).  
The patient with Cpc-PH has precapillary remodelling that is similar to that in IPAH. Reprinted from Diastolic 
Pulmonary Vascular Pressure Gradient, Chest 2013, Gerges C, Gerges M, Lang MB, Zhang Y, Jakowitsch J, Probst 
P, et al, with permission from Elsevier.  
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 Group 3: Pulmonary hypertension due to lung disease or hypoxia (PH-
Lung) 
There is strong interaction between lung and heart disease, mediated by the 
pulmonary vascular system. This is particularly evident in patients with chronic 
obstructive pulmonary disease (COPD), where the presence of pulmonary 
hypertension is a predictor of death and hospitalisation (42–46). There is an inverse 
relationship between mPAP and survival and COPD patients with mPAP ≥25mmHg 
have a 5-year survival rate of only 36% (47). Furthermore, patients with COPD are 
more likely to die or be hospitalised due to cardiovascular rather than respiratory 
complications (48). 
The prevalence of pulmonary hypertension in lung disease is difficult to assess, but it 
is likely that there is a high prevalence of patients with “mild” pulmonary 
hypertension in COPD: reportedly 90% of patients with Gold stage IV COPD have 
mPAP 20-35mmHg. A significantly lower proportion of patients with COPD have 
severe pulmonary hypertension, reported to be around 5% of GOLD stage IV COPD 
patients (44,49,50). Pulmonary hypertension in COPD is thought to result from 
multiple different mechanisms: hypoxic pulmonary vasoconstriction, polycythaemia 
(from chronic hypoxia), destruction of the pulmonary vascular bed by emphysema, 
hyperinflation causing high intrathoracic pressures (above pulmonary venous 
pressure) and endothelial dysfunction and remodelling (43,51,52).  
Idiopathic pulmonary fibrosis (IPF) is a condition with median survival of only 3-5 
years (53). The incidence of pulmonary hypertension in interstitial lung disease 
increases with severity: up to 60% of end-stage idiopathic pulmonary fibrosis 
patients have pulmonary hypertension (54). Again, increasing mean pulmonary 
arterial pressure has been shown to be associated with poor outcome in IPF (53).  
Patients with combined pulmonary fibrosis and emphysema (CPFE) are also at 
significantly increased risk of developing pulmonary hypertension. Interestingly, 
these patients have severe PH and impaired diffusing capacity of the lungs for carbon 
monoxide (DLCO) but relatively normal lung volumes and little or no airflow 
obstruction (55). 
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Pulmonary hypertension in lung disease is categorised into three distinct categories: 
1. COPD/IPF/CPFE without PH: mPAP <25mmHg 
2. COPD/IPF/CPFE with PH: mPAP ≥25mmHg 
3. COPD/IPF/CPFE with severe PH: mPAP ≥35mmHg or mPAP ≥35mmHg with 
low cardiac index (CI ≤2.0) (50) 
This classification is used, as there are important, clinically relevant differences 
between patients with mPAP 25-35 and ≥35mmHg. The severe pulmonary 
hypertension group represents the minority of patients, so the majority of cases fall 
into the 25-35 group. There is an important physiological difference between patients 
in each group: patients with COPD-PH show a respiratory limitation to exercise 
(PaCO2 elevation), whereas patients with severe PH have a cardiovascular limitation 
to exercise (SvO2 reduction with normal PaCO2) (56).  
These differences raise interesting possibilities regarding the phenotyping of lung 
disease associated with pulmonary hypertension. The first possibility is whether 
these patients represent a different response to COPD with more cardiovascular 
involvement. COPD patients show a rapid elevation in mPAP with moderate exercise, 
suggesting a loss of pulmonary vascular distensability and vessel recruitment (57), 
similar to patients with idiopathic pulmonary arterial hypertension. The other 
possibility is that these patients may actually have pulmonary arterial hypertension 
and coexistent lung disease mislabelled as pulmonary hypertension due to lung 
disease (50). Both of these arguments raise a possible role for vasodilator therapy, 
although so far no survival advantage has been shown (58). As such, the identification 
of PH in COPD is made from a prognostic viewpoint, so reducing the requirement for 
invasive investigation would be useful in this regard.  
Assessment of outcome may be challenging in patients with COPD and lung disease as 
a whole as they are a heterogenous cohort. Evidence of PA dilatation on CT has been 
linked with increased risks of exacerbation (59) and patients with COPD have 
increased levels of coronary heart disease (60), making assessment of the cause of 
death potentially erroneous.  
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 Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH) 
Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially curable 
form of pulmonary hypertension (PH) (61). The diagnosis requires a mean pulmonary 
artery pressure (mPAP) ≥25 mmHg at right heart catheterization (RHC), in the 
presence of at least one segmental defect on perfusion imaging or filling defects on 
computed tomography pulmonary angiography (CTPA), after at least 3 months of 
effective anticoagulation (62). The true incidence and prevalence of CTEPH is not 
known, but the cumulative incidence of CTEPH after survival from an acute 
pulmonary embolus is reported as 3.8% at 2 years (63). The pathological process is 
thought to be due to incomplete lysis of the acute pulmonary embolus. The 
subsequent organisation of the obstructing thrombus leads to  obstruction of the 
pulmonary vascular bed (64). This ultimately causes increased pulmonary arterial 
pressure, right ventricular dysfunction and, untreated, the prognosis is poor (65). 
 
 
Patients with CTEPH usually have a history of either pulmonary embolism (PE) or 
deep venous thrombosis (DVT) although, a significant proportion may present with 
unexplained breathlessness or pulmonary hypertension of unknown cause (66,67). It 
is important that the diagnosis of CTEPH is made as pulmonary endarterectomy is 
associated with increased survival and a favourable functional outcome in CTEPH 
(61).  
Figure 1.9: Pulmonary end arterectomy 
specimens from CTEPH.  
This shows the different patterns of clot that are 
surgically operable.  
Reproduced with permission from Wolters 
Kluwer Health. Lang IM, Madani M. Update on 
chronic thromboembolic pulmonary 
hypertension. Circulation. 2014;130(6):508–18.   
(314) 
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 Group 5: Pulmonary hypertension due to unclear or multifactorial 
mechanisms 
This is a heterogenous group of pulmonary hypertension with multiple pathologies 
and aetiologies, including haematological disorders, systemic disorders, metabolic 
disorders and other rare causes of pulmonary hypertension. These are grouped 
together as they share poorly understood mechanisms of development of PH and 
there is no evidence for the use of pulmonary vasodilators in this group.  
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1.4 TREATMENT OF PULMONARY HYPERTENSION 
The treatment of pulmonary hypertension is related to the underlying cause, so it is 
important that once the diagnosis of PH is made, the correct group is identified to 
ensure timely and effective treatment.  
 
There are a number of facets to the treatment of patients with PH in addition to the 
pulmonary vascular therapies outlined below, which include psycho-social support 
regarding a life threatening disease, supervised rehabilitation and supportive therapy 
with oxygen and long term O2. The pulmonary vascular therapies used in PAH are 
outlined below (1,9,68,69).  
 Pulmonary vascular therapies 
1.4.1.1 High dose calcium channel blockers 
Approximately 10% of patients with IPAH show positive vasoreactivity to inhaled 
nitric oxide, which is defined as a reduction in mPAP ≥10mmHg to an absolute value 
Figure 1.10: A diagrammatic representation of the causes of pulmonary hypertension.  
Those on the left have therapies directed at the pulmonary vasculature, in distinction to those on the right. 
Reproduced from Pulmonary hypertension: diagnosis and management, Kiely et al, BMJ, 2013 with permission 
from BMJ Publishing Group Ltd. (9) 
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≤40mmHg. Of these patients a small number will respond to long term calcium 
channel blocker, and those that do have a significantly improved prognosis (70,71).  
1.4.1.2 Endothelin receptor antagonists 
Endothelin receptor antagonists lead to vasodilatation, acting on the pulmonary 
vascular smooth muscle, and have been shown to improve exercise status and prolong 
the time to clinical deterioration (72).  
1.4.1.3 Prostanoids 
Prostacyclin causes vasodilatation and reduces precapillary remodelling. These are 
generally given either intravenously (iloprost) or subcutaneously (Trepostinil) 
(73)(74).  
1.4.1.4 Phosphodiesterase inhibitors 
Phosphodiesterase-5 inhibitors (sildenafil or tadalafil) cause pulmonary vascular 
dilatation via cyclic GMP and also reduce cellular proliferation (75).  
 
 CTEPH 
Patients with CTEPH have a significant improvement in survival from pulmonary 
endarterectomy, when surgically accessible. For those who do not have surgically 
accessible disease, medical therapy as outlined above has also been shown to confer 
an improvement in survival (61).  
 Other causes of Pulmonary Hypertension 
There is currently no body of evidence to support the use of pulmonary vascular 
specific therapies in the other causes of PH, although there is specific interest in 
Figure 1.11: The mechanism of PAH therapies that 
are currently approved. 
(PDE-5: Phosphodiesterase 5 inhibitors) 
Reproduced with permission from Humbert M, 
Ghofrani H-A. The molecular targets of approved 
treatments for pulmonary arterial hypertension. 
Thorax. 2016 Jan;71(1):73–83. 
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certain groups of PH-lung and in PH-left heart disease in the context of clinical trials. 
The current roles of therapy in these groups is directed at the underlying disease.  
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2 IMAGING OF THE CARDIOPULMONARY CIRCULATION: THE 
CURRENT CLINICAL PICTURE 
 
The following chapter summarises the imaging methodologies that are currently used 
in the investigation of pulmonary hypertensioni.  
2.1 CHEST RADIOGRAPHY (CXR) 
The chest radiograph is a well-established first line imaging technique for the 
assessment of known or suspected lung disease, providing a general overview of the 
lungs and pulmonary vasculature. It is helpful in providing a guide to further 
investigation in patients with unexplained breathlessness, but is insensitive for the 
detection of pulmonary hypertension, particularly, where pulmonary artery pressure 
elevation is modest.  It provides limited information on causes of pulmonary 
hypertension, but may identify the presence of significant lung disease such as 
emphysema, pulmonary fibrosis or sarcoidosis. It has the advantage that is widely 
available, utilises minimal doses of radiation and is easily interpreted by medical 
practitioners. Typical findings in pulmonary hypertension are shown in Figure 2.1, 
these include dilatation of the pulmonary arteries, right atrium and ventricle, 
although the latter are features of severe disease. In a historical study of patients with 
IPAH, an abnormality on CXR or ECG was found in 90% of patients at diagnosis (76), 
however, this represents a highly selected population of patients with severe disease 
and the accuracy of CXR in an unselected population of patients with suspected 
pulmonary hypertension has not been evaluated. 
                                                        
i This chapter has been published as two review articles: “Current and Emerging Imaging Methodologies in 
the diagnosis and investigation of Pulmonary Hypertension” in Expert Review of Respiratory medicine (313), 
and “Pulmonary MR angiography and perfusion imaging—A review of methods and applications” in 
European Journal of Radiology (90). 
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Figure 2.1: The typical chest radiographic features of pulmonary hypertension in a patient with IPAH.  
The chest radiograph shows cardiomegaly with dilatation of the main pulmonary artery. There is a tunnelled 
central line for intravenous delivery of iloprost.   
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2.2 ECHOCARDIOGRAPHY (ECHO) 
Echocardiography is widely available and is usually the first non-invasive imaging 
investigation to suggest a diagnosis of pulmonary hypertension. It has the advantage 
of being portable and easily performed at the bedside. Echocardiography has high 
temporal resolution, with direct visualisation of cardiac motion, allowing assessment 
of right and left ventricular function and estimation of pulmonary artery pressure. 
Systolic pulmonary artery pressure can be measured using Doppler 
echocardiography; the peak tricuspid regurgitant jet velocity (v), measured from 
Doppler echocardiography, is used to calculate the trans-tricuspid gradient (TG) 
(pressure difference between right ventricle and right atrium) using the modified 
Bernoulli equation, TG=4v2 (77). This is added to an estimate of right atrial pressure 
to give right ventricular systolic pressure, which, in the absence of pulmonary 
valvular disease, should be equivalent to systolic pulmonary artery pressure. Right 
atrial pressure is estimated as either 5, 10 or 15mmHg based on the diameter and 
respiratory variation of the inferior vena cava (78).  
Currently, the non-invasive estimation of pulmonary arterial pressure is made using 
Doppler echocardiography. Whilst this has the advantage of being cheap and portable, 
it has a number of limitations, which include inter-operator variability, a requirement 
for tricuspid regurgitation and over-estimation of pulmonary arterial pressures in 
certain patients groups.  Several studies have identified a strong correlation of echo 
derived sPAP and right heart catheter measured mPAP in cardiac disease (79,80), 
however, the diagnostic utility of echocardiography derived pulmonary artery 
pressure is less accurate in  pulmonary hypertension in certain conditions, 
particularly in the presence of respiratory disease. A prospective study of unselected 
patients with PH, identified the inaccuracies of Doppler echocardiography derived 
mPAP, with limits of agreement ranging from -40 to 38.8 mmHg (81). 
Echocardiographic estimation of sPAP can only be performed in the presence of 
tricuspid regurgitation and where this is absent, mean pulmonary artery pressure 
may be estimated using systolic time intervals, such as pulmonary acceleration time 
(77,82). 
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Echo can identify morphological characteristics of chronic right ventricular pressure 
overload including flattening of the inter-ventricular septum (IVS), increased 
thickness of the right ventricular free wall and increased left ventricular eccentricity. 
In addition, tissue Doppler is helpful in the assessment of left ventricular diastolic 
function (83). Echocardiography also allows an assessment of the cardiac valves and 
may identify congenital heart defects. Injections of agitated saline (bubble echo) can 
be used to look for right to left shunting and can identify whether this occurs at an 
intra-cardiac or pulmonary level (84,85). Trans-oesophageal echocardiography is 
particularly helpful in the assessment of suspected intra-cardiac defects such as atrial 
septal defects, often not well visualised on transthoracic echocardiography (86).  
 
 
 
 
  
Figure 2.2: Echocardiographic assessment of PH.  
Doppler echocardiograph showing the peak tricuspid regurgitant velocity, which can be used to estimate 
sPAP. Reproduced under creative commons license from (77).  
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2.3 RADIONUCLIDE IMAGING 
 Ventilation/Perfusion single photon emission tomography (SPECT) 
Ventilation/perfusion (V/Q) SPECT is currently recommended by the European 
Society of Cardiology (ESC) as the first line screening test for chronic thromboembolic 
pulmonary hypertension (CTEPH) (1). The perfusion image entails injection of 
100MBq of 99mTc labelled macroaggregated human albumin, exposing the patient to 
ionising radiation with an effective dose of approximately 0.017mSv/MBq (87). The 
macro-aggregated albumin is trapped within the small pulmonary arterioles, and a 
3D image of pulmonary perfusion is acquired over around 10 minutes.  
 
In CTEPH, there are characteristic wedge shaped perfusion defects (Figure 2.3). When 
ventilation imaging is performed, the perfusion defects are mismatched to the 
ventilation. Whilst the recommendation from the ESC/ERS is to perform V/Q 
scanning, many centres (including Sheffield) have removed the ventilation portion of 
the V/Q scan, relying on the assumption of normal ventilation from a normal chest 
radiograph or CT. Ventilation MRI using hyperpolarised gas and perfusion lung 
imaging (as outlined later in this chapter) provides the potential to image both 
ventilation and perfusion in a single scan (88).  
Figure 2.3: Single coronal slice from perfusion SPECT. 
Patient A has a normal SPECT, patient B has CTEPH. Note the typical wedge shaped perfusion defects that are 
seen in patient B. If ventilation imaging is performed these are mis-matched. 
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The advantage of this V/Q scanning over CT is that image interpretation is relatively 
straightforward, and a normal scan essentially excludes the diagnosis of CTEPH. In 
contrast, the absence of perfusion due to attenuated vessels and the presence of endo-
luminal chronic thromboembolic disease may not be appreciated on CT by less 
experienced observers. Initial studies demonstrated that scintigraphy was 
significantly more sensitive than CT, although, more recent studies have 
demonstrated that in expert hands that CT and 3D MR perfusion techniques are 
equally sensitive when compared with scintigraphy (89–91). In addition, imaging of 
systemic vascular beds (kidneys or brain) can be used to quantify the size of a right to 
left shunt and can be considered in a patient with unexplained hypoxemia and 
pulmonary hypertension (86). 
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2.4 COMPUTED TOMOGRAPHY (CT) 
Computed tomography (CT) is the main imaging modality for the assessment of 
pulmonary parenchymal abnormalities (1). CT can be performed either unenhanced, 
or after the administration of intra-venous contrast. The intravenous contrast, which 
may be iodinated or less commonly gadolinium based, increases the density of the 
blood. Depending upon the delay after the injection, the scan may be performed with 
the contrast in the pulmonary arterial, arterial, venous or excretory phase. 
 Computed Tomography Pulmonary Angiography (CTPA) 
In suspected pulmonary hypertension, a CT pulmonary angiogram (CTPA) is usually 
performed: a bolus of iodinated contrast is administered into a large proximal vein 
(typically into a vein in the antecubital fossa) and the scan is acquired at the point of 
optimal opacification of the pulmonary arteries. In Sheffield, CTPA is performed with 
100mls of Iopamidal (“Niopam”) 300 injected at a rate of 5mls/second using an 
injector pump. The national diagnostic reference level (DRL) for CTPA is a dose length 
product (DLP) of 440 mGy cm (92). 
CTPA provides information on the pulmonary vasculature and the size of cardiac 
chambers, and aids identification of the form of pulmonary hypertension. In patients 
with PAH there are characteristic CT findings, which reflect disease severity. In a large 
cohort of patients with pulmonary arterial hypertension a systematic assessment of 
vascular, cardiac, parenchymal and mediastinal features demonstrated characteristic 
features of various forms of PAH and also identified important prognostic markers, 
outlined below (93). 
A well-established feature of pulmonary hypertension is increased pulmonary artery 
(PA) size.  A number of thresholds have been used to identify the presence or absence 
of pulmonary hypertension. In one study, a transverse PA diameter of >29 mm on CT 
was shown to have a high positive predictive value (97%) (94), whereas another 
study used a value of 33 mm (95), and a pulmonary artery with a larger diameter than 
the adjacent ascending aorta (pulmonary artery-aorta ratio >1) has also been shown 
to be predictive of PH (94). In patients where there is a high prevalence of pulmonary 
hypertension, such as systemic sclerosis, interrogation of the CT can be helpful, as an 
enlarged PA may be the first indicator of the presence of pulmonary hypertension. 
Dilatation of the PA in this setting, in particular a pulmonary to aortic ratio of >1.0, 
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can be highly predictive (96,97). Serpiginous vessels within the pulmonary 
parenchyma are seen in severe pulmonary hypertension (Figure 2.4), particularly 
Eisenmenger’s syndrome and IPAH, and are thought to represent neovascularity (98).  
 
CTPA is particularly useful in CTEPH, where the distribution of vascular webs, 
stenosis and mural thrombus allows for treatment planning and assessment of 
suitability for pulmonary endarterectomy. Figure 2.5 shows the typical CT findings in 
a patient with CTEPH. CTPA is sensitive to the diagnosis of CTEPH in expert hands 
(99,100), although there are concerns regarding lower sensitivity with less 
Figure 2.5: Selected images from a CTPA, showing the typical features of CTEPH.  
Coronal reconstruction of a CTPA, showing mural thrombus in the right pulmonary artery and reflux of 
contrast into the IVC. B shows marked dilated of the RA and RV. C shows a dilated pulmonary artery with 
mural thrombus in the right pulmonary artery. D is presented in lung windows and shows mosaic pattern of 
Figure 2.4: Coronal reconstruction of a CTPA from a patient with Eisenmenger syndrome.  
The left image is presented in lung windows and shows corkscrew neovascularity (black arrow) that can be 
seen in patients with group 1 PAH. The right image is presented in soft tissue windows and shows dilatation of 
the bronchial arteries (white arrow). 
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experienced radiologists (1,101). It can also be used to assess the burden of clot 
(102)(103). 
Pulmonary hypertension causes remodelling and eventual failure of the right 
ventricle. Whilst right ventricular dilatation and features reflecting its failure are 
visible on CTPA, these are not features of early disease. CTPA findings of right 
ventricular compromise include dilatation of the right heart chambers, right 
ventricular hypertrophy (wall thickness >4mm) and displacement of the 
interventricular septum towards the left ventricle (104). Changes of right ventricular 
hypertrophy are usually best appreciated in the right ventricular outflow tract, likely 
reflecting the reduced quantity of trabeculation. Reflux of contrast into the inferior 
vena cava and hepatic veins on contrast enhanced CT has been considered to be a 
marker of the severity of tricuspid regurgitation, commonly seen in pulmonary 
hypertension (105), often in PH-LHD, although anecdotally, it correlates poorly with 
the severity of pulmonary hypertension. In severe pre-capillary pulmonary 
hypertension such as PAH, CTEPH and PH associated with respiratory disease (where 
there is severe pulmonary hypertension) the left ventricle is under filled and 
compressed by the dilated RV, causing a small volume left atrium and ventricle. There 
may also be features of cardiac decompensation visible on CT, such as pleural and 
pericardial effusions, and an increase in inferior vena cava size, all of which are 
associated with a  poor prognosis (93).  
After the administration of IV contrast, 4D (time resolved) CT has the potential to 
provide detailed information about lung perfusion (106,107), and has been shown to 
identify abnormal perfusion after acute PE, despite apparent resolution of clot burden 
(108). Technologies such as iodine mapping have the potential to allow for CT 
assessment of a single time point of perfusion, without significant increases in dose 
(109).  
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 Unenhanced Computed Tomography  
Pulmonary parenchymal changes may help to identify the cause of pulmonary 
hypertension, and can be assessed on CTPA or non-contrast enhanced volumetric 
computed tomography (HRCT). In patients with pulmonary hypertension due to lung 
disease, CT can identify the underlying lung disease and monitor changes in severity. 
Patients with PAH including IPAH, PAH with systemic sclerosis and PAH associated 
with congenital heart disease often have centrilobular ground glass opacities (110) 
(Figure 2.6). This is also described in patients with pulmonary veno-occlusive 
disease, where additional features, such as septal lines and lymphadenopathy, may 
also be present (111). Patients with CTEPH often have regions of sub-pleural scarring 
from infarction, and a mosaic pattern of lung attenuation due to perfusion 
heterogeneity.  Although not in routine clinical use, more specialized methodologies 
in CT such as ECG gating (112) and dual energy CT for perfusion imaging are useful 
tools for phenotyping disease (113–115). 
 
In patients with PAH, CT imaging may also give a clue as to the aetiology of the PAH 
(93). Features seen in patients with systemic sclerosis and PAH include dilatation of 
the oesophagus and a ground glass pattern that frequently spares the periphery of the 
lung. Patients with congenital heart disease frequently have very significant 
pulmonary artery enlargement (often with mural thrombus and calcification of the 
pulmonary vasculature) and abnormalities such as pulmonary anomalous venous 
drainage (frequently associated with a sinus venosus defect) may be identified. 
Figure 2.6: Selected CTPA image 
showing centrilobular ground glass 
opacities in a patient with PAH. 
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Dilatation of the left atrium is also suggestive of the presence of left heart disease 
(116). 
 
 Dual Energy Computed Tomography (DECT) 
With dedicated dual or multi-energy CT scanners, it is possible to simultaneously 
image the lungs and pulmonary vasculature at different kVp, either using different x-
ray tubes (115), or oscillating kVp systems (117). This allows images of low and high 
kV spectra to be produced and can “weight” the image to the k-edge of different 
materials (118,119). Scanning at 80kV and 120kV after the administration of 
intravenous (IV) iodinated contrast medium can be used to provide iodine maps, as a 
marker of pulmonary blood volume at the time point of the scan (120), which may be 
useful in the assessment of patients with chronic thrombo-embolic pulmonary 
hypertension (121,122). Dual energy CT may also increase the opacification of the 
pulmonary arteries as it produces photons with kinetic energy closer to the k-edge of 
iodine (122) and provide insights into the perfusion of the left and possibly right 
ventricle (118,120,123). Despite these promising applications in patients with 
pulmonary hypertension, routine clinical use of dual energy CT is limited by 
requirement of expensive specialist CT systems.  
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2.5 MAGNETIC RESONANCE IMAGING (MRI) 
MRI is considered the gold standard for functional and morphological assessment of 
the heart. Standard sequences implemented in pulmonary hypertension include two 
and four chamber cardiac cine steady state free precession imaging (SSFP), black 
blood imaging (dual inversion recovery fast spin echo), contrast enhanced MR 
angiography and 3D dynamic contrast enhanced MR imaging. Cardiac MRI can be used 
to diagnose pulmonary hypertension (124,125), assess prognosis and serial 
measurements can be used to assess response to therapy. 
 The Principles of MRI 
2.5.1.1 The MRI signal 
Magnetic resonance imaging uses the inherent spin properties of protons to generate 
images. The patient is placed inside the bore of a large magnet, which generates a 
strong, constant magnetic field (B0), in this case at 1.5T. Each proton within the 
magnetic field have their own magnetic moment, which aligns with the the B0 field, 
either parallel or antiparallel (although a slight majority will lie parallel, as this 
requires less energy). When placed in an external magnetic field all of the protons 
precess around their own axis, in a similar motion to a spinning top, at a speed that is 
specific to each nuclear species (the Larmor frequency, in this case protons, which 
spin at 42.6MHz/T). At this point, the sum magnetisation is parallel to the B0 field as 
the transverse moments are random and cancel each other out, this state is termed 
longitudinal magnetisation.  
Radiofrequency (RF) energy is emitted by the RF coils within the scanner. When the 
RF pulse has the same frequency as the precession of the protons it can deposit energy 
in them (resonance). This energy deposition causes some protons to flip to the higher 
energy state of being anti-parallel, and also causes the protons to precess in phase (in 
the same direction simultaneously). As the protons are precessing in phase, there is a 
magnetisation vector in the transverse direction, which moves with the precession of 
the protons.  
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As this is a moving magnetisation vector, a current will be generated in any receiver 
coil near the precessing protons, alternating at the Larmor frequency, forming the MR 
signal. After the RF pulse switches off there are 2 relaxation processes that take place: 
the transverse magnetisation disappears (transverse or T2 relaxation) and the 
longitudinal magnetisation returns to it’s original value (longitudinal or T1 
relaxation).  
T1 relaxation occurs due to energy deposition in the surroundings of the protons, 
which results in a return to their original parallel magnetization, and this occurs at 
different rates for different molecules. The T1 time is the length of time for 
longitudinal magnetisation to return from 0 to 1−e−1. T2 relaxation is due to the 
protons falling out of phase, which results from inhomogeneity in the magnetic field 
due to the inherent properties of the B0 field and interaction with the magnetic fields 
from neighbouring nuclei. T2 time is the time taken for transverse magnetisation to 
return to e-1.  
After the RF pulse, the net magnetisation decays following a spiral path, which creates 
a signal in the RF receiver coils. The signal received is termed the free induction decay 
(Figure 2.8, next page), which has a constant frequency (Larmor), initial magnitude 
related to longitudinal relaxation and reducing magnitude due to transverse 
Figure 2.7: Magnetisation recovery after a 90˚ RF 
pulse. 
A. B0 produces a net magnetisation vector in a 
longitudinal direction 
B. The RF pulse creates transverse magnetisation 
and reduces longitudinal magnetisation 
C. Dephasing reduces the transverse signal as 
longitudinal magnetisation increases 
D. Longitudinal recovery (T1 relaxation) 
 
Images reproduced Reproduced from Understanding 
MRI: basic MR physics for physicians. Currie S, 
Hoggard N, Craven IJ, Hadjivassiliou M, Wilkinson ID, 
2013 With permission from BMJ Publishing Group 
Ltd. 
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relaxation (T2* effects). These T2* effects can be counteracted by using 180˚ 
refocussing echoes, such as in gradient echo imaging.   
 
 
2.5.1.2 Image reconstruction 
The MR signal is localised in 3D space using 3 magnetic field gradients: the slice 
selection gradient, the phase encoding gradient and the frequency encoding gradient. 
The slice is selected through applying a gradient in the z direction (parallel to B0), 
altering the Larmor frequency of the protons in the z axis, so only the protons in the 
selected slice are excited by the RF pulse. The slice thickness can be manipulated by 
adjusting the RF pulse bandwidth or the steepness of the gradient. A gradient applied 
in the phase encoding direction causes the spin phase to vary linearly and the 
frequency encoding gradient causes the protons to spin at different frequencies, 
allowing spatial position of the signal to be assessed.   
 
Whilst all protons in the selected slice are simultaneously excited by the RF pulse, only 
a single echo signal is recorded for each phase encoding step. In order to complete the 
image for each slice, the pulse sequence, therefore, has to be repeated many times. 
During this repetition, the slice selection and frequency encoding are kept the same, 
but the phase encoding gradient is incrementally increased. Each of these repetitions 
creates a signal echo, which is stored in a data matrix referred to as k-space. k-space 
is used to store the data of the MR signal in the signal domain. The data stored in k-
 
Figure 2.8: Free induction decay signal 
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space is converted to an image (in the spatial domain) using Fourier transformation, 
as demonstrated by an image of the Polaris team in Figure 2.9, below (126,127). 
 
  
Figure 2.9: A demonstration of the spatial and the frequency domains. 
Left is an image of the Polaris team demonstrated in the spatial domain. Right is the same image in the 
frequency domain (after Fourier transformation). k-space is the placeholder for the frequency information 
acquired by the MRI scanner.  
 
Dr CS Johns  Cardio-Pulmonary MRI in PH   44  
 Cardiac Cine MR Imaging 
Retrospectively ECG gated cardiac cine steady state free procession imaging (SSFP) in 
the two and four chamber views allow for qualitative and quantitative assessment of 
the structure and function of the ventricles (128). Segmentation of the ventricular 
endocardium quantifies the right and left ventricular end-diastolic and end-systolic 
volumes from which stroke volume and ejection fraction can be calculated. Baseline 
RV end-diastolic volume and RV ejection fraction and the change in RV ejection 
fraction over time are both predictive of outcome (129,130). RV stroke volume 
measured using cine imaging is less reproducible due to inaccuracies in contouring 
the ventricles (131), although new software allowing for thresholding of 
trabeculation may improve reproducibility (132). In addition, due to the variable 
nature of tricuspid regurgitation, RV stroke volume measured by volumetry is a poor 
reflector of forward pulmonary arterial flow (131).  
 
The myocardium of the left and right ventricles can be segmented, giving right and 
left ventricular mass. The ratio of these is the ventricular mass index (VMI = RV mass 
/ LV mass), which correlates with mean pulmonary arterial pressure in patients with 
pulmonary hypertension (133).  
Figure 11: The 20 phases from a mid-chamber slice of the short axis SSFP cine images 
This patient has IPAH: note the flattening of the interventricular septum and dilatation of the right ventricle.  
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In health, left ventricular pressure is significantly greater than right ventricular 
pressure, giving a characteristic circular shape to the left ventricle, and a crescentic 
shape to the right ventricle on short axis views. The angle of the inter-ventricular 
septum can be measured, it is increased (deviating towards the LV) in patients with 
pulmonary hypertension (134). This has been shown to correlate with pulmonary 
artery pressure although in the presence of left heart disease septal angle 
measurements are less accurate due to the confounding effect of elevated left 
ventricular diastolic pressures. 
Figure 2.11: Measurement of the epicardial and endocardial contours.  
Diagrammatic representation of the endocardial (white) and epicardial (red) contours from the short axis 
images at end diastole and systole. In this patient with IPAH, the muscle mass of the right ventricle is 
significantly thickened.  
 
Figure 2.10: Measurement of the interventricular septal angle.  
Single slice form a patient with IPAH, left at end diastole and right, at end systole showing the septal position. 
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 Functional Imaging of Pulmonary Arterial Flow and Motion 
Dual inversion recovery fast spin echo (DIR-FSE) Black blood imaging is used to 
provide a morphological assessment of the pulmonary arteries and aorta. The protons 
within the field of view are excited. Any spins that remain in the field of view return 
signal, any protons that flow out of the field of view are replaced by non-excited 
protons and return no signal. In health, this results in high contrast between the 
flowing blood in the pulmonary arteries (no signal/black) and the pulmonary artery 
wall (high signal/white). A reduction in blood velocity and turbulent flow results in 
high signal within the pulmonary arteries, a strongly diagnostic and prognostic 
feature of PH, described as black blood flow artefact (135). Black blood slow flow 
artefact imaging is potentially limited; as the degree of artefact may be related to the 
slice thickness, angle of acquisition and field strength, although these are all 
controllable variables. Care is also required as thrombus also returns high signal, so 
it is important to look at other sequences to ensure that the signal is due to slow flow 
rather than clotted blood.  
 
Phase contrast MRA with velocity sensitising gradients can be used to quantitatively 
map the blood flow in the major vessels in the lungs in 3-dimensions and can provide 
insight in to pulmonary vascular resistance and non-steady and turbulent flow in the 
pulmonary arteries (136,137). Typical velocity encoding settings of Venc 150cm/s 
would be used to map flow in the pulmonary artery but this may need adjustment for 
Figure 2.12: Two examples of black blood imaging.  
The image on the left is a patient with very mild black blood flow artefact in the lobar artery on the right 
(grade 1), the image on the right is a patient with severe black blood flow artefact (grade 4).  
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slower flow in diseases such as pulmonary hypertension where flow velocity is slower 
and directionality is helical. Pulmonary arterial flow, velocity and area change can be 
calculated and have been shown to have clinical value in the assessment of patients 
with PH.   
Recent developments with 3D view shared phase contrast methods allow for the 
acquisition of 4D flow  in the pulmonary arteries (138,139). This can be 
retrospectively interrogated to analyse flow in multiple regions of interest in the heart 
or pulmonary vasculature. In pulmonary hypertension, vortices can be seen within 
the pulmonary artery (140), and the duration of these vortices have been shown to 
be predictive of the presence of PH (141,142). Further research examining the clinical 
utility of 4D flow MRI is warranted.  
  
Figure 2.13: Vortical flow in the main pulmonary artery.  
Sequential images from 2D phase contrast imaging of the main pulmonary artery in a 63 year old patient 
with pulmonary hypertension (mPAP = 51mmHg). a), b), c) and d) are from cardiac phases = 5, 8, 11 and 14 
respectively. Images courtesy of Dr G Collier and Prof JM Wild. 
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 Magnetic Resonance Angiography and Perfusion Imaging 
 
2.5.4.1 Contrast Enhanced MR Angiography 
 T1 shortening contrast agents can be used to produce high spatial resolution images 
of the pulmonary arteries and veins with 3D acquisitions within a single breath-hold. 
Currently, this method is the mainstay of pulmonary MRA in the clinical setting. 
Typically, a bolus of gadolinium-chelated agent is administered into a large vein, 
usually in the antecubital fossa followed by a saline flush. Typical contrast doses are 
0.1 mmol/kg body weight Gadovist followed by a 20ml saline flush injected at 
5ml/sec. In order to reduce venous contamination and gain greatest arterial and 
venous separation, a single dose of gadolinium at a high injection rate should be used. 
The contrast administration is followed by acquisition of a T1 weighted 3D gradient 
echo dataset. Typical imaging parameters are: TR=2.5-3 ms, TE=1.0-1.5 ms, α=30-40°, 
matrix=40×192×256, FOV=460 mm, parallel imaging factor R=2 (143). In order to 
synchronise image acquisition with peak contrast enhancement in the pulmonary 
vessels, a bolus tracking technique can be employed: a test bolus with a time resolved 
test scan is used to assess the optimal time from injection to acquisition of central k-
space, resulting in images from a single time point (143). An important consideration 
in pulmonary MRA is the rapid transit of blood through the lungs (3-5 seconds). 
Centric elliptic phase encoding, with the scan acquisition starting at peak 
enhancement ensures maximum SNR and optimal separation of arterial and venous 
phases. 
  
Figure 2.14: A diagrammatic representation of the basic principles of MR angiography against perfusion MR 
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The contrast bolus passage may also be imaged with time resolved 3D view sharing 
acquisitions, such as TRICKS (Time Resolved Imaging of Contrast KineticS), allowing 
for haemodynamic assessment of the pulmonary circulation (Figure 2.16). These 
view-sharing methods under-sample k-space and share missing k-space between 
datasets, giving a higher nominal temporal resolution, albeit with the risk of spatio-
temporal interpolation artefacts. Other methods for k-space sampling, such as spiral 
acquisition and view sharing can further reduce scan times, with some centres 
producing high spatial resolution MRA images with temporal resolution of 1 second 
through spiral-TRICKS acquisition (144). These methods are useful in the assessment 
of shunting. 
Whilst the majority of clinical MRA is currently performed using extracellular contrast 
media such as gadobutrol (Gadovist TM) and gadobenate dimeglumine (Multihance 
TM), there is also the potential to perform pulmonary MRA using intravascular (blood 
pool) media such as Gadomer-17,  Gadofosveset trisodium and ferumoxytol (145). 
The long residency time of these agents can enable high SNR and spatial resolution 
with averaging over several breath-holds, however arterial and venous phase 
separation is sacrificed (145). Blood pool agents for clinical pulmonary MRA are very 
Figure 2.15: Examples of Magnetic Resonance Angiography. 
These are reconstructed as a maximum intensity projection (MIP) in a patient with CTEPH (left) and a 
normal example (right). Reprinted with permission from European Society of Radiology: Springer. European 
Radiology. Diagnostic accuracy of contrast-enhanced MR angiography and unenhanced proton MR imaging 
compared with CT pulmonary angiography in chronic thromboembolic pulmonary hypertension, Rajaram et 
al. 2012. 
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helpful in patients that cannot hold their breath as non-breath hold, heavily averaged 
MRA acquisition methods can be used. 
 
2.5.4.2 Dynamic Contrast Enhanced Perfusion MRI 
With a similar methodology to contrast enhanced MRA, but using lower spatial and 
higher temporal resolution image acquisitions, T1-weighted dynamic contrast 
enhanced (DCE) perfusion images of the first pass of a gadolinium contrast bolus can 
be performed. Typical imaging parameters would be: TR=2.0-2.5ms, TE=0.8- 1.0ms, 
α=30-40°, matrix=32×96×128, FOV=460mm. A lower dose of contrast is needed e.g.  
0.05ml per kg patient weight of gadobutrol (Gadovist TM). Again, the nominal 
temporal resolution of the acquisition can be increased with parallel imaging and 
view sharing (136) but this can result in spatio-temporal blurring of the signal. In 
Figure 2.16: Selected images from a patient with IPAH with a patent foramen ovale.  
The top row (A) shows the images from the time resolved TRICKs (time resolved contrast kinetics), with 
increasing time to the right of the image. On the early images, there is contrast within the aorta at a time 
point before filling of the pulmonary arteries, in keeping with a right to left shunt. This was confirmed with 
quantitative perfusion single photon emission tomography (SPECT) over the kidneys (D), which shows uptake 
of tracer in the capillary bed of both kidneys. The black blood imaging (B) shows dilated pulmonary arteries 
with slow flow/turbulent blood artefact and the 2-chamber image (C) shows significant flattening of the 
interventricular septum. 
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clinical practice, images acquired with a frame rate of around 0.5 s per 3D lung volume 
can preserve spatial resolution sufficient for diagnostic purposes. This data is often 
presented as the peak signal for each voxel, after the original ‘unenhanced’ dataset 
has been subtracted, giving a peak perfusion image (90). This is particularly useful in 
the assessment of CTEPH and has been shown to be of equivalent sensitivity to 
perfusion SPECT imaging (89). Dynamic contrast enhanced MRI can also be quantified 
(143,146–148), potentially allowing for easier longitudinal follow up of perfusion 
abnormalities in pulmonary hypertension (131).  
 
Perfusion images can be qualitatively assessed by subtraction of the baseline dataset 
from the peak enhancement dataset, allowing for a rapid assessment of perfusion 
defects and their anatomical location. With more detailed post-processing of the 
entire time resolved data, quantitative assessment of contrast passage kinetics can be 
made. Pulmonary blood flow (PBF), pulmonary blood volume (PBV) and mean transit 
time (MTT) can then be quantified and parametric maps of these metrics can be 
generated from voxel-wise analysis. For absolute quantitative analysis an arterial 
input function (AIF) is measured in a large feeding artery, often the main pulmonary 
artery for lung imaging (143). Once the AIF has been established, the signal time curve 
of a voxel can be converted to concentration time course from the assumption of a 
linear relationship between signal intensity and contrast concentration. A model free 
approach using the following equation can be used: 
Figure 2.17: The time-course of DCE-MRI showing a single coronal slice in a healthy volunteer.  
The top row of images shows the non-subtracted “raw” images, the second row shows the subtracted images and 
the bottom row shows the pulmonary parenchymal signal change over time. Please note that the images were 
acquired with a temporal resolution of 0.5 seconds per 3D dataset, but are displayed with a temporal resolution 
of 1.5 seconds. 
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𝐶(𝑡) = 𝑘 
𝑆(𝑡) − 𝑆0
𝑆0
 
Where S(t) is the signal time-course, S0 is the mean signal before contrast 
enhancement and k is an unknown constant. For absolute quantitative analysis, T1 
mapping is required in order to convert signal intensity to contrast agent 
concentration (mmol/litre (mM)). One method of T1 mapping used in quantitative 
perfusion analysis is the variable flip angle approach. Using a Levenberg-Marquardt 
fitting algorithm tissue density at equilibrium (m0) and T1 relaxation at equilibrium 
can be calculated on a voxel-by-voxel basis via: 
𝑠(𝛼) = 𝑚0 sin 𝛼 
1 − 𝐸10
1 − cos 𝛼 . 𝐸10 
 
Where 𝐸10 = exp(-TR.R10). TR = repetition time used in acquiring the T1-weighted 
flip angle images. Most commonly three values of flip angle (α) are used generally in 
the range of 2-35˚. 4D post-injection longitudinal relation rates R1(t) are then 
calculated: 
𝑅1(𝑡) =  − (
1
𝑇𝑅
) . 𝑙𝑛
1 − (𝐴 + 𝐵)
1 − cos 𝛼 . (𝐴 + 𝐵)
  
Where α = flip angle, A = [S(t) – S(0)]/(M0sin α), B = (1 - 𝐸10 )/(1 – cosα 𝐸10 ). 
Gadolinium concentration maps can then be calculated using the equation: 
𝐶(𝑡) =  
𝑅1 (𝑡) − 𝑅10
ℜ1
 
Where ℜ1is the experimental relaxivity of Gadolinium (4.39 s-1 mM-1 at 37 ˚ C) (149). 
Following contrast concentration mapping the concentration time-curves are fitted 
using the Gamma variate function: 
𝐶(𝑡) = 𝐾(𝑡 − 𝐴𝑇)𝑎𝑒 − (𝑡 − 𝐴𝑇)𝑏 
Where K is a constant scale factor, t is time after injection, AT is appearance time of 
the contrast agent in the voxel and a/b are arbitrary parameters. It is worthwhile noting 
that for gadolinium based contrast agents, unlike iodinated contrast agents, contrast 
concentration and signal intensity are not linearly related at higher concentrations. Constant 
K is related to tissue density, imaging sequence parameters, contrast agent and inspiration 
level. Hence, it is important that these are kept constant during the experiment (147). 
Dr CS Johns  Cardio-Pulmonary MRI in PH   53 
Following the indicator dilution theory (150), once the concentration time course of the 
AIF is known, CAIF(t), pulmonary blood flow (PBF) can be calculated: 
𝐶𝑉𝑂𝐼(𝑡) = 𝑃𝐵𝐹 ∫ 𝐶𝐴𝐼𝐹(𝜏). 𝑅(𝑡 − 𝜏)𝑑𝜏
𝑡
0
= 𝑃𝐵𝐹 [𝐶𝑎(𝑡)  ⊗ 𝑅(𝑡)] 
Where CVOI(t) is the contrast time course of the region of interest, R is the 
concentration of contrast remaining at time t and ⊗ denotes the convolution integral 
(146,147). Pulmonary blood volume (PBF) and mean transit time (MTT) are defined 
as (146):  
𝑃𝐵𝑉 =  
∫ 𝐶𝑉𝑂𝐼(𝑡)𝑑𝑡
∞
0
∫ 𝐶𝐴𝐼𝐹(𝑡)𝑑𝑡
∞
0
 and 𝑀𝑇𝑇 =
𝑃𝐵𝑉
𝑃𝐵𝐹
 
Noise filtering is required before these calculations can be reliably made (147) since 
the inherent image SNR is low. In order for perfusion quantification, it is assumed that 
there is a linear relationship between signal and concentration. This is not a true 
assumption and linearity is only seen in a small range of low concentrations of 
contrast. This is a particular problem for the AIF as the contrast passes in a compact 
bolus (i.e. high concentration) (151). A robust contrast administration protocol is 
therefore paramount. One method for overcoming this is to use a smaller dose of 
contrast such as 0.05ml/kg at a rate of 4ml/second as suggested above. This has the 
advantage of only requiring a single injection, but with a reduction in SNR in the 
perfusion image. Another method is to use 2 boluses: a low dose injection to calculate 
the AIF and a second larger dose to give better SNR in the lung perfusion image (152). 
When using this split bolus technique the AIF must be recalculated to match the bolus 
used in the lung imaging part of the sequence. As contrast kinetics are involved, the 
bolus used to calculate the corrected AIF is shifted by injection duration τ (148): 
𝐶𝐴𝐼𝐹(𝑡) =  ∑ 𝐶𝑝 (𝑡 + 𝑞𝜏)
𝑉 𝑉𝑝⁄
 
It is also important to ensure that there is sufficient time between the first and second 
bolus to allow for washout of contrast. 
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2.5.4.3 Non-contrast enhanced MRA and Perfusion imaging 
Long acquisition times and problems with artefacts, such as motion, have limited the 
use of non-contrast enhanced MRA. Improving MR technologies, concerns about the 
use of gadolinium from the risk of nephrogenic systemic fibrosis (153) and the desire 
for non-invasive techniques for paediatrics have increased the motivation for non-
contrast enhanced methodology for MR perfusion and angiography.  
ECG gated 3D partial-Fourier Fast Spin Echo (FSE) sequences utilise the difference 
between fast flow and slow flow on T2 signal. In systole, arterial flow is fast and causes 
a void of T2 signal, whereas in diastole, flow is reduced and returns high T2 signal. 
Venous systems have slow flow in systole and diastole. Hence, a subtraction image of 
the systolic from diastolic image gives high T2 signal in the arterial system (137). This 
method requires ECG gating to allow separation of the diastolic and systolic images, 
and brings with it the risk of mis-registration.  
Balanced steady-state free procession (bSSFP) produces images with the signal 
proportional to the T2/T1, through refocusing gradient echoes and alternating phases 
of RF pulses to create a coherent steady state. The TR must be kept very short as 
bSSFP is susceptible to field inhomogeneity (154). bSSFP is particularly useful in 
imaging the blood, which has long T2 when compared to the surrounding tissues 
(143) and has short acquisition times allowing for short breath-holds (154). The high 
contrast between pulmonary blood pool and lumen make bSSFP an effective tool for 
assessment of thrombus when MRA and CTPA are inconclusive (155) and a fast 3D 
bSSFP acquisition provides a quick and contrast free means of generating a 
pulmonary angiogram (156). 
Figure 2.18: Quantitative analysis of Perfusion imaging.  
Matched slices from a single patient with CTEPH showing the SPECT and the peak enhancement image from a 
DCE perfusion MRI scan used clinically, alongside semi-quantitative perfusion maps (pulmonary blood volume, 
flow, and mean transit time) from a DCE perfusion MRI. 
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Arterial spin labelling (ASL) images are produced by radiofrequency excitation of the 
water protons in blood upstream of the imaging field of view through an inversion 
pulse. These “tagged” protons then flow into the field of view to be imaged 
(137,151,157). A control image is also taken and the images tend to be presented as a 
subtraction of the control image from the tagged image. ASL in the lungs is challenging 
as ECG gating requires a regular heartbeat (151) and spin tagging with selective 
radiofrequency pulses is confounded by B0 and B1 field inhomogeneity. Newer 
labelling techniques including continuous arterial spin labelling (CASL), pulsed 
arterial spin labelling (PASL) and a combination as pseudo-continuous arterial spin 
labelling (pCASL) have the potential to increase the use of ASL in thoracic imaging 
(158). ASL using the spin echo entrapped perfusion image (SEEPAGE) allows for a 
single shot acquisition within 5 seconds. SEEPAGE completely supresses the 
background tissue, so only the “tagged” protons flowing into the field of view return 
signal. This has the advantage of requiring no subtraction (so no mis-registration) and 
allows rapid acquisitions within short breath-holds (159). All of these spin-labelling 
techniques are by nature slice selective methodologies, and therefore are currently 
limited in terms of lung volume coverage.  
Time of flight (TOF) MRA is commonly used in neurovascular and peripheral vascular 
imaging, but poor spatial resolution, sensitivity to motion (cardiac or respiratory), 
multi-planar flow directionality, insensitivity to slow flow and sensitivity to 
susceptibility artefacts limits the utility of TOF MRA in the lungs (160).  
Time resolved imaging of the lungs during free breathing with Fourier decomposition 
(FD) analysis has also been used as a surrogate method to image lung perfusion 
without the need for contrast or ECG gating. Fourier decomposition has recently been 
applied to lung ventilation and perfusion imaging (161). During inspiration, the lungs 
increase in volume, reducing parenchymal signal, increasing again in expiration. 
During systole, high blood velocity causes dephasing of the MR signal, reducing signal. 
The respiratory changes occur at a rate of 12-20 beats per minute and the cardiac 
changes at a rate of 60-80 beats per minutes on average. The difference in frequencies 
allows for separation using Fourier Decomposition (FD), to give ventilation weighted 
or perfusion weighted images (162) which have been used for perfusion 
quantification (163).   
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 Magnetic Resonance Imaging Tissue Characterisation 
Late gadolinium imaging is in common usage in the assessment of patients with 
myocardial infarction, to identify myocardial scar tissue (164). The technique utilizes 
an ECG gated T1-weighted inversion recovery sequence performed 10 to 15 minutes 
after injection of gadolinium (a T1 shortening agent). Normal myocardial tissue 
enhance early, but wash-out. Abnormal cardiac muscle traps gadolinium, remaining 
enhanced on delayed imaging either due to an increase in the extra-cellular space or 
a break down in the cell membrane of myocytes (164,165). In patients with 
pulmonary hypertension, late gadolinium enhancement is seen in the right 
ventricular insertion points and in the interventricular septum (166). It is likely that 
these areas are exposed to mechanical stress. The extent of right ventricular insertion 
point and interventricular septum late gadolinium enhancement has been shown to 
correlate with right ventricular function (167).  
A similar pattern of disease can be seen on native T1 mapping (i.e. non contrast 
enhanced T1 values), with high native T1 values in the RV insertion points (168), 
which correlates with right ventricular dysfunction (169). This allows the potential to 
characterize myocardial tissue, without the use of contrast media and provide a 
method for the identification of patients at risk of adverse right ventricular 
remodelling and right ventricular failure.  
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 Reproducibility of Cardio-Pulmonary Vascular MRI metrics 
Measures of the structure and function of the right ventricle, left ventricle and the 
pulmonary artery have been shown to have high inter and intra-observer 
reproducibility. Table 2.1 summarizes the previously calculated inter and intra-
observer reproducibility metrics for commonly measured MRI metrics of the right 
and left ventricle and the pulmonary artery in 30 patients with pulmonary 
hypertension (170). 
 
Table 2.1: Reproducibility of cardio-pulmonary vascular MRI metrics in pulmonary hypertension.   
  Inter  Intra  
  ICC 95% CI ICC 95% CI 
Right Ventricle     
 RVEDV 0.988 0.974 - 0.994 0.996 0.991 - 0.998 
 RVESV 0.991 0.981 - 0.996 0.988 0.974 - 0.994 
 RVEF 0.957 0.910 - 0.979 0.940 0.875 - 0.972 
 RVSV 0.928 0.848 - 0.966 0.990 0.979 - 0.995 
 RV mass 0.947 0.763 - 0.980 0.990 0.979 - 0.999 
 VMI 0.959 0.910 - 0.981 0.984 0.966 - 0.992 
Left Ventricle     
 LVEDV 0.991 0.981 - 0.996 0.996 0.992 - 0.998 
 LVESV 0.959 0.810 - 0.986 0.986 0.970 - 0.993 
 LVEF 0.918 0.718 - 0.968 0.973 0.942 - 0.987 
 LVSV 0.979 0.922 - 0.992 0.973 0.903 - 0.990 
Interventricular Septal Position    
 IV septal angle systole 0.972 0.907 - 0.989 0.988 0.975 - 0.995 
Pulmonary Arterial Structure/Function   
 PA systolic area 0.995 0.990 - 0.998 0.996 0.992 - 0.998 
 PA diastolic area 0.986 0.957 - 0.995 0.986 0.957 - 0.995 
 Phase contrast MRI forward flow 0.999 0.997 - 0.999 0.999 0.997 - 0.987 
 Phase contrast MRI backward flow 0.902 0.795 - 0.953 0.997 0.992 - 0.999 
Reproduced with permission from Dr AJ Swift (170). 
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2.6 DIGITAL SUBTRACTION PULMONARY ANGIOGRAPHY (DSA) 
Digital subtraction angiography (DSA) of the pulmonary artery is an invasive test, in 
which iodinated contrast is administered through a catheter in the pulmonary artery 
under fluoroscopic visualisation. DSA is used in many centres in patients with chronic 
thromboembolic disease to guide surgical intervention (171) and is currently 
recommended in the ESC guidelines as a final step in the surgical assessment of 
CTEPH. It can be performed in conjunction with balloon pulmonary angioplasty, a 
treatment methodology for non-surgical CTEPH which has increasing interest (172–
175). The advent of CTPA and MR angiographic techniques provide an alternative 
non-invasive approach to assess suitability for pulmonary endarterectomy. As a 
result, digital subtraction angiography is reserved for problem solving in the Sheffield 
Pulmonary Vascular Disease Unit (176). 
2.7 RESEARCH BASED METHODOLOGIES 
 Positron Emission Tomography (PET) 
Fluorodeoxyglucose (FDG) is a glucose analogue, which is typically bound to 18-
Fluorine, a positron emitter. 3D images of the uptake of FDG can be produced using a 
PET scanner (positron emission tomography), which allows for qualitative and 
quantitative assessment of tissue glucose uptake and therefore, an assessment of 
metabolic activity. As the spatial resolution of PET scanning is relatively low (typical 
voxel sizes are 5mm (92)), the scan is performed at the same time as CT, for 
anatomical location. In IPAH, there is heterogenous uptake within the lung 
parenchyma and significantly increased FDG uptake within the right ventricle, a 
prognostic marker (177–180). In a few centres the availability of PET-MRI scanners 
allows anatomical location of the uptake on cardiac MRI (181), providing clearer 
anatomical detail from the soft tissues and simultaneous assessment of cardiac 
function.  
In addition, PET may be used in patients with proximal CTEPH, particularly when 
extending into the pulmonary trunk when conditions such as pulmonary sarcoma are 
suspected. Whereas, tumour would be expected to show increased uptake of FDG this 
would not be the case with chronic clot, Error! Reference source not found. (113,182). T
his information can be used to inform discussions with patients prior to surgery. 
Dr CS Johns  Cardio-Pulmonary MRI in PH   59 
 Optical Coherence Tomography (OCT) 
CTPA and DSA are frequently used in the assessment of vascular defects in patients 
with CTEPH; however, they only provide information on the lumen, with limited 
information about the vessel wall. Optical coherence tomography is an invasive 
technique, performed at pulmonary angiography, which uses near infra-red light to 
image the vessel wall, with resolutions of 10-20µm (183). OCT can demonstrate the 
intimal thickening that is characteristic of PAH (184,185), subclinical pre-capillary 
remodelling in patients with borderline pulmonary arterial pressures (mPAP 21-
24mmHg) (184) and reversal of remodelling after vasodilator therapy (184,186). In 
CTEPH, OCT can be used as an adjunct to balloon pulmonary angioplasty and allows 
for the assessment of the underlying morphology of vascular lesions (187). It has the 
potential to separate fresh ‘red’ thrombus from chronic ‘white’ thrombus (188), 
identifying suitable targets for balloon angioplasty. Due to the invasive nature of this 
test and requirement of specialist equipment and expertise, it is currently confined to 
a small number of centres. 
  
Figure 2.19: A selection of images from a patient with a pulmonary artery angiosarcoma.  
There is a soft tissue density filling defect on the CTPA within the proximal pulmonary artery, extending into 
both left and right pulmonary arteries (A), and also extending into the right upper lobe (B). This is hot on the 
PET-CT scan (C+D). SSFP cine cardiac MRI demonstrates the mass as an isodense filling defect in the pulmonary 
arteries (E) and there is a perfusion defect in the right upper lobe (F).    
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2.8 CLINICAL APPLICATIONS OF IMAGING PH 
The key steps for the investigation of patients with suspected pulmonary 
hypertension are: i) diagnose, ii) identify the cause, iii) identify at risk patients, and 
iv) assess response to treatment. The role of imaging in this regard is outlined below. 
 Making the Diagnosis of Pulmonary Hypertension 
The possibility of pulmonary hypertension is usually first suggested by 
echocardiography although it may be made incidentally by an imaging investigation 
performed for unexplained breathlessness (e.g. demonstrating enlargement of the 
central pulmonary arteries on chest radiograph or CT). The diagnostic approach for 
patients with suspected PH was highlighted in the most recent ERS/ESC guideline (1), 
however, the approach is dependent in part on local availability of imaging and 
expertise.   
Figure 2.20: Investigation flow chart in the Sheffield Pulmonary Vascular Disease Unit.  
ECG: Electrocardiogram, PH: Pulmonary Hypertension, PH-Resp: Pulmonary Hypertension Due To 
Respiratory Disease, PH-LHD: Pulmonary Hypertension Due To Left Heart Disease, CTEPH: Chronic Thrombo-
Embolic Pulmonary Hypertension, PAH: Pulmonary Arterial Hypertension, Q SPECT: Perfusion Single 
Positron Emission Computed Tomography, HRCT: High Resolution Computed Tomography, CTPA: Computed 
Tomography Pulmonary Angiography, CMR: Cardiac Magnetic Resonance Imaging, MRA: Magnetic 
Resonance Angiography, Tricks: Time Resolved Imaging Of Contrast Kinetics, RHC: Right Heart Catheter, 
USS: Ultrasound, IPAH: Idiopathic Pulmonary Arterial Hypertension, CHD: Congenital Heart Disease. 
 
Dr CS Johns  Cardio-Pulmonary MRI in PH   61 
Diagnostic strategies to confirm or refute the diagnosis of pulmonary hypertension, 
including deciding on the need for cardiac catheterisation and the approach to 
imaging is dependent on the physician ensuring that further investigation is in the 
best interests of the patient. An appreciation of factors that increase the pre-test 
probability of forms of PH likely to benefit from therapy is crucial in this respect. In 
the Sheffield Pulmonary Vascular Unit, a tertiary PH referral centre for pulmonary 
hypertension, patients are initially assessed in an out-patient clinic with an 
electrocardiogram, exercise and lung function testing and echocardiography. For 
appropriately identified patients, a multimodality approach is used combining 
radionuclide imaging, CT, MRI and cardiac catheterisation as shown in Figure 2.20. As 
many patients travel long distances for their investigations, this multimodality 
approach is taken to reduce the requirement for repeat visits and recognises the 
complementary information provided by different imaging investigations. In other 
centres, a step-wise approach may negate the need for some of the diagnostic tests, as 
advocated by current ESC/ERS guidelines.  
 Identifying the Cause of Pulmonary Hypertension 
One of the major values in using a multimodality approach is the provision of detailed 
information to aid phenotyping pulmonary hypertension. The identification of the 
cause of PH is key in defining treatment: patients with PAH benefit from drug therapy 
and patients with CTEPH can be potentially cured by pulmonary endarterectomy. 
Whilst invasive haemodynamics are the gold standard for the measurement of 
pressure, imaging features can also give an indication as to the likelihood and severity 
of PH in addition to providing detailed information on the likely underlying cause. 
Information from imaging is integrated with other investigations including blood 
testing and lung function testing.  
Group 1: The typical imaging findings in patients with idiopathic pulmonary arterial 
hypertension (IPAH) are pulmonary artery enlargement, right ventricular and atrial 
dilatation, right ventricular hypertrophy (usually most apparent in the outflow tract) 
and septal bowing, as shown in Figure 2.22. In addition, the left atrium and left 
ventricle are often reduced in volume due to poor filling. On CT, patients with PAH 
often have centrilobular ground glass nodules (Figure 2.6), and if this is seen 
centrally may suggest systemic sclerosis-PAH, especially if the oesophagus is dilated. 
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A diagnoses of IPAH requires and exclusion of other causes. Time resolved contrast 
imaging such as TRICKs might be of use in the identification of right to left shunts, as 
shown in Figure 2.16, which demonstrates a right to left shunt in a patient with IPAH 
and a patent foramen ovale. 
Group 2: Patients with PH due to left heart disease often have biatrial dilation and a 
varying amount of left ventricular, right ventricular and right atrial enlargement 
(figure 3). Features of pulmonary hypertension seen in IPAH, such as septal flattening 
may be masked due to high left ventricular filling pressures, and the presence of a 
flattened septum in addition to features of left heart disease suggests a pre-capillary 
Figure 2.21: Typical imaging features in a patient with idiopathic pulmonary arterial hypertension. 
The chest radiograph shows cardiomegaly with dilatation of the pulmonary artery, the patient has a PICC for 
intravenous delivery of iloprost. Black blood imaging (B) and CTPA (D) confirm the dilated pulmonary 
artery. Further features of pulmonary hypertension are shown with slow flow artefact on black blood (B), 
flattening of the interventricular septum (C) and dilatation of the right sided chambers (C and D). Note is 
also made of poor filling of the left sided chambers and a moderate pericardial effusion. 
 
Figure 2.22: Typical features of pulmonary hypertension due to left heart disease.  
A chest radiograph (A) showing moderate cardiomegaly and upper lobe venous distension. Subsequent 
magnetic resonance imaging (MRI) shows bi-atrial dilatation (B), flattening of the interventricular septum 
(C) and slow flow black blood artefact (D). The flattening of the interventricular septum suggests that there 
is a pre-capillary component to the pulmonary hypertension.  
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component to the PH. There may be features of previous cardiac surgery or valvular 
replacement. Patients with left heart disease may also have features of cardiac 
decompensation such as pleural effusions, septal lines, ascites and reflux of contrast 
into the IVC/hepatic veins.  
Group 3: Imaging evidence of lung disease is helpful in ensuring that patients with 
PH-Lung are not misclassified as IPAH and characteristic features of the form of 
parenchymal lung disease are easily appreciated. It is important to recognize that 
patients with severe emphysema may have normal spirometry (although these 
patients usually have a severe reduction in gas transfer) and in patients with 
interstitial lung disease (particularly in the setting of connective tissue disease) the 
spirometry may be normal.  
Group 4: The diagnosis of CTEPH may be suggested by a mosaic attenuation pattern 
on CT, due to underlying perfusion abnormalities and sub-pleural scarring due to 
pulmonary infarction. These features should trigger a thorough assessment of the 
pulmonary arteries for features of chronic thrombo-embolic disease, shown in Figure 
2.5. It should also be appreciated that patients may have overlapping features of 
different forms of pulmonary hypertension. 
Group 5: Conditions such as sarcoidosis, lymphangioleiomyomatosis and Langerhans 
histiocytosis have classical radiological features and haematological conditions may 
also have typical changes on CT, such as expansion of the medullary cortex of bones 
in patients with thalassemia. 
Figure 2.23: Coronal reconstruction of CTPAs from patients with pulmonary hypertension due to 
respiratory disease.  
A – Emphysema, B – idiopathic pulmonary fibrosis (IPF), C – combined pulmonary fibrosis and emphysema 
(CPFE) 
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Table 2.2: Specific imaging features present in each World Health Organization classification of PH 
  1. PAH 2. Left Heart Disease 3. Lung Disease 4. CTEPH 5. Misc 
RHC mPAP: ↑↑  mPAP: ↑ mPAP: ↑       mPAP: ↑↑ mPAP: ↑ or ↑↑ 
 PAWP: ↔ PAWP:↑ PAWP:↔  PAWP:↔ or mild↑ PAWP:↔ 
 CO: ↔, ↓ or ↓↓   CO: ↔ or ↓ CO: ↔ or ↓ CO: ↔, ↓ or ↓↓   CO: ↔, ↓, ↓↓ or ↑ 
  RA: ↔ or ↑ RA: ↑ or ↑↑ RA: ↔ or ↑ RA: ↔ or ↑ RA: ↔, ↑ or ↑↑ 
CT PA: ↑ or ↑↑ PA: ↔ or ↑ PA: ↑ or ↑↑ PA: ↑ or ↑↑ PA: ↑ or ↑↑ 
 RV: ↑ or ↑↑ RV: ↔ or ↑ RV: ↑ or ↑↑ RV: ↑ or ↑↑ RV: ↑ or ↑↑ 
 LV and LA:↓↓  LA:↑↑     
 Flattened IVS  Parenchymal lung disease Chronic emboli: webs, CT evidence of disease  
 Centrilobular nodules  Pleural or pericardial effusions      e.g. Emphysema or fibrosis  stenoses, mural thrombus              e.g. sarcoidosis 
 Neovascularity   Mosaic perfusion  
CMRI PA: ↑ or ↑↑ PA: ↔ or ↑ PA: ↑ or ↑↑ PA: ↑ or ↑↑ PA: ↑ or ↑↑ 
 RV: ↑ or ↑↑ RV: ↔ or ↑ RV: ↑ or ↑↑ RV: ↑ or ↑↑ RV: ↑ or ↑↑ 
 LV and LA:↓↓  LV: ↔ or ↑, LA:↑↑     
 Flattened IVS Septum only flattened in Cpc-PH Flattened IVS  
  Pleural/Pericardial Effusions   Chronic emboli on MRA   
V/Q SPECT No segmental defects            No segmental defects            No segmental defects            Segmental perfusion defects No segmental defects            
  Renal uptake in R-L shunt   Abnormal due to lung disease     
PAH: Pulmonary arterial hypertension, CTEPH: Chronic thrombo-embolic pulmonary hypertension, mPAP: Mean pulmonary arterial pressure, PAWP: Pulmonary arterial wedge pressure, 
CO: Cardiac output, RA: Right atrium, LV: Left ventricle, LA: Left atrium, IVS: Interventricular septal angle, MRA: Magnetic resonance angiography, V/Q SPECT: ventilation/perfusion 
single photon emission computed tomography.  
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 Prognostic evaluation of patients with pulmonary hypertension 
The assessment of prognosis is important when counselling patients and planning 
treatment, in particular when considering interventions such as initiation of 
parenteral prostanoid therapy and triggering referral for transplantation.  This 
assessment is usually based on an assessment of clinical status, exercise capacity and 
right ventricular function. Increasingly imaging has been used to aid assessment of 
ventricular function and aid the classification of PH, which also influences prognosis. 
An important question surrounds the benefit of increasingly complex tests in the 
prognostic assessment of PH.  
Helpful prognostic information can be gained from a simple assessment of the clinical 
status of the patient, and World Health Organization (WHO) functional class is a useful 
tool in this regard. A historical study showed that patients with WHO functional class 
IV had median survival of 6 months, class III had a median survival of 2.5 years and 
class I and II had a median survival of 6 years without treatment(2). In the modern 
age, pulmonary vascular therapies have improved median survival in PAH to 4 years 
and 100 days (189,190). Older age, male sex are associated with a worse prognosis 
and the cause of pulmonary hypertension also impacts on outcome. Exercise capacity, 
which was traditionally used as end-point for many of the pivotal drug trials, has also 
been shown to be an important prognostic indicator. (191–196). 
Right ventricular function may be measured in different ways. Traditionally a right 
heart catheter has been used to provide prognostic information on right ventricular 
function, including right atrial pressure, cardiac output/index, stroke volume index 
and mixed venous oxygen saturation. A number of echocardiographic measures have 
prognostic value including, tricuspid annular plane systolic excursion (TAPSE) (197), 
RV Doppler index (198,199), interventricular septal displacement (200) and right 
atrial area index (200).  Serum levels of NT-proBNP are also linked to right ventricular 
dysfunction, and have been shown to have prognostic value in PAH (201). Cardiac MRI 
is also a useful tool in the assessment of prognosis, and Table 2.3 provides the 
evidence for assessment of prognosis using cardiac MRI parameters.  Multiple studies 
have identified that stroke volume, RVEF, LV and RV end diastolic volumes are 
associated with outcome (202,203), particularly when adjusted for age and sex (204). 
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The strength of RVEF as a predictor of outcome in PAH was highlighted in a recently 
published systematic review (205). More recently, a larger study of 576 patients from 
Sheffield showed that right ventricular end systolic volume (indexed for age and sex) 
and pulmonary arterial relative area change were independent predictors of 
mortality, providing added prognostic value to patient age, sex, subgroup diagnosis 
and WHO functional class (124). The presence of a pericardial effusion on 
echocardiography, CT or cardiac MRI is also associated with a poor prognosis (200), 
and other features of cardiac decompensation such as pleural effusions and ascites 
are predictive of a poor outcome.   
A number of parameters have been identified as important for assessing disease 
severity, stability and importance and have produced the “traffic light” approach to 
prognosis in patients with PH, as outlined in Figure 2.24 below. The number of “low 
risk” features has been shown to predict survival in a large cohort of patients (206).  
 
Figure 2.24: Parameters that have been established for the assessment of prognosis, severity and prognosis 
in PAH.  
Reproduced with permission from Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS 
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and 
Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory 
Society (ERS): Endor. Eur Heart J. 2016 Jan 1;37(1):67–119 (1).  
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Table 2.3: Cardiopulmonary MRI predictors of outcome in PH 
RVEF: right ventricular ejection fraction, RVESVI: right ventricular end systolic volume index, LVEDVI: left 
ventricular end diastolic volume index, LVESVI: left ventricular end systolic volume index, SVI: stroke volume index, 
RAC: relative area change, VMI: ventricular mass index, RVIP-LGE: right ventricular insertion point late gadolinium 
enhancement, FWHM: full width half maximum, PTT: pulmonary transit time, RV: right ventricle, * p <0.05, ** p 
<0.001 
 
The challenge facing clinicians is how to incorporate large amounts of data from 
various imaging modalities and how best to integrate these with other data from the 
clinic to aid treatment decisions in a way that is meaningful and beneficial to patients 
and is cost effective. The lack of a current consensus reflects a paucity of head-to-head 
comparisons of different prognostic approaches and the recent emergence of new 
tools such as MRI. 
Author Number of 
patients 
Follow up CMR 
metric 
Hazard 
Ratio (confidence interval)  
 
Van de 
Veerdonk 
(130)  
 
110 PAH 1 year Baseline 
RVEF  
0.938 (0.902–0.975)** 
One year ΔRVEF 0.929 (0.875–0.985)* 
RVESVI (ml/m2) 
 
1.014 (1.001-1.027)* 
LVEDVI (ml/m2) 0.962 (0.931–0.994)** 
LVESVI (ml/m2) 0.942 (0.888-0.998)* 
Van Wolferen 
(129) 
 
64 IPAH 1 year SVI (Phase contrast at 
pulmonary artery) (ml/m2) 
0.32 (0.13-0.84)* 
LVEDVI (ml/m2) 0.31 (0.13-0.81)* 
RVEDVI (ml/m2) 4.2 (1.31-8.30).* 
Gan (207) 70 4 years RAC (%) right main PA 0.87(0.76-0.96)** 
Swift (208) 134 20 months RAC (%) main PA 0.85 (0.74-0.98)* 
Hagger (209) 40 PAH-SSc  VMI N/A – Kaplan Meier analysis 
Rajaram (210) 81  RVEDV 
 
1.02 (1.01-1.03)** 
 
VMI 5.56 (1.50-35.5)* 
Freed (211) 
 
58 10 months RVIP-LGE 10.0 (1.3 to 77.1)* 
Swift (212) 79 2 years FWHM lung perfusion MRI 
 
1.08 (1.01 to 1.16)* 
 
PTT 
 
1.10 (1.03 to 1.18)* 
Dawes (213) 256 4 years 3D RV motion 2.75 (1.73 to 4.35)** 
Swift (124) 576 30 months RVESVI (%pred) 1.217 (1.06 to 1.54)**      
RAC 0.76 (0.623 to 0.93)** 
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One area of growing interest is in modelling methods to streamline the decision 
making pathway, with the increasing implementation of automated methodologies 
(214–216). There is interest in the use of empirical linear regression models 
(125,217) and more physiologically linked models, such as the Windkessel model 
(218,219), which are likely to aid the diagnosis of pulmonary hypertension and refine 
assessment of progression or response to therapy. As computing processing power 
and research datasets increase, it is likely that we will see machine learning 
approaches, either from large volumes of prior measurements (220) or directly from 
images themselves (213). There is great interest in precision medicine and tailored 
drug therapy (221), the integration of imaging metrics and the study of “omics” are 
likely to be driving factors (222).  
 
 Follow-up of patients with pulmonary hypertension 
Currently, several parameters are used to assess patients, including WHO functional 
class (195), exercise tests (223–225) and widely available blood test such as N-
terminal BNP (226,227). There has been some concern regarding the ability of the 
6MWT to reflect changes in pulmonary vascular status and this has led to a drive to 
explore other markers that are more likely to be sensitive to change. Consequently, 
there has been a lot of recent interest in cardiac MRI as a highly reproducible, non-
invasive, non-ionizing tool to assess right ventricular function. Van de Veerdonk and 
colleagues, showed that cardiac MRI is sensitive to change, with right ventricular 
volume changes preceding clinical deterioration in apparently clinically stable 
patients with idiopathic pulmonary arterial hypertension (228). The same group also 
showed that changes in stroke volume were a marker of clinical improvement in 
patients after 1 year of treatment (202). Furthermore, measures of right ventricular 
function on cardiac MRI have been shown to be highly reproducible (124).  
In SPVDU, a multi-modality approach is used to assess response to treatment based 
on clinical assessment, exercise testing and MRI to assess right ventricular function, 
given its excellent reproducibility and sensitivity to change. Cardio-pulmonary 
vascular MRI is not readily available in all centres, so the choice of follow up modality 
is based on real life local availability of tests. Echocardiography is an alternative for 
follow up, able to objectively quantify right ventricular function using TAPSE, right 
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ventricular tissue Doppler and right ventricular free wall strain, although there are 
concerns regarding the reproducibility of this technique and how it performs as a 
follow-up tool in routine clinical practice (229–231). Recently a study has shown that 
using a simple assessment of symptoms (WHO FC), exercise capacity (6 minute walk 
test distance) and BNP at follow-up, could be used to risk stratify patients, with no 
additional benefit provided by performing cardiac catheterisation (176), although in 
this study MRI was not evaluated.  
Quality of life has consistently been identified by patients as an important goal of 
therapy, so assessment of follow up should also take into account patient reported 
symptoms, such as emPHAsis-10 (232). This is a 10 point questionnaire that has been 
shown to be sensitive to changes in clinical parameters such as WHO functional class.  
In summary, a number of approaches are used in the follow-up of patients that should 
include a measurement of symptoms, exercise capacity, right ventricular function and 
also patient reported outcome measures such as emPHAsis-10.  
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2.9 THE CHOICE OF IMAGING MODALITY 
As outlined above, there a number of imaging modalities available for the 
investigation of patients with pulmonary hypertension. Each of these investigations 
has their pros and cons and the choice of the correct modality can be challenging. 
The chest radiograph is widely available and easily interpreted by many practitioners. 
It is however limited by low sensitivity and specificity for pulmonary hypertension 
but can often be useful in the assessment of underlying lung disease.  
Echocardiography has the advantage of being cheap and readily available and 
provides useful information regarding pulmonary arterial pressures and is therefore 
a useful tool to screen patients for the presence of PH.  
Computed Tomography can give useful information regarding the pulmonary artery 
and the right ventricle along with parenchymal lung disease as outlined above. It is 
easily performed in centres across the world and is therefore a useful test in the 
identification of patient with PH. It is also useful in the assessment of surgical options 
in patients with CTEPH. Whilst MRI also provides useful structural and functional 
information, it is currently limited to specialist centres due to limited availability and 
expertise. 
 
 
Figure 2.25: Diagnostic algorithm for 
PH recommended by the ERS/ESC 
guidelines.  
Reproduced with permission from Galiè 
N, Humbert M, Vachiery J-L, Gibbs S, 
Lang I, Torbicki A, et al. 2015 ESC/ERS 
Guidelines for the diagnosis and 
treatment of pulmonary hypertension: 
The Joint Task Force for the Diagnosis 
and Treatment of Pulmonary 
Hypertension of the European Society 
of Cardiology (ESC) and the European 
Respiratory Society (ERS): Endor. Eur 
Heart J. 2016 Jan 1;37(1):67–119 (1). 
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3 RESEARCH QUESTIONS, AIMS AND METHODOLOGY 
 
Whilst cardiac MRI is considered the gold standard for the assessment of left  
ventricular function (233), there remains heavy reliance upon invasive measures of 
pressure for the diagnosis, phenotyping and prognostic assessment of pulmonary 
hypertension (1). The overall aim of this PhD thesis is to evaluate the role of cardiac 
MRI in the non-invasive investigation of pulmonary hypertension, ultimately aiming 
to reduce the requirement for right heart catheterisation. The assessment of patients 
with suspected PH can be split into three distinct themes, as outlined in the previous 
chapter: diagnosis, phenotyping and risk assessment, which follows the pathway of 
clinical decision making in patients with suspected pulmonary hypertension. The 
structure of chapters in this thesis follow these key themes and allocated as below:   
 
Figure 3.1: The clinical decision pathway in suspected pulmonary hypertension.  
 
3.1 HYPOTHESES 
1. Quantifiable cardiac MRI metrics can be used to assess pulmonary arterial 
pressure and therefore identify patients with pulmonary hypertension. 
2. Dynamic contrast enhanced pulmonary perfusion MRI (DCE-MRI) can be used 
to screen for patients with CTEPH in patients with unexplained PH.  
3. Cardio-pulmonary vascular MRI can be used to phenotype patients with 
pulmonary hypertension due to left heart disease. 
4. Cardio-pulmonary vascular MRI is a useful tool for the assessment of prognosis 
in patients with PH due to respiratory disease, and PH due to left heart disease. 
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3.2 AIMS 
 Diagnosis (Chapter 4) 
The first aim of this body of work is to improve the non-invasive assessment of mean 
pulmonary arterial pressure using cardio-pulmonary vascular MRI, and assess its role 
in the diagnosis of pulmonary hypertension. This is clearly key to the initiation of 
treatment. Improvements in non-invasive methodologies have the potential to reduce 
the burden of late diagnosis in pulmonary hypertension. 
 Phenotyping (Chapter 5) 
The second aim of this PhD is to improve the non-invasive phenotyping of pulmonary 
hypertension patients using cardiac MRI. The correct identification of the WHO group 
of pulmonary hypertension is essential to initiate the correct therapy for each patient.   
The key patients to identify are those who have “pre-capillary” pulmonary arterial 
remodelling. In current clinical practise, this patient group mainly comprises patients 
with group 1: pulmonary arterial hypertension. There is, however, increasing 
evidence that patients with other forms of PH also have a degree of pre-capillary 
pulmonary vascular remodelling, in a model that is similar to that seen in PAH. Whilst 
treatment with pulmonary vasodilators is currently only recommended in patients 
with PAH and non-surgical CTEPH, there is significant interest in the potential for 
pulmonary vascular therapy in specific patients with PH due to left heart disease and 
lung disease. 
Figure 3.2: Multiple causes of PH share pre-capillary pulmonary vascular remodelling. 
Chapter 5 explores the role of MRI in the identification of each of these causes of PH.  
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 Prognostic Assessment (Chapter 6) 
The third aim of this PhD thesis is to identify the role of cardiac MRI in the prognostic 
evaluation of patients with pulmonary hypertension. The role of cardio-pulmonary 
vascular MRI in the risk assessment of patients with idiopathic pulmonary arterial 
hypertension has been examined in previous work from Sheffield (124) and other 
centres (124,129,130,207–213).  
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3.3 MATERIALS & METHODS 
This chapter describes the methods that are used throughout this thesis. In order to 
allow for chapters to be read in isolation, the relevant methods are repeated in the 
chapter specific methods section. The data that is analysed in this thesis was acquired 
as part of the routine clinical pathway of patients in the Sheffield Pulmonary vascular 
disease unit. The MRI and clinical metrics were all measured at the time of the scan 
by the clinical team. I collected all of the relevant databases and joined them together, 
analysed the data and wrote all of the text for this thesis. 
 The ASPIRE PH MRI Sub-Database 
Sheffield is one of seven UK tertiary referral centres for adult pulmonary 
hypertension. In 2016, there were 1,675 active patients at the Sheffield Pulmonary 
Vascular Disease Unit (SPVDU), representing 24% of 7,035 active patients in the 
United Kingdom (234).  
All patients who underwent cardiac MRI at the Sheffield Pulmonary Vascular Disease 
Unit from April 2012 to October 2017 were entered into an anonymised database. 
Each patient was given a unique identifier, with a document linking the patient to the 
identifier stored on a password protected departmental computer.  
All patient data was downloaded from the clinical database (Infoflex). Matlab 
scripting was used to create a table of each investigation for each patient. These were 
then joined to create database of the incident cardiac MRI data with closest right heart 
catheter, exercise test, pulmonary function test data allowing with diagnostic, 
demographic and treatment data. A similar methodology was implemented to identify 
the scan closest to 1-year follow up.  
Ethical approval was granted from a local ethics committee for this retrospective 
study, written consent was waived (ref c06/Q2308/8).  
3.3.1.1 Inclusion and Exclusion Criteria 
All patients studied in this thesis were referred to the Sheffield Pulmonary Vascular 
Disease Unit with suspected pulmonary hypertension. In order to be included, the 
patients were required to have had both MRI and right heart catheter. Any MRI that 
was not of diagnostic quality was excluded from analysis. Study specific inclusion and 
exclusion criteria will be explained, as relevant, in each chapter.  
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3.3.1.2 Incident Cases 
The ASPIRE MRI sub-registry contains 2437 MRI scans for patients with suspected or 
confirmed pulmonary hypertension. Within this database, there are 1272 incident 
cases with suspected pulmonary hypertension, of which 957 (75%) had RHC and MRI 
within 14 days. 
 
 
Figure 3.3: Flow chart demonstrating the split of incident cases within the ASPIRE MRI sub-registry 
 
 
There was no difference in survival (log rank chi-squared = 2.8, p=0.097) or in length 
of follow up (p=0.661) between the cases who were included and those who were 
excluded due to the catheter being more than 2 weeks from the MRI.  
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Table 3.1: Baseline demographics of the incident patients within the MRI ASPIRE sub-registry, mean with standard 
deviation 
 All patients Not PH 1: PAH 2: PH-LHD 3: PH-Resp 4: CTEPH 5: PH Multi 
Number 957 146 347 134 88 213 24 
Age (years) 65 (13) 60 (16) 62 (14) 72 (8) 67 (10) 66 (12) 66 (10) 
Sex (F/M) 591/366 105/41 242/105 88/46 42/46 98/116 13/11 
WHO 
functional 
class 
(I,II,III,IV) 
3,106,740,8
7 
1,52,78,3 0,10,289,44 1,14,113,6 0,8,61,19 1,22,175,14 0,0,22,1 
ISWT (m) 207 (182) 293 (222) 189 (173) 145 (116) 143 (109) 248 (199) 164 (147) 
mPAP 
(mmHg) 
41.0 (14.6) 19.7 (3.1) 47.2 (13.0) 40.0 (10.0) 40.0 (10.8) 45.8 (12.2) 46.5 (11.1) 
mRAP 
(mmHg) 
10.4 (5.8) 5.8 (3.3) 10.9 (6.2) 14.6 (5.3) 9.4 (4.5) 10.6 (5.0) 10.2 (5.7) 
PAWP 
(mmHg) 
13.3 (5.8) 10.5 (3.6) 11.6 (4.0) 22.6 (5.7) 12.7 (4.2) 12.2 (3.7) 12.7 (3.8) 
CI 2.7 (2.6) 3.1 (0.9) 2.6 (0.8) 2.7 (0.7) 2.8 (0.8) 2.4 (0.7) 2.8 (1.0) 
PVRI 
(dyne.s/cm
5) 
294 (242) 80 (43) 415 (268) 169 (131) 256 (145) 342 (221) 369 (214) 
SvO2 (%) 64.9 (9.0) 71.5 (7.4) 63.7 (9.6) 65.2 (9.0) 66.1 (6.9) 61.9 (7.6) 63.7 (8.5) 
FEV1 (% 
predicted) 
0.78 (0.23) 0.88 (0.22) 0.77 (0.23) 0.72 (0.19) 0.62 (0.27) 0.84 (0.21) 0.68 (0.20) 
FVC (% 
predicted) 
0.80 (0.23) 0.83 (0.19) 0.77 (0.22) 0.71 (0.16) 0.74 (0.29) 0.91 (0.22) 0.71 (0.24) 
FEV1/FVC 0.69 (0.12) 0.73 (0.11) 0.70 (0.12) 0.68 (0.10) 0.61 (0.18) 0.67 (0.1) 0.68 (0.14) 
TLCO 3.71 (2.04) 5.0 (1.7) 3.0 (2.0) 3.7 (1.3) 2.2 (1.0) 4.7 (1.9) 2.3 (0.9) 
Days 
between 
RHC & MR 
0 (2) 0 (2) 1 (2) 1 (2) 0 (1) 0 (1) 1 (3) 
WHO: World Health Organisation, RHC: right heart catheter, mPAP: right heart catheter measured mean 
pulmonary artery pressure, mRAP: mean right atrial pressure, PAWP: pulmonary artery wedge pressure, CI: cardiac 
index, PVRI: pulmonary vascular resistance index, SvO2: mixed venous oxygen saturation, FEV1: Forced expiratory 
volume in 1 second, FVC: Forced vital capacity, TLCO:  transfer for carbon monoxide, 4 cases had no diagnosis of PH 
group. 
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 Standard Cardiac and Pulmonary Vascular MRI Protocol 
3.3.2.1 MRI Sequences 
MRI was performed as part of the routine clinical care on a GE HDx 1.5-T whole body 
scanner (GE Healthcare, Milwaukee, Wisconsin), using an 8-channel cardiac coil, with 
the patient supine.  
Table 3.2: Standard MRI sequences used in the Sheffield Academic Radiology Department for patients in the 
Sheffield Pulmonary Vascular Disease Unit. 
Cardiac Cine Black Blood Q Flow +/-   
 4 Chamber  Pulmonary artery  Pulmonary Artery Contrast enhancement 
 Short axis    Aorta  Pulmonary Perfusion 
 LIFOF      Pulmonary Angiography 
 LVLA      Late Gadolinium 
 RIFOF                      Enhancement 
  RVOT             
LIFOF: Left ventricle inflow outflow, LVLA: Left ventricle long axis, RIFOF: right ventricle inflow outflow, RVOT: 
Right ventricle outflow tract. 
 
3.3.2.1.1 FIESTA (Fast Imaging Employing Steady State Acquisition) 
Proton anatomical imaging was performed as a coronal stack of 2D bSSFP images in 
inspiration with a single breath hold of 12 seconds. The following parameters were 
used: TR 2.8 ms, TE 0.79ms, flip angle 50°, FOV 48 x 43 cm, 256 x 256 Matrix, 125 kHz 
bandwidth and slice thickness 10mm. 
 
Figure 3.4: coronal and axial FIESTA images from a patient with CTEPH.  
Note the change in signal in the right main pulmonary artery due to mural thrombus.  
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3.3.2.1.2 Cardiac Cine 
4 chamber, short axis, left ventricle long axis (LVLA), left ventricle inflow outflow 
(LIFOF), right ventricle inflow outflow (RIFOF) and right ventricle outflow tract 
(RVOT) cardiac cine imaging was acquired using a retrospectively cardiac gated 
multi-slice steady-state free precession (SSFP) sequence (FIESTA).  
A stack of axial images in the short axis (SA) plane with slice thickness of 8 mm with 
a 2 mm inter-slice gap or 10 mm with no inter-slice gap were acquired, covering both 
ventricles from base to apex. The SSFP sequence parameters were: TR 2.8 ms, TE 
1.0ms, flip angle 50°, field of view 48x43.2, 256x256 matrix, 125 kHz bandwidth, and 
slice thickness 8 to 10 mm. 
 
Figure 3.5: Cardiac MRI SSFP cine views.  
LIFOF: left ventricle inflow outflow, LVLA: left ventricle long axis, RIFOF: right ventricle inflow outflow, RVOT: right 
ventricle outflow tract  
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3.3.2.1.3 Black Blood Imaging 
Axial black blood imaging of the pulmonary arteries was performed using a double 
inversion recovery fast spin echo sequence (DIR-FSE), with a stack of 8mm slices with 
10mm spacing taken through the long axis plane of the pulmonary artery acquired 
using an 8 channel cardiac coil during a breath-hold. There is a 180˚ non-selective 
inversion pulse, immediately followed by a slice-selective 180˚ de-inversion pulse. 
The TI is then calculated based on the R-R interval on the ECG, it is 650ms at 60bpm. 
The other sequence parameters were: TR around 1000ms (dependent upon R-R 
interval), TE 40ms, FSE flip angle 90˚, echo train length 32 with approximately 2.5ms 
between echoes, field of view 4cm, 256x256 matrix, 31.2 kHz bandwidth, ASSET 
parallel imaging factor 2.  
  
Figure 3.6: Black blood imaging.  
Due to flow there is no signal returned from the pulmonary artery or aorta in health. 
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3.3.2.1.4 Phase Contrast Flow Sensitized Imaging 
Phase contrast imaging was performed perpendicular to the pulmonary trunk and 
ascending aorta. The phase contrast imaging was performed using a 2D gradient echo 
sequence, the imaging parameters were: TR 5.6 ms, TE 2.7 ms, slice thickness 10 mm, 
FOV 48x28.8, bandwidth 62.5 kHz, matrix 256x128 and velocity encoding (Venc) 150 
cm/s. The images were retrospectively ECG gated with 40 phases.  
 
 
Figure 3.7: Phase contrast imaging of the pulmonary artery. Magnitude (left) and flow (right) images of the PA. 
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3.3.2.1.5 Dynamic Contrast Enhanced MRI and MR Angiography 
Dynamic contrast enhanced MRI and MRA was undertaken when there was a clinical 
suspicion of CTEPH. DCE-MRI was performed using a contrast injection of a 0.05ml 
per kg patient weight dose of Gd-BT-D30A (Gadovist, Schering, Berlin, Germany) was 
injected at a rate of 4 ml per second with the injection rate controlled using an 
activated pump injector (Spectris, MedRad, Warrendale, Pennsylvania) typically via a 
vein in the antecubital fossa using an 18G cannula, followed by a 20ml saline flush. 
Subsequently serial 3D gradient echo images of the chest were acquired. The 
sequence parameters were: TE=1.1 ms, TR=2.5 ms, Flip angle 30°, FOV 48 cm x 48 cm, 
parallel imaging in plane x 2, in plane resolution 200x80, bandwidth 250 kHz, slice 
thickness 10 mm, approximately 32 slices, 48 time points with an overall effective 3D 
frame rate of ~ 0.5 s. Images were acquired in a coronal orientation.  
 
Figure 3.8: Contrast enhanced MRA and dynamic contrast enhanced MRI. 
Note the wedge shaped perfusion defect in the DCE perfusion imaging in this patient with chronic pulmonary 
emboli. 
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3.3.2.2 Image Analysis 
MR images were analysed manually analysed by DC (a cardiac MRI radiographer of 9 
years cardiac MRI experience) on a GE Advantage Workstation 4.4 using GE 
Advantage Workstation ReportCard software, blinded to all clinical information and 
other investigations. The MRI was considered non-diagnostic if the volumetric 
analysis could not be adequately performed. Reproducibility metrics for these cardiac 
MRI metrics in our centre have been previously published (124). Where appropriate, 
these metrics were indexed to body surface area. In the future, increasingly 
automated methods for the segmentation of cardiac contours are likely to be 
implemented (235). 
3.3.2.2.1 Biventricular Volumes 
The endocardial surfaces of the left and right ventricles were traced on the short axis 
images to give the left and right ventricular end-diastolic volume, end-systolic 
volumes. The smallest volume was considered end systole and the largest end-
diastole. Right and left ventricular stroke volume and mass were calculated as the 
difference of end diastolic and end systolic volume. Right and left ventricular ejection 
fraction were calculated as 𝑅𝑉𝐸𝐹 =  
𝑅𝑉𝐸𝐷𝑉−𝑅𝑉𝐸𝑆𝑉
𝑅𝑉𝐸𝐷𝑉
.  
 
Figure 3.9: The endocardial contour on short axis images.  
The right ventricle is the chamber on the left, and in this patient with IPAH is markedly dilated.   
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3.3.2.2.2 Ventricular Mass 
On the short axis images, the endocardial and epicardial contours were traced for the 
left and right ventricles. The interventricular septum was considered part of the left 
ventricle. The myocardial volume was calculated as the sum of the myocardial area 
multiplied by slice thickness. When multiplied by the assumed myocardial density 
(1.05g/cm3) this gave the myocardial mass. Ventricular mass index was calculated as 
RV mass divided by LV mass (133).  
3.3.2.2.3 Interventricular Septal Angle 
The interventricular septal angle was measured as the angle formed between the 
insertion points of the ventricles to the mid-point of the septum, measured on a mid-
chamber slice at end-systole (125,134,236). Page 123 shows this has a high 
reproducibility. 
Figure 3.10: Ventricular Mass.  
The ventricular mass of the left and right ventricle can be calculated as the difference between the 
endocardial and epicardial contours. This is often expressed as ventricular mass index (VMI), the ratio of 
right to left ventricular mass, elevated in this case with IPAH.   
 
Figure 3.11: Measurement of the 
interventricular septal angle.  
The measurement is taken from the short 
axis SSFP cardiac cine, from a mid-
chamber slice. The angle between the RV 
insertion point and the mid septum is 
quantified. The patient on the left has a 
normal septal angle and the patient on 
the right has a flattened septum.  
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3.3.2.2.4 Pulmonary Arterial Area  
On the magnitude phase contrast images of the pulmonary artery, the maximal and 
minimal PA areas were manually traced. Pulmonary artery relative area change was 
defined by the following equation: 𝑃𝐴 𝑅𝐴𝐶 =  
𝑀𝑎𝑥 𝑃𝐴 𝑎𝑟𝑒𝑎−𝑀𝑖𝑛 𝑃𝐴 𝑎𝑟𝑒𝑎
𝑀𝑖𝑛 𝑃𝐴 𝑎𝑟𝑒𝑎
 (208). It is also 
possible to perform this measurement on ECG gated CT (112). 
 
3.3.2.2.5 Black Blood Flow Artefact 
From the dual inversion recovery fast spin echo pulmonary arterial black blood 
images, black blood slow flow artefact was scored. A semi-quantitative scale from 0 
to 5 was used (0 = absent, 1 = segmental, 2 = lobar, 3 = distal main, 4 = proximal main 
and 5 = trunk) (135).  
Figure 3.12: Images from 
the magnitude images of 
phase contrast imaging  
The images are taken 
perpendicular to the main 
pulmonary artery. The left 
image is taken at minimum 
PA size, the right is taken at 
maximum PA size.  
Figure 3.13: Scoring of black blood slow flow artefact.  
Adapted by permission from European Springer European Radiology, Black blood MRI has diagnostic and 
prognostic value in the assessment of patients with pulmonary hypertension, Swift et al, copyright 2012. 
Dr CS Johns  Cardio-Pulmonary MRI in PH   87 
3.3.2.2.6 Left Atrial Volume 
Left atrial volume was calculated using the bi-plane area length method, using the 
LVLA and 4-chamber cardiac cine. 𝐿𝐴 𝑣𝑜𝑙𝑢𝑚𝑒 =  
(0.85×𝐴1×𝐴2)
𝐿1×𝐿2 2⁄
 where A1 is the area on 
the 4Ch, L1 is length on the 4 chamber, A2 is the area on LVLA and L2 is length on 
LVLA (237). Thresholds of ≥41ml/m2 and ≥43ml/m2 have been proposed for the 
diagnosis of PH-left heart disease (238,239). 
3.3.2.2.7 Phase Contrast Flow Imaging 
The contours of the vessel were automatically traced, with manual correction when 
required. The software then calculated the velocity of all the pixels included within 
the region of interest (ROI). Pulmonary artery average velocity was calculated as 
QFlow forward PA velocity/diastolic PA size.  
Figure 3.14: Calculation of left atrial volume using the bi-plane area length method.  
Area (dotted outline) and length (arrows) derived from the four chamber and left ventricle long axis views. 
Figure 3.15: Phase contrast imaging of the pulmonary artery.  
A: the magnitude image, B- The phase contrast image, C: the flow time curve derived from the Q-flow data. 
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3.3.2.2.8 Dynamic Contrast Enhanced MRI Transit Times 
Signal enhancement time curves were generated from the dynamic contrast enhanced 
MRI images, for a region of interest within the pulmonary artery and the left atrium. 
Figure 3.16 shows the typical time signal curves for a healthy volunteer. The 
pulmonary transit time (PTT) was calculated as the time delay from peak signal in the 
pulmonary artery and peak signal in the left atrium. The full-width-half-maximum 
(FWHM) of the contrast bolus passage was calculated as the time between half the 
maximum signal intensity on the up and down-slopes of the pulmonary artery time-
enhancement curve as previously described (212)(240).  
 
 
 
  
Figure 3.16: Signal-time curves for dynamic contrast enhanced imaging. 
The black line shows the contrast enhancement curve of the pulmonary artery and the grey line the left 
atrium in a healthy volunteer. The calculations of PTT and FWHM are shown.  
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 Single Photon Emission Computed Tomography 
Single photon emission computed tomography (SPECT) imaging was performed on a 
General Electric Infinia SPECT system using a low energy general-purpose collimator. 
100MBq 99mTc MAA was administered through a direct intravenous injection with a 
needle of 21G or larger. The image acquisition parameters were: acquisition matrix 
128x128, 60 projections per detector and 7 seconds per projection. Images were 
acquired prone, and where possible, with the patient’s arms extended above their 
heads.  
 
 Computed Tomography 
In the chapter assessing phenotypes of pulmonary hypertension due to lung disease, 
the CTPA was analysed to confirm the underlying cause of pulmonary hypertension. 
This was used to classify the patients as chronic obstructive lung disease (COPD), 
interstitial lung disease (ILD) or combined fibrosis and emphysema syndrome 
(CPFE).  
When performed at the local centre, CTPA images were acquired on a 64-slice MDCT 
(Light-Speed General Electric Medical) during a single breath-hold. Typical 
acquisition parameters were: 100 mA with automated dose reduction, 120 kV, pitch 
of 1, rotation time 0.5 s and 0.625-mm collimation, field of view = 400×400 mm, 
acquisition matrix 512× 512. 100 mL of intravenous contrast agent (Ultravist 300; 
Bayer Schering, Berlin, Germany) was administered at a rate of 5 mL/s, typically 
through an 18G cannula in the antecubital fossa. CT images from other centres were 
also used when no local imaging was available, as long as they were considered to be 
of diagnostic quality.  
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 Statistical Analysis 
Statistical analysis was performed using SPSS version 22 (IBM, Chicago) and figures 
were created using GraphPad Prism (GraphPad Software, San Diego). When required 
mathematical scripting was performed using Matlab R2017a (MathWorks, MA). A p 
value of <0.05 was considered statistically significant, except when multiple 
hypotheses were tested in which case Bonferroni correction was applied to reduce 
the risk of type 1 error. The following sections detail the main statistical 
methodologies used in this thesis.  
3.3.5.1 Group comparisons 
Comparison of metrics between groups was performed using independent t-test for 
continuous data and chi-squared test for categorical data. When multiple groups were 
analysed, ANOVA testing with Bonferroni correction was used.  
3.3.5.2 Relationship between MRI and RHC metrics 
Correlations between continuous data were calculated using Person’s correlation 
coefficient and for discrete data, Spearman’s rank was used.  
3.3.5.3 Linear Regression Fitting 
To calculate predictive non-invasive equations for right heart catheter 
measurements, multivariable linear regression curve fitting was used. This uses 
multiple independent variables (MRI metrics) to predict a single dependent variable 
(RHC measured mPAP). A least squares approach was used, which builds a model 
which serially reduces the sum of the squares of the residuals with each new equation 
produced. The analysis was performed using SPSS in a forward direction. Any metrics 
that significantly correlated with mPAP at univariate analysis after Bonferroni 
correction were entered into the linear regression analysis. As the linear regression 
modelling requires/infers a linear relationship, a scatter plot between all 
independent metrics and mPAP was examined to ensure linearity and where 
appropriate the log10 was taken for inclusion in the regression analysis. 
3.3.5.4 Diagnostic performance 
Diagnostic performance was assessed using receiver operator characteristics (ROC) 
curve analysis. ROC curve analysis was first developed during World War 2 to analyse 
radar signals after the attack on Pearl Harbour, but has now been widely adopted in 
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medicine as a method to assess the diagnostic accuracy of a test. The curve is created 
by plotting the sensitivity (true positive rate) against 1-specificity (false positive rate) 
at each value of the variable that is being examined, as a predictor of a dichotomous 
outcome/diagnosis. A metric that does not predict the outcome will have a straight 
line at 45˚ from 0 to 1 (ie. at each threshold true positive rate = false positive rate, so 
it is not discriminatory). A perfect test will have a single point at X=0 and Y=1. 
Diagnostic accuracy is often quantified by the area under the ROC curve.  
 
When a threshold was derived this was first derived from the Youden index of the 
ROC curve in a derivation cohort (Youden’s J = sensitivity + specificity - 1) unless 
otherwise specified. An example of the Youden index is shown in Figure 3.18. This 
was then tested in a separate validation cohort.   
 
Sensitivity, specificity, negative and positive predictive values were calculated from a 
2x2 contingency table and Fisher’s exact test was used to determine the statistical 
significance.    
Figure 3.18: ROC curve showing the Youden index. 
An example of ROC analysis, the red cross shows the point 
which balances the sensitivity and specificity (as per 
Youden’s index). 
Figure 3.17: An example of a ROC curves. 
This diagram gives an example of a non-diagnostic test, a 
reasonably diagnostic test and a perfect test. 
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3.3.5.5 Prognosis 
For prognosis, the interval between the MRI or right heart catheter to all cause of 
death or census was considered the follow up period. Cox proportional hazards 
regressions analysis was used to generate hazard ratios for death for demographic, 
MRI and right heart catheter data. In order to account for the scale of the variable, all 
metrics were first standardised to the z score for the population studied, 𝑧 =
𝑥−𝜇
𝜎
, 
where µ is the mean for the population and σ is the standard deviation of the 
population.  
Kaplan-Meier plots were generated using published thresholds, where available. 
Where no threshold was available, patients were dichotomised by the median value. 
Log rank χ2 was calculated for the Kaplan Meier data. ROC curve analysis was also 
performed for the prediction at death at a time point that balanced patient numbers 
and number of deaths. 
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4 CARDIAC MRI CAN DIAGNOSE PULMONARY HYPERTENSION 
The first step in the management of patients with suspected pulmonary hypertension 
is to identify the presence of a raised pulmonary arterial pressure (mPAP ≥25mmHg). 
The first body of original research in this thesis centres on improving the non-invasive 
diagnosis of pulmonary hypertension using magnetic resonance imagingii.  
4.1 RATIONALE 
Pulmonary hypertension (PH) is a condition with a poor morbidity and mortality. It 
has a varied aetiology, but is defined invasively at right heart catheterisation by a 
mean pulmonary artery pressure (mPAP) ≥25mmHg at rest (1). Right heart 
catheterisation is the gold standard for the diagnosis of pulmonary hypertension, 
although this is an invasive test with 1% serious complication rate (8).  
Current guidelines recommend echocardiography to screen patients with suspected 
pulmonary hypertension: using an assessment of the risk of the presence of PH, as 
either low, medium or high (1). Doppler echocardiographic measurement of systolic 
pulmonary arterial pressure requires an estimation of right atrial pressure, and the 
current estimation from IVC size doesn’t accurately predict the true right atrial 
pressure on right heart catheterization (81). Assessment of pulmonary arterial 
pressures on echocardiography also requires the patient to have tricuspid 
regurgitation. Whilst commonly seen in pulmonary hypertension it is not always 
present, and severe tricuspid regurgitation causes erroneously low or high 
echocardiographic predictions of mean pulmonary arterial pressures (241). As such, 
estimation of pulmonary arterial pressures shows only moderate agreement with 
right heart catheter measured mean pulmonary arterial pressure (242), with 95% 
limits of agreement on Bland Altman analysis ranging from +38.8 to -40.0 mm Hg (81). 
A large meta-analysis showed only modest diagnostic accuracy for the presence of 
pulmonary hypertension with sensitivity and specificity of 83% and 72% respectively 
(243). Furthermore, echocardiography is not possible in the context of severe lung 
                                                        
ii The work presented in this chapter has been submitted to Radiology and is currently under review.  
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disease, due to loss of acoustic windows, and when it is measurable it is often 
erroneous (244).  
A number of cardiac MRI metrics have been identified as predictors of raised 
pulmonary arterial pressures, and a number of models (both empirical and 
physiological), have been proposed. These are summarised in Table 4.6. These 
previously identified markers have been tested in single centres in relatively small 
numbers, and often have modest diagnostic accuracy.  
A specific test to identify raised mean pulmonary arterial pressures in patients with 
suspected pulmonary hypertension would have the potential to reduce the number of 
invasive right heart catheters that are performed and also allow for simultaneous 
assessment of prognosis, such as right ventricular function (124). 
 Hypotheses 
1. Quantifiable cardiac MRI metrics can predict right heart catheter measured 
mean pulmonary arterial pressure in patients with suspected PH. 
2. The prediction of mean pulmonary arterial pressure and diagnostic accuracy 
of cardiac MRI can be improved by using a linear regression modelling. 
 
 Aims 
The aim of this chapter was to derive and assess a new regression model for 
estimation of mPAP using MRI measurements, and assess the diagnostic accuracy of 
this model in a different patient cohort. A secondary outcome was to assess the 
accuracy of previously published MRI based metrics.  
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4.2 MATERIALS AND METHODS 
 Patients 
Consecutive incident patients with suspected pulmonary hypertension who were 
referred to a tertiary PH centre from April 2012 to October 2016 were identified from 
the ASPIRE database (Assessing the Spectrum of Pulmonary hypertension Identified 
at a REferral centre) (245). The first half were used as a derivation cohort and the 
second half were used as a validation cohort. Only incident patients with MRI and RHC 
within 14 days were included. Any patient with a left atrial volume index of ≥41 was 
excluded as this is a potential MRI marker of PH due to left heart disease (PH-LHD) 
(239). The 2015 ESC/ERS guidelines recommend that these patients are not referred 
to tertiary referral centres, unless there are features of severe PH or RV dysfunction. 
Furthermore, as septal angle and VMI are highly correlated with mPAP and previous 
work has used these as a model for mPAP estimation, it was expected that patients 
with left heart disease would potentially require a different model. Ethical approval 
was granted from a local ethics committee for this retrospective study and written 
consent was waived (ref c06/Q2308/8).  
 
 Image Acquisition 
Cardiac MRI was performed on a GE HDx 1.5-T whole body scanner (GE Healthcare, 
Milwaukee, Wisconsin), with the patient supine, using an 8-channel cardiac coil. Four-
chamber (4Ch) and short axis (SA) cine images were acquired using a retrospectively 
cardiac gated multi-slice steady-state free precession (SSFP) sequence, as previously 
published (217). A stack of axial images in the SA plane with slice thickness of 8 mm 
with a 2 mm inter-slice gap or 10 mm with no inter-slice gap were acquired, covering 
both ventricles from base to apex. The SSFP sequence parameters were: TR 2.8 ms, 
TE 1.0ms, flip angle 50°, field of view 48x43.2, 256x256 matrix, 125 kHz bandwidth, 
and slice thickness 8 to 10 mm.  
Phase contrast imaging was performed perpendicular to the pulmonary trunk. The 
phase contrast imaging parameters were: TR 5.6 ms, TE 2.7 ms, slice thickness 10 mm, 
FOV 48x28.8, bandwidth 62.5 kHz, matrix 256x128 and velocity encoding 150 cm/s. 
The images were retrospectively ECG gated with 40 phases.  
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Black blood imaging of the pulmonary arteries was performed using a double 
inversion recovery fast spin echo sequence (DIR-FSE), with a stack of 8mm slices with 
10mm spacing taken through the long axis plane of the pulmonary artery acquired 
using an 8 channel cardiac coil during a breath-hold. There is a 180˚ non-selective 
inversion pulse, immediately followed by a slice-selective 180˚ de-inversion pulse. 
The TI is then calculated based on the R-R interval on the ECG, it is 650ms at 60bpm. 
The other sequence parameters were: TR around 1000ms (dependent upon R-R 
interval), TE 40ms, FSE flip angle 90˚, echo train length 32 with approximately 2.5ms 
between echoes, field of view 4cm, 256x256 matrix, 31.2 kHz bandwidth, ASSET 
parallel imaging factor 2. 
 
 Image Analysis 
MR images were manually analysed by DC (a cardiac MRI radiographer of 9 years 
cardiac MRI experience) on a GE Advantage Workstation 4.4 and GE Advantage 
Workstation ReportCard software, blinded to all clinical information and other 
investigations. Left and right ventricular end-diastolic volume, end-systolic volumes, 
right and left ventricular stroke volume and mass were calculated (all indexed to body 
surface area), right and left ventricular ejection fractions, ventricular mass index (RV 
mass divided by LV mass) (133) and interventricular septal angle were measured as 
previously described (125). Maximal and minimal PA areas were manually traced, 
and relative area change was defined by the following equation: RAC= (maximum 
area-minimum area)/minimum area (208). Pulmonary artery average velocity was 
calculated as QFlow forward PA velocity/diastolic PA size. Reproducibility metrics for 
these cardiac MRI metrics for DC and AJS have been previously published (124). Black 
blood slow flow artefact was scored using a semi-quantitative scale from 0 to 5 (0 = 
absent, 1 = segmental, 2 = lobar, 3 = distal main, 4 = proximal main and 5 = trunk), and 
has been shown to have good inter-observer reproducibility (135). A diagram of the 
key imaging metrics that were measured is shown in Figure 4.1. Multiple previously 
published parametric models, developed for diagnostic assessment of pulmonary 
hypertension, were derived from Cardiac MRI. These are summarised in Table 4.6: 
Previously published models and their diagnostic accuracy..  
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Figure 4.1: Multi-figure showing the MRI metrics used in this chapter. 
A, a diagrammatic representation of the semi-quantitative scoring of black blood slow flow artefact from the 
dual inversion recovery fast spin echo black blood images, and inset an example of a case with a score of 1 
and a score of 4. B, calculation of pulmonary arterial relative area change (PA RAC) from the systolic and 
diastolic steady state free procession (SSFP) images of the pulmonary artery. C, the ventricular mass index 
(VMI), which is the ratio of muscle mass of the right and left ventricular myocardium taken from the 2 
chamber SSFP cardiac cine. And D, the interventricular septal angle, taken from the 2 chamber SSFP images 
at end-systole. Black blood slow flow scoring reprinted with permission from Springer Nature: Black blood 
MRI has diagnostic and prognostic value in the assessment of patients with pulmonary hypertension. Swift, 
A.J., Rajaram, S., Marshall, H. et al. Eur Radiol (2012) (135). 
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 Right Heart Catheterisation 
Right heart catheterisation was performed using a balloon tipped 7.5Fr 
thermodilution catheter (Becton-Dickinson, Franklin Lakes, New Jersey). Pulmonary 
hypertension was defined as a resting mPAP ≥25mmHg, as per recognised guidelines 
(1). Cardiac output was measured using thermodilution. 
 
 Statistical Analysis 
Statistical analysis was performed using SPSS 22 (IBM, Chicago) and graphs were 
produced using GraphPad Prism. Unless otherwise stated, a p value of <0.05 was 
considered statistically significant. 
 
4.2.5.1 Derivation cohort 
The first half of the patients were used as a derivation cohort to derive a new model 
of mean pulmonary artery pressure estimation. The Pearson correlation coefficient 
between quantifiable cardiac MRI characteristics and RHC-mPAP were calculated. As 
multiple correlations were assessed, the risk of type 1 error was reduced using 
Bonferroni correction and therefore a p-value of <0.002 was considered statistically 
significant (30 different correlations were assessed). Scatter plots were constructed 
to ensure linearity between the cardiac MRI metric and mPAP. Any statistically 
significant correlations were used to calculate a linear regression equation for 
estimation of mPAP. An ROC curve was constructed to assess a suitable diagnostic 
threshold for the new model, one that was highly specific and one that had a balance 
of specificity and sensitivity (the Youden index). ROC curves were also constructed 
for the CMR-PARV model to identify a threshold with high specificity, for assessment 
in the validation cohort.  
 
4.2.5.2 Validation cohort 
The second half of the patients were used as a validation cohort. The correlation of 
the new regression equation for mPAP prediction against RHC measured mPAP was 
calculated and diagnostic performance was assessed using ROC curve analysis, 
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sensitivity and specificity, negative and positive predictive values. The accuracy of the 
model was assessed using Bland-Altman plot.  
The accuracy of the other previously published models was also assessed. The 
Pearson correlation coefficient for each model with mPAP or PVR was calculated. ROC 
curve analysis, sensitivity and specificity, negative and positive predictive values 
were also calculated for each of these models to assess their diagnostic performance. 
Table 4.1 provides the equations for the calculation of the new and previously 
published models. 
 
Table 4.1: Models referred to in this chapter. 
Name Equation 
α index Minimum PA area/RVEF 
RVCMR –4.6 + (inter- ventricular septal angle x 0.23) + (ventricular mass index x 16.3) 
PAWPCMR 6.43 + (LA Volume Index * 0.22) 
PVRCMR (RVCMR – PAWPCMR)/COCMR 
PARVCMRiii -21.806 + (IVS angle x 0.31) + (VMI x 11.5) + (diastolic PA area x 0.01) – (PA RAC x 0.22) 
RVBBCMR -178.7 + (42.730 * log10 IVS angle) + (7.569 * log10 VMI) + (3.393 * BB) 
PA: Pulmonary artery, RVEF: Right ventricle ejection fraction, LA: Left atrium, COCMR: Cardiac output calculated 
from CMR = stroke volume * heart rate, IVS: Interventricular septal angle, VMI: Ventricular mass index, BB: Black 
blood slow flow artefact score. 
 
 
  
                                                        
iii The PARVCMR model is discussed in Chapter 6, but in this chapter is tested in a separate cohort of all 
patients with suspected PH.  
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4.3 RESULTS 
 Patients 
The ASPIRE MRI sub-registry contains 2437 MRI scans for patients with suspected or 
confirmed pulmonary hypertension. Within this, there are 1272 incident cases with 
suspected pulmonary hypertension, of which 957 had RHC and MRI within 14 days. 
603 of these cases had a left atrial volume index of <41, so were included in this study. 
The first 300 patients were used as the derivation cohort and the second 303 were 
used as a validation cohort. Figure 4.2 shows the process of patient selection. The 
baseline clinical and RHC characteristics of the patients are provided in Table 4.2. 
Aside from cardiac index, there were no significant differences in the clinical 
demographics of patients between the derivation and validation cohorts as shown in 
Table 4.3. The difference in cardiac index between the two groups was very small and 
unlikely to be of clinical significance. There were 93 cases with no pulmonary 
hypertension, 264 cases with PAH, 11 with PH-LHD (even after exclusion of the 
dilated left atria), 60 with PH due to respiratory disease, 157 with CTEPH and 18 with 
PH due to unclear or multifactorial mechanisms.  
Figure 4.2: Patient flow 
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Table 4.2: Baseline demographics for all cases, mean with standard deviation, p-value between each PH group, 
calculated using ANOVA 
 All patients Not PH PAH PH-
LHD 
PH-Resp CTEPH PH 
Multi 
P-value  
Number 603 93 264 11 60 157 18 <0.0001 
Age (years) 61 (14) 56 (16) 60 (14) 62 (12) 66 (10) 64 (12) 62 (9) <0.0001 
Sex (F/M) 365/238 63/30 188/76 10/1 25/35 70/87 9/9 <0.0001 
WHO functional 
class (I,II,III,IV) 
1,64,459,63 0,33,48,3 0,7,216,37 1,2,8,0 0,5,42,13 0,17,130,9 0,0,15,1 <0.0001 
ISWT (m) 225 (191) 296 
(218) 
200 (182) 180 
(157) 
150 
(115) 
263 (199) 191 
(181) 
<0.0001 
mPAP (mmHg) 42 (16) 20 (3) 49 (13) 34 (9) 40 (11) 47 (12) 47 (13) <0.0001 
mRAP (mmHg) 10 (6) 6 (3) 11 (6) 12 (3) 9 (4) 11 (5) 10 (7) <0.0001 
PAWP (mmHg) 11 (4) 10 (4) 11 (3) 20 (7) 12 (4) 11 (3) 11 (4) <0.0001 
CI 2.6 (0.8) 3.1 (0.7) 2.5 (0.8) 2.7 
(0.5) 
2.8 (0.7) 2.4 (0.7) 2.6 (0.9) <0.0001 
PVRI 
(dyn.s/cm5) 
336 (260) 75 (40) 438 (268) 152 
(114) 
260 
(157) 
362 (234) 397 
(251) 
<0.0001 
SvO2 64 (9) 71 (7) 63 (9) 71 (9) 66 (6) 62 (8) 64 (8) <0.0001 
FEV1 (% 
predicted) 
78 (24) 87 (21) 76 (23) 66 (24) 60 (29) 84 (22) 64 (22) <0.0001 
FVC (% 
predicted) 
81 (24) 84 (19) 76 (22) 65 (15) 72 (31) 92 (22) 76 (28) <0.0001 
FEV1/FVC 69 (13) 74 (12) 71 (12) 68 (15) 62 (18) 67 (11) 65 (14) <0.0001 
TLCO (% 
predicted) 
46 (23) 62 (18) 37 (21) 44 (15) 29 (14) 58 (18) 34 (19) <0.0001 
Days between 
RHC & MR 
1 (2) 1 (2) 1 (2) 1 (4) 1 (0) 1 (1) 1 (4) 0.076 
 
Table 4.3: Demographics of the training and validation cohorts 
 Derivation Validation P-value  
Number 300 303  
Age (years) 60 (14) 61 (14) 0.279 
Sex (F/M) 189/111 176/127 0.243 
WHO functional class (I,II,III,IV) 0,34,223,33 1,30,236,30 0.084 
ISWT (m) 228 (184) 223 (198) 0.776 
mPAP (mmHg) 42 (16) 42 (15) 0.943 
mRAP (mmHg) 10 (6) 10 (6) 0.317 
PAWP (mmHg) 11 (4) 11 (4) 0.248 
CI (L/min/m2) 2.8 (0.8) 2.5 (0.8) <0.0001 
PVRI (dyns) 326 (241) 345 (277) 0.389 
SvO2 (%) 64 (9) 64 (9) 0.934 
FEV1 (% predicted) 78 (24) 78 (25) 0.885 
FVC (% predicted) 82 (23) 80 (24) 0.864 
FEV1/FVC (ratio) 68 (13) 70 (12) 0.240 
TLCO (% predicted) 46 (23) 46 (21) 0.978 
Days between RHC & MR 1 (2) 1 (2) 0.591 
WHO: World Health Organisation, RHC: right heart catheter, mPAP: right heart catheter measured mean 
pulmonary artery pressure, mRAP: mean right atrial pressure, PAWP: pulmonary artery wedge pressure, CI: cardiac 
index, PVRI: pulmonary vascular resistance index, SvO2: mixed venous oxygen saturation, FEV1: Forced expiratory 
volume in 1 second, FVC: Forced vital capacity, TLCO:  transfer for carbon monoxide 
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 Derivation cohort 
Table 4.4 shows the Pearson’s correlation coefficient for each cardiac MRI metric 
with right heart catheter measured mPAP and PVR. The strongest correlations with 
mPAP were for systolic interventricular septal angle, black blood artefact score, RV 
ejection fraction, right ventricular end systolic volume index and ventricular mass 
index (R=0.740, 0.694, -0.602, 0.585 and 0.529, respectively all p values <0.0001). 
Increasing RV volumes (RV end diastolic and end systolic volumes), reducing LA 
volume index and LV end diastolic volume, increasing PA size and reducing PA 
relative area change and velocity all showed statistically significant correlations with 
increasing mean pulmonary arterial pressure. Visual inspection of the scatter plots of 
interventricular septal angle and ventricular mass index revealed an exponential 
relationship, so the log10 of these metrics was used in further calculations.  
Regression analysis, performed in a forwards direction for any metric that showed a 
statistically significant correlation with mPAP (p<0.05) produced the following 
equation:  
𝑅𝑉𝐵𝐵𝐶𝑀𝑅 = −178.7 + 42.730 × IVS𝑎𝑛𝑔𝑙𝑒 + 7.569 × 𝑙𝑜𝑔10(𝑉𝑀𝐼) + 3.393 × 𝐵𝐵 
where,  IVSangle is the interventricular septal angle, VMI is the ventricular mass index 
and BB is the black blood slow flow artefact. ROC curve analysis in the derivation 
cohort identified 41mmHg as a threshold that was highly specific (98%), with 
reasonable sensitivity (72%). A separate threshold of 25mmHg was identified that 
was a balance of sensitivity and specificity (Youden index), with sensitivity of 96% 
and specificity of 73%. The RVCMR model has a previously published threshold for 
diagnosis set at 25mmHg to mimic the threshold for mPAP. 36mmHg was identified 
as a highly specific threshold (100% specific) within the derivation cohort. 
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  mPAP PVR AUC 
RVEDVI 0.480* 0.480* 0.782 
RVESVI 0.585* 0.611* 0.854 
RVEF -0.602* -0.623* 0.835 
RVSVI -0.101 -0.159* 0.573 
LVEDVI -0.396* -0.502* 0.738 
LVESVI -0.091 -0.107 0.531 
LVEF -0.302* -0.368* 0.703 
LVSVI -0.491* -0.597* 0.805 
RV mass 0.535* 0.138* 0.862 
LV diastolic mass -0.031 -0.227* 0.512 
LV systolic mass -0.145 -0.336* 0.598 
IV Septal angle (systole) 0.740* 0.704* 0.908 
IV Septal angle (diastole) 0.548* 0.530* 0.794 
4Ch LA area -0.254* -0.380* 0.643 
4Ch LA length -0.038 -0.115 0.535 
2Ch LA area 0.04 -0.123 0.566 
2Ch LA length 0.102 -0.032 0.608 
LA volume index -0.183* -0.277* 0.552 
Aortic flow -0.290* -0.470* 0.653 
PA flow -0.138 -0.330* 0.586 
Systolic PA area 0.411* 0.234* 0.817 
Diastolic PA area 0.504* 0.342* 0.878 
PA RAC -0.357* -0.382* 0.664 
Black blood score 0.694* 0.654 0.909 
Diastolic VMI 0.529* 0.533* 0.872 
Systolic VMI 0.553* 0.563* 0.897 
Av PA velocity -0.505* -0.548* 0.828 
 
 
Threshold 
(mmHg) Sensitivity (%) Specificity (%) 
20 100 32 
25 96 73 
30 92 87 
35 85 98 
40 75 98 
45 59 100 
50 41 100 
  
Table 4.4: Training cohort correlations with 
mPAP and PVR and area under the ROC curve for 
the diagnosis of PH. 
RVEDV: right ventricular end-diastolic volume, 
RVESV: right ventricular end-systolic volume, 
RVEF: right ventricular ejection fraction, RV: right 
ventricle, LVEDV: left ventricular end-diastolic 
volume, LVESV: left ventricular end-systolic 
volume, LVEF: left ventricular ejection fraction, PA 
RAC: pulmonary artery relative area change, VMI: 
ventricular mass index, IVS: interventricular 
septum, *p<0.001 
 
 
Table 4.5: Sensitivity and specificity data from the 
ROC curve in the training cohort for the RVBBCMR 
model. 
A threshold of 25 was identified as the Youden 
index to balance sensitivity and specificity and 41 
was identified as a highly specific threshold. 
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 Validation cohort 
The newly derived model for mPAP prediction correlated strongly with right heart 
catheter measured mPAP (R= 0.798, p<0.001). It showed high diagnostic accuracy 
(AUC = 0.951, p<0.001), and the more specific threshold (41mmHg) had 62% (56-
68%) sensitivity, 100% (92-100%) specificity, 100% (98-100%) positive predictive 
value and 32% (24-40%) negative predictive value. The threshold that balanced 
sensitivity and specificity (25mmHg) had 93% sensitivity, 79% specificity, 96% 
positive predictive value and 67% negative predictive value. Bland-Altman analysis 
showed a small bias (3.9%), with reasonable 95% agreement (-42 to 50%).  
The next best model was the PARVCMR model, which strongly correlated with mPAP 
(R=0.753, p<0.0001), and showed good diagnostic accuracy (AUC 0.914, p<0.001). 
The highly specific threshold of 36mmHg identified in the derivation cohort had 57% 
sensitivity, 100% specificity, 100% positive predictive value and 29% negative 
predictive value. The threshold that was previously published as a balance of 
sensitivity and specificity (25mmHg) had 91% sensitivity, 62% specificity, 93% 
positive predictive value and 55% negative predictive value. Bland Altman analysis 
showed a reasonable bias (14%) with reasonable 95% agreement (-35 to 64%). 
Figure 4.3 shows the scatter and Bland-Altman plots for the RVBBCMR and PARVCMR 
models.  
Figure 4.3: Correlation of the RVBBCMR and PARVCMR models with right heart catheter measured mPAP (top 
row) and the corresponding Bland-Altman plot (bottom row) in the validation cohort.  
The dotted line shows the bias and the dashed line the 95% levels of agreement. 
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Table 4.6 shows how the previously published metrics and models perform as 
diagnostic tools in pulmonary hypertension. The remaining models all had reasonable 
diagnostic accuracy for the presence of pulmonary hypertension, figure 4 shows the 
diagnostic performance of each of the models and the incremental benefit provided 
by the newly derived RVBBCMR model.  
 
 
 
 
Figure 4.4: ROC curve for 
each of the models. All p-
values are statistically 
significant. 
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Table 4.6: Previously published models and their diagnostic accuracy.  
Author Year Cases RHC metric CMR marker Initial publication 
 
Validation cohort Diagnostic accuracy for PH 
  
    
 
    Correlation AUC Threshold Correlation AUC Sensitivity Specificity PPV NPV p-value 
Roeleveld (246) 2005 44/0 mPAP VMI 0.56* 
 
0.6 0.705** 0.887 25 (20-30) 100 (92-100) 100 (94-100) 19 (14-24) <0.0001 
Sanz (247) 2007 42/17 mPAP Average PA velocity -0.73** 0.9 11.7cm/s -0.538**  0.858 4 (2-7) 73 (59-84) 45 (27-65) 12 (9-16) <0.0001 
    
Diastolic PA area 0.67** 0.95 6.6cm2 0.445** 0.871 81 (76-86) 80 (66-89) 96 (91-98) 43 (33-54) <0.0001 
   
PVRI Average PA velocity -0.86** 0.92 11.7cm/s -0.521** 0.802 4 (2-7) 73 (59-84) 45 (27-65) 12 (9-16) <0.0001 
    
Diastolic PA area 0.64** 0.93 6.0cm2 0.235** 0.756 92 (86-95) 40 (31-48) 66 (59-72) 79 (59-72) <0.0001 
Gan (207) 2007 70/16 mPAP PA RAC 0.47* 
  
-0.352** 0.607 77 (72-82) 36 (23-50) 87 (82-91) 21 (14-32) <0.0001 
Garcia-Alvarez (248) 2011 100/0 PVR PVRCMR 0.84** 0.97 4.2WU 0.631** 0.878 96 (93-98) 38 (25-52) 90 (86-93) 65 (46-81) <0.0001 
Swift (208) 2012 194/39 mPAP VMI 0.78** 0.91 0.4 0.705** 0.887 55 (49-61) 100 (92-100) 100 (97-100) 28 (21-35) <0.0001 
    
Diastolic PA area 0.35* 0.82 6.0cm2 0.445** 0.871 88 (83-91) 69 (51-80) 94 (90-96) 50 (38-62) <0.0001 
    
PA RAC -0.54** 0.87 ≤15% -0.352** 0.607 77 (72-82) 36 (23-50) 87 (82-91) 21 (14-32) <0.0001 
Moral (249)  2012 152/33 mPAP α index 0.61** 0.97 7.2 0.528** 0.885 99 (97-100) 13 (6-26) 87 (82-90) 75 (41-96) 0.0002 
Swift (125) 2013 64+64/12+10 mPAP RVCMR model 0.82** 0.96 ≥32mmHg 0.787** 0.911 88 (84-92) 60 (46-74) 93 (89-96) 47 (35-60) <0.0001 
   
PVR PVRCMR model 0.87** 0.94 ≥3WU  0.805 0.860 90 (85-93) 45 (32-60) 91 (86-94) 43 (30-58) <0.0001 
Johns (217) 2017 87/15 (COPD) mPAP PARVCMR model 0.732** 0.93 25mmHg 0.753** 0.914 91 (87-94) 62 (48-75) 93 (89-96) 55 (41-68) <0.0001 
Johns  2017 300/302 mPAP RVBBCMR N/A N/A 25mmHg 0.798 0.951 93 (89-96) 79 (65-89) 96 (93-98) 67 (53-78) <0.0001 
mPAP: mean pulmonary arterial pressure, VMI: ventricular mass index, PVR(I): pulmonary vascular resistance (index), PA: pulmonary artery PA RAC: Pulmonary arterial relative area change, LGE: late 
gadolinium enhancement, * p <0.05, ** p <0.001. CMR PVR = 19.38 - (4.62*Ln average Pa velocity) - (0.08 * RVEF), α=minimum PA area/RVEF, RVCMR model = –4.6 + (inter- ventricular septal angle x 0.23) + 
(ventricular mass index x 16.3), PVRCMR model = (mPAPCMR – PAWPCMR)/CO, PARVCMR model = -21.806 + (inter- ventricular septal angle x 0.31) + (ventricular mass index x 11.5) + (diastolic pulmonary artery 
area x 0.01) – (PA relative area change x 0.22), RVBBCMR = -178.7 + 42.730 * log10 IVS angle + 7.569 * log10 VMI + 3.393 * BB. 
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4.4 DISCUSSION 
This chapter shows that multiple cardiac MRI metrics have high diagnostic accuracy 
for the presence of pulmonary hypertension, which can be improved when combined 
as regression model. We have derived a new linear regression model (in 300 cases) 
and shown high diagnostic accuracy in a large validation cohort of cases (a further 
303). We have also validated previously published models for the prediction of PH, 
and shown high diagnostic accuracy. Whilst echocardiography is currently the 
mainstay of non-invasive estimation of pulmonary arterial pressures, it has only 
modest diagnostic accuracy and is limited in certain aetiologies (244,250). Cardiac 
MRI is well established as a highly reproducible method for non-invasive assessment 
of right ventricular function (251,252), which is sensitive to change (130,253,254) 
and does not require exposure to ionising radiation and is therefore potentially 
suitable as a screening tool for PH.  
Currently, whilst echocardiography is recommended for screening patients with 
suspected pulmonary hypertension, the diagnosis is made invasively using mean 
pulmonary arterial pressure, measured on right heart catheter (1). We have shown 
that a model based upon easily measured cardiac MRI metrics (that have been 
previously shown to be of high reproducibility) can be used to predict pulmonary 
arterial pressure with reasonable accuracy. More importantly, for a diagnostic test, 
we have shown that this model has very high diagnostic accuracy, and a threshold of 
41mmHg on the model can identify patients with pulmonary hypertension with 98-
100% specificity. Whilst this data requires validation in a different cohort of patients 
with suspected pulmonary hypertension, identifying patients who have PH using a 
threshold of 41 on this model would have the potential to reduce the number of 
diagnostic right heart catheters performed in our centre by 333 over the 4.5 years 
studied. Although clearly, further work is required in the assessment of cardiac and 
pulmonary vascular MRI in this regard, as patients with PAH will still require 
vasoreactivity testing and identification of patients with PH due to left heart disease 
(who do not respond to treatment) requires pulmonary arterial wedge pressure 
measurement. Increasing the use of non-invasive methodologies with “off the shelf” 
cardiac MRI sequences, will also help with screening for patients with PH in the 
clinical context of unexplained breathlessness, where a more sensitive threshold 
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(such as the 25mmHg threshold proposed in this paper) may be useful in identifying 
patients before referral to specialist centres. The newly defined model was derived in 
a training cohort and tested in a validation cohort. There was a statistically significant 
difference in the cardiac index between the 2 cohorts, although this was unlikely to 
be of clinical significance (both had significantly reduced cardiac index) and is likely 
to represent type 1 error.  
Whilst not assessed in this thesis, the ability to non-invasively predict pulmonary 
arterial pressure would be useful at follow up and to assess response to treatment. 
RHC is advocated for assessment of treatment response when clinical assessment, 
exercise testing and echocardiography are equivocal (1). Some physicians follow an 
approach combining both right heart catheter and cardiac MRI to identify when falls 
in pulmonary vascular resistance (PVR) measured at RHC are actually due to failure 
of the right ventricle, rather than response to treatment. Furthermore, a number of 
cardio-pulmonary vascular MRI metrics which reflect right ventricular 
structure/function and pulmonary arterial stiffness have been identified as strong 
markers of prognosis in patients with PH, and can be assessed in the same sitting 
(124). These markers are reproducible (251,252) and sensitive to change 
(130,253,254), making them perfect candidates for assessment at follow up.   
We recommend the use of the RVBBCMR model proposed from linear regression in this 
paper as it is the most accurate predictor of right heart catheter measured mPAP. It 
comprises measurement of displacement of the interventricular septum (a marker of 
the pressure and volume differential between the left and right ventricle), 
remodelling of the right ventricle (ventricular mass index - VMI) and slow or 
turbulent flow artefact in the pulmonary artery on black blood imaging. These 
measurements are easily acquired from standard MRI sequences, require little post-
processing time and are reproducible (124). Black blood pulmonary arterial flow 
artefact is a reproducible marker of outcome in PAH (135). It is likely to be a 
composite of slow flow and vortical or turbulent flow within the pulmonary artery. 
The increasing use of 4D phase contrast flow imaging will likely allow this metric 
within the model to be improved upon (140–142). The parameters of black blood 
imaging that are susceptible to flow artefacts (slice thickness, TI, TE, echo train length, 
cardiac triggering point) were kept the same between subjects, and could be easily 
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adopted for standardized use in different centres. In centres where black blood 
imaging is not available or adopted, a previously published model (PARVCMR) using 
the interventricular septal angle, ventricular mass index, diastolic pulmonary arterial 
size and pulmonary arterial relative area change can be implemented with a threshold 
(36mmHg) that has similarly high specificity of 100%.  
In patients with pulmonary hypertension due to left heart disease, treatment is aimed 
at the underlying cause (often left ventricular diastolic dysfunction) and not at the 
pulmonary vasculature. As such, current guidelines recommend that patients with 
suspected pulmonary hypertension, who have left heart disease and no features of 
severe PH are not referred to specialist pulmonary hypertension centres (1). We have 
considered this recommendation in our patient selection, using CMRI derived left 
atrial volume index (255)  (≥41ml/m2) as a cardiac MRI marker for the presence of 
left heart disease (239). Further work is required to improve the identification of 
patients with PH due to left heart disease using cardiac MRI such as trans-mitral flow 
and left atrial and ventricular filling parameters.   
This work presents data from a large cohort of incident patients with suspected 
pulmonary hypertension. It is however, limited by its single centre, retrospective 
design. In order to further assess the validity of the newly derived model it would be 
useful to assess the diagnostic accuracy in a cohort of suspected pulmonary 
hypertension in a different centre. The tertiary referral centre population potentially 
limits it’s applicability in the wider clinical setting. 
4.5 CONCLUSION 
Cardiac MRI has high diagnostic accuracy in a cohort of incident patients referred to 
a tertiary referral centre with suspected pulmonary hypertension. A model 
comprising simple, reproducible and easy to obtain metrics (interventricular septal 
angle, ventricular mass index and black blood score) is able to identify patients with 
pulmonary hypertension with 100% specificity, potentially reducing the current 
reliance upon invasive right heart catheterisation. 
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5 CARDIAC MRI CAN PHENOTYPE PULMONARY 
HYPERTENSION 
Once the diagnosis of pulmonary hypertension has been made, identification of the 
underlying cause of pulmonary hypertension is key to initiating the correct treatment. 
The following chapter explores the use of cardiac MRI in the phenotyping of patients 
with pulmonary hypertension.  
Patients with group 1: PAH and group 4: CTEPH can be successfully treated with 
pulmonary vasodilators, and in the case of CTEPH, cured with pulmonary end-
arterectomy. It is therefore vital that these patients are correctly identified from the 
other groups of pulmonary hypertension. There are two key clinical questions in this 
regard. The first challenge is to identify those patients with chronic thrombo-embolic 
pulmonary hypertension, to correctly identify those patients who should be 
considered for curative therapy with pulmonary end-arterectomy. The second big 
challenge is the identification of patients with group 1: pulmonary arterial 
hypertension from those patients with pulmonary hypertension due to left heart 
disease. This is particularly hindered by a phenotype of patients with pulmonary 
hypertension with combined pre and post pulmonary hypertension, due to additional 
pre-capillary pulmonary arteriolar remodelling.  
The following chapter is split into three partsiv: i) identifying patients with pulmonary 
hypertension due to left heart disease (group 2), who have a pre-capillary component 
to their pulmonary hypertension, ii) assessing the differences and similarities in 
cardiac phenotype between PH-lung patients (group 3), and iii) identifying patients 
with chronic thrombo-embolic pulmonary hypertension (group 4).   
 
                                                        
iv Each section of this chapter makes up work in separate papers.  
Cardiac MRI Can Identify and Phenotype PH in Left Heart Disease is based upon a manuscript currently 
under second review with Radiology. 
Cardio-Pulmonary MRI Can Screen For CTEPH has been published in in the Journal of Magnetic Resonance 
imaging entitled “Lung Perfusion: MRI vs. SPECT for Screening in Suspected Chronic Thromboembolic 
Pulmonary Hypertension” (89) 
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5.1 CARDIAC MRI CAN IDENTIFY AND PHENOTYPE PH IN LEFT HEART DISEASE 
 Rationale 
Patients with left heart disease commonly develop pulmonary hypertension (PH) 
(28). This initially results from passive backward transmission of high left ventricular 
filling pressures through the pulmonary circulation. Current guidelines define this 
post-capillary disease by a pulmonary arterial wedge pressure (PAWP) >15mmHg 
(22).  Some patients with post-capillary disease may subsequently develop a degree 
of pre-capillary vascular remodelling due to prolonged elevation of pulmonary 
arterial pressures (22,30–37). Previously, the difference between mean pulmonary 
arterial pressure (mPAP) and PAWP (the trans-pulmonary gradient, TPG) was used 
to identify patients with PH “out of proportion” to left heart disease. Subsequently a 
study by Gerges et al identified the diastolic pulmonary pressure gradient (DPG = 
diastolic pulmonary artery pressure  -  mean PAWP) as a superior prognostic 
parameter in patients with post-capillary disease (30). The 5th world PH symposium 
therefore introduced the classification of combined pre and post capillary pulmonary 
hypertension (Cpc-PH), defined as mPAP ≥ 25mmHg, PAWP >15 mmHg,  DPG of ≥7 
and/or pulmonary vascular resistance (PVR) >3 WU (22). Patients with Cpc-PH are at 
greater risk of deterioration than those with isolated post-capillary PH (Ipc-PH), but 
may benefit from PAH-specific therapy, especially in the context of randomized 
controlled trials (37,40,41) (and ClinicalTrials.gov identifier: NCT02070991). 
Previous non-invasive techniques using MRI measured left atrial volume index (255), 
echocardiographic parameters (256) or a combination of clinical, 
electrocardiographic and echocardiographic features (33) have been shown to 
distinguish between pre- and post-capillary disease. However, there currently is no 
non-invasive method for identifying patients likely to have Cpc-PH. As the 
interventricular septal angle is likely to represent a maker of the pressure differential 
between the right and left ventricles we anticipated that the interventricular septal 
angle was a marker of the diastolic pulmonary gradient, and therefore the presence 
of combined pre and post capillary pulmonary hypertension. We also aimed to assess 
other cardiac MRI metrics as markers of the diastolic pulmonary gradient. 
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5.1.1.1 Hypotheses  
1. The interventricular septal angle is a marker of the pressure differential 
between the left and right ventricle 
2. Patients with combined pre and post capillary pulmonary hypertension have 
flattening of the interventricular septum. 
3. Left atrial volume index has limited diagnostic utility in the assessment of the 
pulmonary arterial wedge pressure. 
5.1.1.2 Aims  
The aim of this chapter is to assess the interventricular septal angle, measured by MRI 
as a diagnostic tool to differentiate isolated post capillary pulmonary hypertension 
from combined pre and post capillary pulmonary hypertension in pulmonary 
hypertension due to left hear disease. 
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 Methods 
All consecutive, incident patients with suspected pulmonary hypertension, who 
underwent cardiopulmonary MRI at a pulmonary hypertension referral centre (245) 
from April 2012 to April 2017 were identified. Patients who had MRI and right heart 
catheter performed on the same day were included in the study. Ethical approval was 
granted from a local ethics committee for this retrospective study, written consent 
was waived (ref c06/Q2308/8).   
5.1.2.1 Image acquisition and analysis 
All patients underwent cardiac MRI at a pulmonary hypertension referral centre as 
part of the routine clinical pathway. MRI was performed on a GE HDx 1.5-T whole 
body scanner (GE Healthcare, Milwaukee, Wisconsin), with the patient supine, using 
an 8-channel cardiac coil. Short axis (SA) cine images were acquired using a 
retrospectively cardiac gated multi-slice steady-state free precession (SSFP) 
sequence during a breath-hold, with 20 phases per cardiac cycle. A stack of axial 
images with slice thickness of 8 mm with a 2 mm inter-slice gap or 10 mm with no 
inter-slice gap was acquired, covering both ventricles from base to apex. The SSFP 
sequence parameters were: TR 2.8 ms, TE 1.0ms, flip angle 50°, field of view 48x43.2, 
256x256 matrix and 125 kHz bandwidth. 
MR images were analysed on a GE Advantage Workstation 4.4 using GE Advantage 
Workstation ReportCard software by DC (a cardiac radiographer with 9 years 
experience), blinded to all clinical information and other investigations. Right and Left 
ventricular mass, volumes and ejection fraction were measured as previously 
described (257). The interventricular septal angle was measured as the angle formed 
between the insertion points of the ventricles to the mid-point of the septum, 
measured at end-systole (125,134,236). Figure 6 shows the measurement of septal 
angle in a patient with a high DPG and in a patient with low DPG. Left atrial volume 
was measured using the 2 and 4 chamber views and was calculated using the bi-plane 
area-length method (258).  
To assess the reproducibility of the interventricular septal angle measurement, I (a 
radiologist with 6 years’ experience) analyzed the interventricular septal angle in the 
first consecutive 20 patients with a raised pulmonary arterial wedge pressure. In a 
separate sitting, the same 20 patients were re-analysed. 
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5.1.2.2 Right heart catheterisation 
Right heart catheterisation was performed at a pulmonary hypertension referral 
centre using a balloon-tipped 7.5 Fr thermodilution catheter (Becton-Dickinson, 
Franklin Lakes, NJ), introduced using a Swann-Ganz catheter, usually with vascular 
access via the internal jugular vein. Left heart disease was defined as a pulmonary 
arterial wedge pressure (PAWP) of >15mmHg (1). The diastolic pressure gradient 
(DPG) was calculated as diastolic pulmonary arterial pressure – mean pulmonary 
artery wedge pressure (22), and a threshold of ≥7mmHg was considered diagnostic 
for combined pre and post capillary pulmonary hypertension, as per recognized 
guidelines (1,259).  Cardiac output was measured by thermodilution. Pulmonary 
vascular resistance was defined as (mPAP –PAWP)/cardiac output. Further analysis 
was performed using pulmonary vascular resistance, with a threshold of >3 Woods 
units (or 240 dyne.s), in order to assess the interventricular septal angle as a marker 
for Cpc-PH using both potential methods.  
Figure 5.1: Representative images from a patient with a negative DPG and normal septal angle (left) and a 
patient with an elevated DPG with a high septal angle (right). 
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5.1.2.3 Statistical analysis 
To test the accuracy of cardiac MRI measured structural and functional quantitative 
parameters in the assessment of diastolic pressure gradient, the correlation 
coefficient was calculated to assess for the strength of correlation between each 
variable with the diastolic pulmonary gradient, trans-pulmonary gradient and 
pulmonary vascular resistance. Scatter plots of the metrics with strongest correlation 
with diastolic pulmonary gradient, trans-pulmonary gradient and pulmonary 
vascular resistance were interrogated to ensure linearity. Receiver operating 
characteristic (ROC) curve analysis was performed to assess the diagnostic accuracy 
of each MRI parameter as a potential diagnostic tool and to assess a suitable 
diagnostic threshold. Analysis was also performed in the after exclusion of patients 
with normal pulmonary arterial wedge pressure, to ensure that the results were valid 
in the patients who had pulmonary hypertension due to left heart disease (PAWP 
>15mmHg and mPAP ≥25mmHg). 
To assess the hemodynamic basis of the interventricular septal angle as a predictor of 
the diastolic pulmonary gradient all incident patients were assessed. The correlation 
of interventricular septal angle and diastolic pulmonary gradient with the mean, 
systolic and diastolic pulmonary arterial to systemic pressure ratios were analysed. 
In order to assess the underlying mechanism for the interventricular septal angle as 
a marker of the trans pulmonary gradient linear regression analysis of significant 
candidate correlates, including inter ventricular septal angle with other significant 
cardiac MRI volumetric data was assessed. In addition right and left ventricular end 
diastolic and end systolic volumes and the ratio of right to left end diastolic and end 
systolic volumes was calculated and were included in the regression if significant at 
univariate analysis. The Z score from the left heart disease population was calculated 
(𝑧 =
𝑥−𝜇
𝜎
 , where µ is the mean and σ is the standard deviation), to allow comparison 
of the independent associations of MRI metrics with trans-pulmonary gradient.  
Census was performed on 16/06/17 and all-cause mortality was used as the outcome. 
The study period was defined as MRI to census or all-cause mortality. Survival 
analysis was performed using Cox proportional hazards regression analysis and the 
log rank test at Kaplan-Meier curve analysis. For ready comparison between the 
measurements on Cox proportional hazards regression analysis, the measurements 
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were standardized by the z-score. Kaplan-Meier plots were constructed using 
recognized diagnostic thresholds, where available. For interventricular septal angle, 
the newly identified diagnostic threshold was used. ROC curve analysis was also used 
to assess for each variable’s strength of prediction of death. ROC curve analysis for 
prediction of death was chosen at 2 years, as this had a balance of patient numbers 
(n=122) and number of deaths (n=36).  Analysis of the 2x2 contingency table and chi-
square test were used to determine sensitivity, specificity, positive and negative 
predictive (PPV, NPV) values. 
The intra and inter-observer reproducibility using intra class coefficient (using two-
way mixed absolute agreement) and construction of Bland-Altman graphs.   
In order to assess cardiac MRI as a non-invasive tool to identify patients with left heart 
disease, the diagnostic accuracy of left atrial volume index was assessed in the entire 
cohort of incident cases. This has previously been shown to identify patients with left 
heart disease, with a threshold of ≥43ml/m2 being identified to have 97% sensitivity 
and 100% specificity (255). A scatter plot of left atrial volume index against PAWP 
and ROC curve for the diagnosis of left heart disease were interrogated. 
Statistical analysis was performed using SPSS 22 (IBM, Chicago) and GraphPad Prism 
7 (GraphPad Software, San Diego). A p-value of <0.05 was considered statistically 
significant. The data is presented as mean (standard deviation), unless otherwise 
stated.  
  
Dr CS Johns  Cardio-Pulmonary MRI in PH   118  
 Results 
In the period studied, 2643 patients underwent cardio-pulmonary MRI in pulmonary 
hypertension service. 1315 were incident patients, of which 758 had their MRI and 
right heart catheter on the same day. In 50 cases, the PAWP was not recorded. 171 
patients had a PAWP >15 and 537 had PAWP ≤15mmHg. Figure 5.2 shows the 
algorithm for selection of patients.  
 
5.1.3.1 Prediction of a high diastolic pulmonary gradient 
In the left heart disease cohort (PAWP >15mmHG), the average age was 70 (±10) 
years, 61% were female. Fifty-six (32%) had a diastolic pulmonary gradient (DPG) 
≥7mmHg, 57 (33%) a DPG 0-7mmHg and 58 (33%) a negative DPG. Table 5.1 
presents the demographic and right heart catheter data. Five patients had a wedge 
pressure >15mmHg but did not have pulmonary hypertension (these all had a  
Figure 5.2: Patient 
flow 
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Table 5.1: Baseline patient demographics, haemodynamics and cardiac MRI metrics for the whole cohort split by 
PAWP of 15mmHg. 
WHO-FC: World Health Organization-Functional Class, ISWT: incremental shuttle walk test, mPAP: mean 
pulmonary artery pressure, mRAP: mean right atrial pressure, PAWP: pulmonary arterial wedge pressure, CI: 
cardiac index, PVRI: pulmonary vascular resistance index, SvO2: Mixed venous oxygen saturations, TPG: trans 
pulmonary pressure gradient (mPAP-PAWP), SPG: systolic pressure gradient (sPAP-PAWP), RVEDV: right 
ventricular end-diastolic volume, RVESV: right ventricular end-systolic volume, RVEF: right ventricular ejection 
fraction, RV: right ventricle, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end-systolic 
volume, LVEF: left ventricular ejection fraction, PA RAC: pulmonary artery relative area change, VMI: ventricular 
mass index, IVS: interventricular septum 
 
    PAWP<15 PAWP >15 p-value 
 Number 537 171  
Demographics    
 Age (years) 63 (13) 70 (10) <0.001 
 Sex (F/M) 346/191 105/66 0.473 
 WHO functional class (I,II,III,IV) 3,75,404,46 0,18,144,9 0.166 
 ISWT (m) 224 (195) 158 (126) <0.001 
 Survival (years) 1.3 (1) 2.1 (1.3) 0.945 
RHC    
 mPAP (mmHg) 39 (15) 43 (12) <0.001 
 mRAP (mmHg) 9 (5) 15 (5) <0.001 
 PAWP (mmHg) 11 (3) 21 (5) <0.001 
 CI (L/m2) 2.7 (0.9) 2.6 (0.7) 0.514 
 PVRI (dyne.s.m2) 997 (764) 720 (483) <0.001 
 SvO2 (%) 66 (9) 64 (9) 0.027 
 DPG (mmHg) 12 (10) 4 (9) <0.001 
 TPG (mmHg) 28 (15) 21 (11) <0.001 
 SPG (mmHg) 53 (26) 47 (21) 0.002 
CMRI 
   
 RV EDV index (ml.m
-2) 80 (30) 89 (31) 0.001 
 RV ESV index (ml.m
-2) 48 (26) 48 (23) 0.44 
 RVEF (%) 43 (14) 46 (13) 0.006 
 RV mass index (ml.m
-2) 19 (11) 19 (10) 0.623 
 LV EDV index (ml.m
-2) 54 (16) 68 (21) <0.001 
 LV ESV index (ml.m
-2) 18 (10) 24 (14) <0.001 
 LVEF (%) 68 (10) 65 (12) 0.014 
 LV mass index (ml.m
-2) 48 (11) 56 (20) <0.001 
 PA RAC (%) 12 (9) 12 (9) 0.691 
 VMI (ratio) 0.42 (0.24) 0.36 (0.19) 0.003 
 IV septal angle (˚) 161 (24) 154 (20) <0.001 
 LA vol index (ml.m
-2) 34 (16) 62 (28) <0.001 
 Stroke volume (ml) 67 (23) 82 (25) <0.001 
  Black blood score 3 (2) 3 (1) 0.853 
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diastolic pulmonary gradient <7). 103 patients had pulmonary hypertension due to 
left heart disease alone, 32 patients had combined pre and post capillary pulmonary 
hypertension, 17 had coexistent lung disease and 19 had co-existent chronic 
thrombo-embolic disease, as defined by the multidisciplinary team meeting upon 
review of all imaging and clinical details. Left heart disease was due to left ventricular 
diastolic dysfunction in 149 cases, left ventricular systolic dysfunction in 9 and valve 
disease in 13 (mitral regurgitation – 5, aortic stenosis – 5, aortic regurgitation – 1, 
mixed mitral and aortic disease – 1, unknown - 1). 127 of the patients with left heart 
disease did not receive vasodilator therapy. 31 of the cases were treated with 
sildenafil alone and 13 were treated with dual therapy (sildenafil with macitentan - 8, 
bosentan - 4 or ambrisentan - 1). 
Systolic interventricular septal angle correlated with diastolic pulmonary pressure 
gradient (r=0.739, p-value <0.001) and pulmonary vascular resistance (r=0.626, p-
value <0.001). Figure 5.3 presents scatter plots of interventricular septal angle 
against diastolic pulmonary gradient and pulmonary vascular resistance. Systolic 
interventricular septal angle correlated with TPG, PAWP and mPAP (r= 0.772, 
p<0.001, r=-0.203, p=0.008 and r= 0.637, p<0.001 respectively). Other MRI predictors 
had weak or modest correlations with diastolic pulmonary gradient (r=0.033, 
p=0.668 to r=0.550, p=<0.001). Table 5.2 shows the correlations and p-values for 
each metric with diastolic pulmonary gradient, trans-pulmonary gradient and 
pulmonary vascular resistance.  
Figure 5.3: Scatter plot showing the relationship between systolic interventricular septal angle with 
diastolic pulmonary pressure gradient and pulmonary vascular resistance. 
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Table 5.2: Cardiac MRI metrics linear correlations with DPG, TPG and PVR, for the patients with pulmonary arterial 
wedge pressure (PAWP) >15mmHg. 
 DPG   TPG   PVR   
  r p-value r p-value r p-value 
Systolic IVS angle 0.739 <0.001 0.772 <0.001 0.626 <0.001 
Diastolic IVS angle 0.534 <0.001 0.534 <0.001 0.575 <0.001 
RVEDVI 0.118 0.124 0.095 0.219 0.079 0.304 
RVESVI 0.356 <0.001 0.219 0.004 0.279 <0.001 
RVEF -0.550 <0.001 -0.516 <0.001 -0.469 <0.001 
RVSVI -0.297 <0.001 -0.28 <0.001 -0.262 0.001 
LVEDVI -0.398 <0.001 -0.296 <0.001 -0.287 <0.001 
LVESVI -0.205 0.007 -0.194 <0.001 -0.162 0.034 
LVEF -0.033 0.668 0.046 0.546 0.000 1.000 
LVSVI -0.441 <0.001 -0.283 <0.001 -0.304 <0.001 
RV mass index 0.323 <0.001 0.333 <0.001 0.293 <0.001 
LV mass index -0.249 0.001 0.127 0.098 -0.247 0.001 
LA volume index -0.326 <0.001 -0.257 0.001 -0.206 0.007 
Systolic PA area 0.301 <0.001 0.348 <0.001 0.254 0.001 
Diastolic PA area 0.364 <0.001 0.422 <0.001 0.329 <0.001 
PA RAC -0.230 0.003 -0.288 <0.001 -0.285 <0.001 
Black Blood Score 0.432 <0.001 0.405 <0.001 0.455 <0.001 
VMI 0.500 <0.001 0.465 <0.001 0.463 <0.001 
RVEDVI: right ventricular end-diastolic volume index, RVESVI: right ventricular end-systolic volume index, RVEF: 
right ventricular ejection fraction, RV: right ventricle, LVEDVI: left ventricular end-diastolic volume index, LVESVI: 
left ventricular end-systolic volume index, LVEF: left ventricular ejection fraction, PA RAC: pulmonary artery 
relative area change, VMI: ventricular mass index, IVS: interventricular septum, DPG: diastolic pulmonary gradient, 
TPG: trans pulmonary gradient, PVR: pulmonary vascular resistance 
 
Receiver operating characteristics (ROC) curve analysis (Figure 5.4) showed that 
septal angle was predictive of the presence of an elevated diastolic pulmonary 
gradient (defined by a DPG ≥7) with an area under the curve of 0.911 (p <0.001). 
Interventricular septal angle was also predictive of the presence of an elevated 
pulmonary vascular resistance (defined by a PVR >3 Woods units, or >240 Dyne.s) 
with an area under the curve of 0.783 (p <0.001). Analysis of the ROC data showed 
that a septal angle of 160˚ represented a reasonable diagnostic threshold to predict a 
DPG of ≥7mmHg, with 70% sensitivity, 93% specificity, 83% positive predictive value 
and 86% negative predictive value (p <0.0001).   
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After exclusion of the patients without pulmonary hypertension (n=5) there was still 
a significant correlation between the interventricular septal angle and DPG (r=0.716, 
p<0.001), PVR (r=0.596, p<0.001). The area under the ROC curve for the diagnosis of 
a raised DPG was 0.907 (p<0.001). A septal angle of 160˚ gave sensitivity of 70%, 
specificity of 93%, positive predictive value 86% and negative predictive value 86%.  
  
5.1.3.2 Haemodynamic Basis of Interventricular Septal Angle 
Table 5.3 shows the correlation between interventricular septal angle and diastolic 
pulmonary gradient with the ratio of mean, diastolic and systolic pulmonary artery to 
systemic pressure ratio. This is provided in Table 5.3 for the whole cohort of incident 
cases and the cases with left heart disease (PAWP >15mmHg). Whilst interventricular 
septal angle and diastolic pulmonary gradient correlated with all three ratios, the 
strongest was with systolic pulmonary arterial pressure and systolic systemic 
pressure ratio (for septal angle: 0.728 for all cases and 0.674 for the raised PAWP 
cases, and for the DPG 0.759 for all cases and 0.702 for the raised PAWP cases).  
Systolic interventricular septal angle had modest correlations with right ventricular 
end diastolic volume (R=0.257, p=0.001), right ventricular end systolic volume 
(R=0.302, p <0.001), left ventricular end diastolic volume (R=-0.231, p=0.002), left 
Figure 5.4: ROC analysis for Septal angle to assess for an elevated DPG or PVR 
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ventricular end systolic volume (R=-0.140, p=0.067) and the ratio of right:left end 
diastolic volume (R=0.420, p<0.001) and end systolic volume (R=0.462, p<0.001). On 
multivariate analysis, DPG was independently associated with the interventricular 
septal angle (hazard ratio 11.807, 95% CI 9.7-13.9), right:left end-systolic volume 
ratio (HR 3.400, 95% CI 1.3-5.5).  
Table 5.3: Correlations between haemodynamic measures in the whole cohort of patients and in the left heart 
disease cohort alone. 
 mPAP:MAP sPAP:SAP dPAP:DAP 
  All Raised PAWP All Raised PAWP All Raised PAWP 
IVS angle 0.570 0.557 0.728 0.674 0.646 0.514 
DPG 0.626 0.637 0.759 0.702 0.761 0.662 
IVS: interventricular septum, DPG: diastolic pulmonary gradient, TPG: trans pulmonary gradient, PVR: pulmonary 
vascular resistance, mPAP: mean pulmonary arterial pressure, MAP: mean systemic arterial pressure, sPAP: systolic 
pulmonary arterial pressure, SAP: systemic systolic blood pressure, dPAP: diastolic pulmonary arterial pressure, 
DAP: diastolic systemic blood pressure, PAWP: Pulmonary arterial wedge pressure. All correlations were significant 
(p<0.05). 
 
5.1.3.3 Reproducibility of the interventricular septal angle measurement 
There was excellent inter-observer agreement with intra class correlation (ICC) of 
0.902 (p<0.001), Bland-Altman plot showed a tiny bias of -2% and close 95% limits 
of agreement of -12 to 8%. There was also excellent intra-observer agreement, with 
ICC of 0.979 (p<0.001), Bland-Altman showed a tiny bias of 2% and 95% limits of 
agreement of -4 to 8%. Figure 5.5 provides the Bland-Altman plots for intra and inter-
observer reproducibility. 
 
Figure 5.5: Bland-Altman plots of inter and intra-observer agreement for systolic interventricular septal 
angle. 
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5.1.3.4 Prediction of outcome 
Median follow up was 2.4 years (SD 1.3), during which time there were 48 deaths. 
Systolic interventricular septal angle was predictive of outcome on univariate 
analysis, with a Cox proportional hazards ratio of 1.615 (95% confidence interval 
1.253-2.082, p-value <0.001), when standardized to the z score for the left heart 
disease population. Kaplan-Meier curve analysis, dichotomized by the threshold of 
160˚, showed a significant difference in outcome (Figure 5.6) with Log-Rank chi-
square 11.02 (p-value=0.0009).  
 
DPG, PVR and TPG were predictive of death with standardized Cox proportional 
hazards ratio of 1.708, 1.667 and 1.609 respectively (all p values <0.05). The 
interventricular septal angle, DPG and PVR all predicted death at 2 years (AUC 0.71, 
0.71 and 0.71, and p-values 0.0003, 0.0002 and 0.0001 respectively), see Figure 5.7. 
 
Figure 5.6: Kaplan Meier analysis  
Patients with elevated PAWP dichotomized by interventricular septal angle, diastolic pulmonary gradient 
and pulmonary vascular resistance. The interventricular septal angle does not have a published threshold so 
the diagnostic threshold identified in this chapter is used. 
 
Figure 5.7: ROC curve analysis for the prediction of death at 2 years  
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On univariate analysis, treatment with PAH vasodilator therapy was associated with 
death, with Cox univariate hazard ratio 1.83 (95% CI 1.026-3.266, P = 0.041) and log-
rank chi-square 4.316 (p = 0.038). However, when treatment was entered as a dummy 
variable into a multi-variate Cox proportional hazards assessment individually with 
septal angle or the hemodynamic parameters, it did not reach statistical significance 
(p=0.257). 
 
5.1.3.5 Prediction of a raised PAWP 
Left atrial volume index showed reasonable correlation with pulmonary arterial 
wedge pressure measurement (r2=0.30) and reasonable diagnostic accuracy with 
area under the receiver operating curve of 0.825 (p<0.0001). The previously 
published threshold of ≥43ml/m2 had 74% sensitivity, 79% specificity, 53% positive 
predictive value and 91% negative predictive value for the presence of a PAWP >15. 
Figure 5.8 shows a scatter plot of left atrial volume index against PAWP and the ROC 
curve for the diagnosis of left heart disease.  
 
 
 
Figure 5.8: Diagnostic accuracy of left atrial volume index.  
A scatter plot of LA volume index against pulmonary arterial wedge pressure, and an ROC curve for left 
atrial volume index to identify the presence of PAWP>15mmHg. 
Dr CS Johns  Cardio-Pulmonary MRI in PH   126  
 Discussion 
The data presented in this section of the thesis shows that interventricular septal 
angle can be used to predict the presence of Cpc-PH in a cohort of incident patients 
referred to a pulmonary hypertension referral centre with a pulmonary arterial 
wedge pressure (PAWP) >15mmHg. In our cohort of pulmonary hypertension 
patients with raised PAWP, a systolic interventricular septal angle of 160˚ accurately 
identified patients with a raised diastolic pulmonary gradient, with 70% sensitivity 
and 93% specificity. The interventricular septal angle threshold of 160˚ also 
dichotomised patients into higher and lower risk categories for death.  
We postulate that the interventricular septal angle represents a good quantitative 
marker that reflects the trans-pulmonary gradient as it is responsive to the pressure 
difference between the left and right ventricle (260). Although, it should be noted that 
this is different from the diastolic pressure gradient, which is a measure of the 
pressure differential between the pulmonary artery and the mean pulmonary arterial 
wedge pressure (used as a surrogate marker for left atrial pressure). In the absence 
of invasive measures of left ventricular pressure, we have shown that the ratio of 
pressures between the pulmonary arterial and the systemic circulations, particularly 
at systole are accurately reflected by the interventricular septal angle. We have also 
demonstrated a strong relationship between the pulmonary arterial to systemic 
pressure ratio and the diastolic pulmonary gradient. We have shown that the 
association of flattening of the interventricular septal angle and trans pulmonary 
gradient is independent of other cardiac volumetric and functional measurements. 
However, the relative volumes of the right and left ventricle also contribute, though 
to a lesser extent when compared to septal flattening. We have shown that whilst 
there is a modest correlation between right ventricular and left ventricular volumes, 
and the ratio of these, the strongest correlation is with DPG, suggesting that the 
flattening is most associated with the pressure gradient between the right and left 
ventricles.  
Patients with combined pre and post capillary pulmonary hypertension had features 
of precapillary pulmonary hypertension on cardiac MRI. The patients with Cpc-PH 
had significantly increased right ventricular end systolic volumes and mass (and 
therefore ventricular mass index), reduced stroke volume and right ventricular 
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ejection fraction, due to increased right ventricular afterload. In the Cpc-PH cohort 
the left ventricular end diastolic volume and the left atrial volume index were reduced 
due to reduced filling. Supporting the model that pre-capillary pulmonary vascular 
remodelling causing reduced precapillary arterial compliance in the patients with 
Cpc-PH, pulmonary arterial relative area change was significantly reduced. These 
findings may suggest the presence of the pre-capillary PH in patients with left heart 
disease, but the strongest predictor was the systolic interventricular septal angle, as 
discussed above. The systolic interventricular septal angle is easily measured on 
commercially available PACS stations and we have shown that it has excellent inter 
and intra-observer reproducibility, it is likely that the small variability that has been 
demonstrated (around ±10% intra and inter-observer 95% agreement) explains the 
slightly reduced sensitivity. As the analysed images are cardiac cine SSFP sequences, 
the time-point of measurement of the interventricular septal angle measurement is 
important. In the data that we present, we show that the systolic interventricular 
septal angle is the most predictive of the diastolic pulmonary gradient, likely as this is 
the time in the cardiac cycle when the pressure difference in the right and left 
ventricle is most marked.  
Left heart disease is an increasingly prevalent disease (23), and whilst the prevalence 
of PH in left heart disease is not fully known (27,261), it is associated with a poor 
outcome (24,25). The differentiation of left heart disease from idiopathic pulmonary 
arterial hypertension is often hard to make (9), and this is further compounded by the 
fact that a subgroup of patients have combined pre and post capillary pulmonary 
hypertension, thought to be due to pre-capillary vascular remodelling (30). 
Previously published non-invasive techniques which utilize left atrial volume index 
measured at MRI have had a high diagnostic accuracy in the assessment of left heart 
disease (255). Further centres have also studied the echocardiographic parameters 
(256) or a combination of clinical, electrocardiographic and echocardiographic 
features (33) as non-invasive methods to distinguish between pre- and post-capillary 
disease. The work presented in this chapter furthers these tools, allowing the non-
invasive identification of patients who have elevated trans pulmonary gradient in 
patients with pulmonary hypertension owing to left heart disease. 
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There is ongoing debate regarding the best way to assess for combined pre and post 
capillary pulmonary hypertension. Initially, the trans-pulmonary gradient (TPG, 
mean pulmonary arterial pressure minus mean pulmonary arterial wedge pressure) 
was used to identify patients who had a precapillary component to their pulmonary 
hypertension, with 12mmHg being used as a cut-off (22). As the trans-pulmonary 
gradient is affected by cardiac output, pulmonary vascular resistance and pulmonary 
arterial wedge pressure, it is now recommended that a diastolic pressure gradient of 
≥7mmHg and/or pulmonary vascular resistance of >3 Woods units, should be used to 
define the presence of combined pre and post capillary pulmonary hypertension 
(259,262). This is felt to represent a physiologically more reliable measure of the 
pressure drop across the pulmonary vasculature. The interventricular septal angle 
correlated more strongly with the DPG than the PVR, likely because it changes in 
response to the pressure differences rather than the vascular resistance, which is also 
related to cardiac output. There have been multiple discussions over the significance 
of a negative diastolic pressure gradient, with reports of a negative diastolic 
pulmonary gradient being associated with a favourable outcome, rather than a 
representation of the inaccuracies of pulmonary arterial wedge pressure 
measurement (263). The underlying mechanisms are not entirely clear, but it is 
plausible that the reason for a negative diastolic pulmonary gradient is due to the use 
of mean pulmonary artery wedge pressure in the DPG calculation, rather than the 
diastolic pulmonary artery wedge pressure. Further work is warranted to identify the 
most robust hemodynamic marker for Cpc-PH.  
It would be useful to identify a non-invasive methodology for the accurate 
identification of patients with left heart disease in the population of patients with 
suspected pulmonary hypertension. In a comparison between idiopathic pulmonary 
arterial hypertension and PH owing to left heart disease, it was shown that a left atrial 
volume index of ≥43ml/m2 was highly predictive of the presence of left heart disease 
(255). The results from our population of 708 incident cases showed that the left atrial 
index is diagnostic, but not to the same high accuracy (AUC 0.825, p<0.001). Part of 
this may be related to the population studied: In this section, we assess the left atrial 
volume index in all incident patients with suspected pulmonary hypertension, rather 
than in the selected idiopathic pulmonary arterial hypertension vs left heart disease 
cases. Furthermore, the pulmonary arterial wedge pressure reading has inherent 
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inaccuracies as a measurement of left ventricular end-diastolic pressure, potentially 
adding error (264,265). Further work is required to identify more robust non-
invasive measures of left ventricular dysfunction as a cause for pulmonary 
hypertension.  
Current recommendations for pulmonary hypertension due to left heart disease 
centre on treatment of the underlying left heart disease, for example correcting 
valvular heart disease and optimizing volume status or heart failure therapy. There is 
currently no body of evidence to support the use of targeted pulmonary vascular 
therapies in patients with left heart disease as a whole, nor in combined pre and post 
capillary pulmonary hypertension (Cpc-PH). Although there is increasing interest in 
potential treatment options in these patients as they have worse outcome and pre-
capillary remodelling, similar to pulmonary arterial hypertension (PAH) patients. It 
would be useful to have a non-invasive and simple measurement from imaging, such 
as interventricular septal angle to differentiate Cpc-PH from Ipc-PH for inclusion in 
potential clinical trials (10–13).  
This study is limited by its retrospective design, conducted in a pulmonary 
hypertension referral centre, where the incidence of pulmonary hypertension is 
significantly higher than in the general population of left heart disease patients. As 
such, the results are only valid in patients in this setting, and not necessarily 
applicable to the wider population of left heart disease. Furthermore, we have 
assessed a potential threshold of interventricular septal angle to identify patients 
with high diastolic pressure gradients, but this requires validation in a separate 
cohort. Future work is required to evaluate the threshold we have defined, to assess 
the role of septal measurement in a more general cohort of left heart disease patients, 
and to assess the similarities with idiopathic pulmonary arterial hypertension. 
Furthermore, as discussed above, further work is required to assess the non-invasive 
estimation of left ventricular filling pressures and their role in diagnosis and 
prognosis.  
 Conclusion 
Cardiac MRI derived interventricular septal angle can be used to non-invasively 
predict the presence of an elevated diastolic pressure gradient in suspected 
pulmonary hypertension patients with elevated pulmonary arterial wedge pressures. 
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The interventricular septal angle can predict left heart disease patients with a poor 
outcome and in the future, may offer the potential to identify patients for targeted 
therapy. 
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5.2 CARDIAC MRI PHENOTYPES OF PH - LUNG DISEASE 
 Rationale 
Pulmonary hypertension is a common complication of chronic lung disease and is 
defined on right heart catheter (RHC) by a mean pulmonary arterial pressure (mPAP) 
≥25mmHg. Reportedly as many as 90% of patients with COPD Gold stage IV have a 
mean pulmonary artery pressure of 20-35mmHg but only 5% have a mean pulmonary 
artery pressure ≥35mmHg, which defines a cohort of lung disease patients as severe 
pulmonary hypertension (44,49,50). In lung disease, the presence of pulmonary 
hypertension is associated with a universally poor prognosis (42–46,53). Pulmonary 
hypertension is likely to represent the end-stage of pulmonary disease: for example 
COPD patients are more likely to die or be hospitalised due to cardiovascular rather 
than respiratory complications (48).  
The development of pulmonary hypertension in COPD is thought to result from 
multiple different mechanisms: hypoxic pulmonary vasoconstriction, polycythaemia 
from chronic hypoxia, destruction of the pulmonary vascular bed by emphysema, 
hyperinflation causing intrathoracic pressures that are greater than pulmonary 
venous pressure and endothelial dysfunction and remodelling (43,51,52). The 
mechanisms by which pulmonary hypertension develops in ILD and CPFE appears to 
be much less understood. A potential difference in the development of pulmonary 
hypertension in lung disease is highlighted by the high incidence of severe pulmonary 
hypertension in combined pulmonary fibrosis and emphysema (CPFE), in contrast to 
patients with chronic obstructive pulmonary disease (COPD) and interstitial lung 
disease (ILD), in whom severe pulmonary hypertension is rare (50,267). 
 
5.2.1.1 Hypothesis 
1. The difference in prevalence and severity of PH and outcome in patients with 
PH due to COPD, ILD and CPFE are due to an underlying difference in the 
cardiac phenotype. 
 
5.2.1.2 Aims 
The aim of this study was to identify any differences in the cardiac phenotype of 
patients with pulmonary hypertension due to lung disease, through assessment of the 
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baseline demographic, haemodynamic and cardiac MRI characteristics of patients 
with pulmonary hypertension at a tertiary referral centre.  
 
 Methods 
All consecutive patients who underwent MRI at a pulmonary hypertension referral 
centre (245) from April 2012 to October 2016 with suspected pulmonary 
hypertension were assessed for inclusion. All patients with PH due to lung disease 
were identified, as defined at the weekly PH multi-disciplinary team meeting. Any 
patients without a thoracic CT for analysis were excluded and any patients with more 
than 30 days between MRI and right heart catheterisation were excluded. A further 
cohort of patients with idiopathic pulmonary arterial hypertension who were 
scanned over the same time was also included for comparison. Ethical approval was 
granted from a local ethics committee for this retrospective study, written consent 
was waived (ref c06/Q2308/8).  
5.2.2.1 Right Heart Catheterisation 
Right heart catheterisation was performed using a balloon tipped 7.5Fr 
thermodilution catheter (Becton-Dickinson, Franklin Lakes, New Jersey). Pulmonary 
hypertension was defined as a resting mPAP ≥25mmHg and severe pulmonary 
hypertension as a resting mPAP ≥35mmHg. Cardiac output was calculated using 
thermodilution.  
5.2.2.2 Pulmonary Function Testing 
All patients underwent lung function testing as part of routine care. All spirometry is 
presented as percentage of predicted value. 
5.2.2.3 Image Acquisition  
Cardiac MRI was performed supine on a GE HDx 1.5-T whole body scanner (GE 
Healthcare, Milwaukee, Wisconsin), using an 8-channel cardiac coil. Four-chamber 
(4Ch) and short axis (SA) cine images were acquired using a retrospectively cardiac 
gated multi-slice steady-state free precession (SSFP) sequence. A stack of axial images 
in the SA plane with slice thickness of 8 mm with a 2 mm inter-slice gap or 10 mm 
with no inter-slice gap were acquired, covering both ventricles from base to apex. The 
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SSFP sequence parameters were: TR 2.8ms, TE 1.0ms, flip angle 50°, field of view 
48x43.2, 256x256 matrix, 125 kHz bandwidth, and slice thickness 8 to 10 mm.  
Axial black blood imaging was performed using a dual inversion recovery fast spin 
echo sequence, with a stack of 8mm slices with 10mm spacing taken through the long 
axis plane of the pulmonary artery. The sequence parameters were: TR 984ms, TE 
40ms, flip angle 90˚, echo train length 32, field of view 4cm, 256x256 matrix, 31.2 kHz 
bandwidth on an 8 channel cardiac coil. 
Phase contrast imaging was performed perpendicular to the pulmonary trunk and 
ascending aorta. The phase contrast imaging parameters were: TR 5.6 ms, TE 2.7 ms, 
slice thickness 10 mm, FOV 48x28.8, bandwidth 62.5 kHz, matrix 256x128 and 
velocity encoding (Venc) 150 cm/s. The images were retrospectively ECG gated with 
40 phases.  
DCE-MRI was performed using a contrast injection of 0.05ml per kg dose of Gd-BT-
D30A (Gadovist, Schering, Berlin, Germany), injected at a rate of 4 ml per second with 
the using an activated pump injector (Spectris, MedRad). Typically administered via 
a vein in the antecubital fossa using an 18G cannula. This was followed by a 20ml 
saline flush. Serial 3D gradient echo images of the chest were acquired with the 
following sequence parameters: TE=1.1 ms, TR=2.5 ms, Flip angle 30°, FOV 48 cm x 
48 cm, parallel imaging in plane x 2, in plane resolution 200x80, bandwidth 250 kHz, 
slice thickness 10 mm, approximately 32 slices, 48 time points with an overall 
effective 3D frame rate of ~ 0.5 s. Images were acquired in a coronal orientation. 
When performed at the local centre, CTPA images were acquired on a 64-slice MDCT 
(Light-Speed General Electric Medical) during a single breath-hold. The acquisition 
parameters were: 100 mA with automated dose reduction, 120 kV, pitch of 1, rotation 
time 0.5 s and 0.625-mm collimation, field of view = 400×400 mm, acquisition matrix 
512× 512. 100 mL of intravenous contrast agent (Ultravist 300; Bayer Schering, 
Berlin, Germany) was administered at a rate of 5 mL/s, typically through an 18G 
cannula in the antecubital fossa. CT images from other centres were also used when 
no local imaging was available, as long as they were considered to be of diagnostic 
quality. 
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5.2.2.4 Image Analysis 
MR images were analysed on a GE Advantage Workstation 4.4 with GE Advantage 
Workstation ReportCard software, the observer was blinded to all clinical 
information and other investigations. Left and right ventricular end-diastolic volume, 
end-systolic volumes, right and left ventricular stroke volume and mass were 
calculated (all indexed to body surface area), right and left ventricular ejection 
fractions, ventricular mass index (RV mass divided by LV mass) (133) and 
interventricular septal angle were measured as previously described (125). Maximal 
and minimal PA areas were manually traced, and relative area change was defined by 
the following equation: RAC= (maximum area-minimum area)/minimum area (14, 
28).  
From the dual inversion recovery fast spin echo pulmonary arterial black blood 
images black blood slow flow artefact was scored. A semi-quantitative scale from 0 to 
5 was used (0 = absent, 1 = segmental, 2 = lobar, 3 = distal main, 4 = proximal main 
and 5 = trunk) (135). From the phase contrast imaging data, the contours of the vessel 
were automatically traced, with manual correction when required. The software then 
calculated the velocity of all the pixels included within the region of interest (ROI). 
Pulmonary artery average velocity was calculated as QFlow forward PA 
velocity/diastolic PA size.  
Signal enhancement versus time curves were generated from the dynamic contrast 
enhanced MRI images, for regions of interest in the pulmonary artery and the left 
atrium. Pulmonary transit time (PTT) was calculated as the time delay between peak 
pulmonary arterial signal and peak left atrial signal. The full-width-half-maximum 
(FWHM) of the contrast bolus passage was calculate as the time delay between half 
maximum signal intensity on the up and down-slopes of signal in the pulmonary 
artery enhancement curve.  
The closest CT to the date of the MRI was chosen to identify the cause of the 
pulmonary disease. The cases were reviewed by 2 radiologists, a general radiologist 
(CSJ, 5 years’ experience) and a chest radiologist (AJS, 11 years’ experience), who 
were blinded to all other clinical and imaging information. Images were reviewed on 
a clinical workstation in the clinical radiology department, on diagnostic quality Barco 
screens (Barco, UK). CT images were reviewed using lung windows. Cases were split 
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into interstitial lung disease, chronic obstructive pulmonary disease (emphysema and 
bronchitis) or combined pulmonary fibrosis and emphysema based on agreed 
qualitative CT evidence of each of the diseases (268). Any cases without CT evidence 
of lung disease were classified as “other”. Any disagreements were corrected by 
consensus between the two radiologists, again blinded to other clinical and imaging 
data. The severity of lung disease was given a score of 0-3 for each case.  
5.2.2.5 Statistical Analysis 
Statistical differences between each group of PH-lung disease were calculated for all 
demographic, right heart catheter and cardiac MRI indices using ANOVA.  
Statistical analysis was performed using SPSS (IBM, Chicago), and all graphs were 
produced using GraphPad prism 7 (GraphPad Software, San Diego). A p-value of <0.05 
was considered statistically significant.  
In order to correct for the discrepancy in severity of PH between the different groups, 
sub-analysis was performed in the patients with severe pulmonary hypertension 
(mPAP ≥35 mmHg).   
Dr CS Johns  Cardio-Pulmonary MRI in PH   136  
 Results 
Over the period studied, 2437 patients in the pulmonary hypertension referral centre 
underwent a cardio-pulmonary MRI; of these 1272 were incident cases. 190 patients 
had PH due to lung disease and right heart catheter within 30 days of MRI. Two were 
excluded as there was no thoracic CT available to review and two were excluded as 
the CT was non-diagnostic due to artefact. Over the same time, 111 patients with 
idiopathic pulmonary arterial hypertension (IPAH) had right heart catheter within 30 
days of MRI and were used as a comparison group. Figure 5.9 shows the flow of 
patients. 
 
Of the cases with PH lung (190), 68 had chronic obstructive pulmonary disease 
(COPD), 55 interstitial lung disease (ILD), 32 combined pulmonary fibrosis and 
emphysema (CPFE) and 31 had other respiratory disease. Baseline demographic data 
is provided in Table 5.4 and Table 5.5. Analysis of the baseline characteristics and 
outcome in other lung diseases group has not been performed due to the 
heterogeneous nature of this group of patients, which is made up of small numbers of 
sleep disordered breathing and alveolar hypoventilation disorders.  
Figure 5.9: Patient Flow 
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Table 5.4: Patient demographics, mean with standard deviation and ANOVA p-value between the subgroups. 
Significant differences are shown by the icon below. 
  All COPD ILD CPFE p-value 
 Number 190 68 55 32  
Demographics      
 Age (years) 67 (10) 68 (9) 65 (11) 69 (9) 0.183 
 Sex (F/M) 103/87 34/34 33/22 12/20 0.126 
 WHO functional class 
(II,III,IV) 
8,141,40 3,54,10 3,38,14 0,22,10 0.249 
 ISWT (m) 137 (145) 131 (102) 152 (225) 141 (90) 0.120 
 Days RHC to MR 0 (1) 0 (1) 0 (0) 0 (0) 0.106 
 Survival (years) 2.5 (0.1) 2.8 (0.2) 1.7 (0.2) 2.5 (0.3) 0.029 
RHC      
 mPAP (mmHg) 43 (11) 42 (10) † 41 (12) † 48 (10) ‡* 0.011 
 mRAP (mmHg) 10.1 (5.2) 10.1 (4.8) 8.7 (5.6) 10.6 (4.9) 0.190 
 PAWP (mmHg) 12.7 (0.8) 12.6 (3.8) 11.7 (5.5) 11.7 (3.4) 0.475 
 CI (L/m2) 2.6 (0.8) 2.7 (0.8) † 2.7 (0.8) † 2.3 (0.6) ‡* 0.024 
 PVRI (dynes) 318 (199) 308 (190)  307 (239)  402 (168) 0.083 
 SvO2 (%) 64 (8) 65 (8) 67 (7) † 62 (7) * 0.042 
Spirometry      
 FEV1 (% predicted) 67 (26)  56 (29) †* 70 (22) ‡ 80 (21) ‡ <0.001 
 FVC (% predicted) 75 (27) 79 (31) * 64 (20) †‡ 90 (24) ‡* <0.001 
 FEV1/FVC 64 (17) 50 (13) †* 77 (12) †‡ 65 (13) ‡* <0.001 
 TLCO (% predicted) 27 (15) 25 (17) 26 (10) 24 (8) 0.726 
*significant difference to ILD, †significant difference to CPFE, ‡significant difference to COPD 
 
Table 5.5: Baseline cardiopulmonary MRI characteristics, mean with standard deviation and ANOVA p-value 
between the subgroups. Significant differences are shown by the icon below. 
 All COPD ILD CPFE p-value 
RV EDV index (ml/m2) 85.7 (34.6) 90.8 (37.9)  78.8 (31.9) 89.1 (6.3) 0.155 
RV ESV index (ml/m2) 55.1 (30.8) 57.6 (34.6) 49.8 (27.3) 33.2 (11.9) 0.203 
RVEF (%) 38.4 (13.1) 40.6 (14.4) † 39.1 (12.8) † 33.2 (11.9) ‡* 0.038 
RVSVI (ml/m2) 30.9 (12.2) 33.2 (10.0) † 29.0 (11.1) 27.3 (10.9) ‡ 0.015 
RV mass index (g/m2) 22.1 (13.9) 24.9 (17.7) * 18.5 (11.4) ‡ 22.6 (9.7)  0.052 
LV EDV index (ml/m2) 52.9 (17.5) 56.1 (19.8) 50.3 (17.4) 48.6 (13.5) 0.078 
LV ESV index (ml/m2) 18.5 (9.9) 20.3 (12.6) 16.2 (8.7) 18.8 (8.0) 0.106 
LVEF (%) 65.5 (11.6) 64.6 (12.4) 68.1 (11.9) 61.8 (11.6) 0.055 
LVSVI (ml/m2) 34.5 (11.9) 35.9 (12.4) 34.0 (12.5) 29.8 (9.1) 0.058 
LV mass index (g/m2) 51.0 (12.3) 52.7 (14.4) 49.2 (11.6) 48.4 (9.9) 0.199 
LA volume index (ml/m2) 35.4 (18.7) 39.0 (19.9) † 35.4 (19.6) † 26.2 (7.2) ‡* 0.005 
PA RAC (cm2) 9.5 (6.5) 9.6 (7.0) 9.8 (7.3) 8.2 (4.9) 0.579 
Diastolic PA size 851 (233) 872 (273) 831 (203) 838 (189) 0.597 
Systolic PA size 929 (254) 955 (298) 911 (216) 908 (215) 0.553 
VMI  0.46 (0.28) 0.50 (0.34) 0.42 (0.25) 0.49 (0.23) 0.279 
IVS angle (˚) 168 (21) 166 (20) † 166 (21) 179 (22) ‡ 0.006 
Average PA velocity (cm/s) 6.0 (2.2) 6.1 (2.0) 6.3 (2.5) 5.3 (1.6) 0.133 
Distensibility 0.19 (0.18) 0.18 (0.16) 0.21 (0.22) 0.16 (0.11) 0.422 
Compliance 1.6 (1.6) 1.6 (1.6) 1.7 (1.8) 1.4 (0.95) 0.629 
Ees/Ea 0.84 (0.58) 0.92 (0.66) † 0.90 (0.56) † 0.60(0.34) ‡* 0.026 
*significant difference to ILD, †significant difference to CPFE, ‡significant difference to COPD 
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Table 5.6: Patient demographics for the patients with severe PH. An IPAH cohort is provided for reference. 
  All lung COPD ILD CPFE p-value IPAH 
 Number 134 48 33 28  92 
Demographics       
 Age (years) 68 (9) 68 (9) 67 (10) 69 (8) 0.885 58 (17) 
 Sex (F/M) 73/65 22/26 20/13 10/18 0.144 63/30 
 WHO functional 
class (II,III,IV) 
2,102,33 1,36,10 0,23,10 0,19,9 0.643 1,76,14 
 ISWT (m) 130 (157) 119 (96) 153 (288) 146 (94) 0.700 218 (190) 
 Days RHC to MR 0 (2) 1 (1) 0 (0) 0 (0) 0.106 2 (5)  
 Survival (years) 1.4 (1.0) 1.6 (1.1) * 1.0 (0.8) ‡ 1.3 (1.0) 0.022 3.3 (0.2) 
RHC       
 mPAP (mmHg) 48 (9) 47 (8) 49 (9) 50 (8) 0.228 56 (11)  
 mRAP (mmHg) 11 (5) 11 (5) 11 (6) 11 (5) 0.996 12 (6) 
 PAWP (mmHg) 13 (4.9) 13 (4) 12 (6) 12 (3) 0.577 12 (4) 
 CI (L/m2) 2.5 (0.8) 2.5 (0.8) 2.5 (0.1) 2.3 (0.7) 0.335 2.3 (0.7) 
 PVRI (dynes) 377 (202) 368 (197) 414 (254) 424 (167) 0.460 536 (291) 
 SvO2 (%) 63 (8) 63 (9) 64 (8) 62 (7) 0.450 59 (8) 
Spirometry       
 FEV1 (%) 71 (24) 59 (24) †* 74 (23) ‡ 82 (20) ‡ <0.001 79 (21) 
 FVC (%) 80 (24) 83 (25) * 67 (21) ‡†  94 (21) * <0.001 81 (18) 
 FEV1/FVC 63 (17) 50 (14) †* 77 (12) ‡† 64 (13) ‡* <0.001 69 (13) 
 TLCO (%) 27 (13) 24 (10)  24 (7) 24 (8) 0.998 44 (21) 
*significant difference to ILD, †significant difference to CPFE, ‡significant difference to COPD 
 
Table 5.7: Baseline cardiac MRI characteristics for the patients with severe PH lung.  
 All COPD ILD CPFE p-value IPAH 
RV EDV index (ml/m2) 91 (31) 101 (36) 91 (33) 86 (22) 0.141 101 (36) 
RV ESV index (ml/m2) 60 (28) 66 (34) 60 (29) 59 (21) 0.481 63 (27) 
RVEF (%) 36 (12) 37 (14) 36 (12) 34 (12) 0.541 35 (10) 
RVSVI (ml/m2) 31 (11) 34 (10) † 30 (11)s 28 (11) ‡ 0.027 32 (12) 
RV mass index (g/m2) 25 (15) 29 (19) 22 (13) 22 (9) 0.092 26 (11) 
LV EDV index (ml/m2) 51 (18) 54 (21) 47 (18) 47 (13) 0.184 46 (14) 
LV ESV index (ml/m2) 18 (10) 21 (14) 16 (9) 18 (7) 0.223 16 (8) 
LVEF (%) 65 (12) 63 (14) 66 (12) 62 (12) 0.367 66 (10) 
LVSVI (ml/m2) 33 (12) 34 (12) 31 (12) 30 (9) 0.315 30 (10) 
LV mass index (g/m2) 51 (12) 52 (15) 49 (12) 49 (10) 0.458 47 (11) 
LA volume index 
(ml/m2) 
37 (20) 40 (22) † 39 (23) † 26 (7) *‡ 0.008 32 (20) 
PA RAC (cm2) 8.5 (5.6) 8.5 (6.3) 7.6 (5.3) 8.6 (5.0) 0.742 8.1 (5.1) 
Diastolic PA size 894 (229) 907 (263) 882 (216) 848 (190) 0.574 892 (223) 
Systolic PA size 968 (250) 985 (291) 947 (227) 922 (218) 0.565 966 (251) 
VMI  0.52 (0.29) 0.58 (0.36) 0.52 (0.28) 0.49 (0.22) 0.414 0.60 (0.25) 
IVS angle (˚) 173 (20) 172 (19) 173 (19) 180 (23) 0.208 181 (21) 
Black blood score      5.0 (1.8) 
PA to LA TTP (s) 7.3 (2.6) 7.2 (2.4) 5.2 (0.9) 8.2 (0.9) 0.016 0.14 (0.10) 
Average PA velocity 
(cm/s) 
5.8 (2.1) 5.7 (1.9) 5.9 (2.5) 5.4 (1.5) 0.683 1.4 (1.0) 
Distensibility 0.17 (0.13) 0.19 (0.17) 0.15 (0.13) 0.17 (0.10) 0.605 58 (11) 
Compliance 1.5 (1.3) 1.7 (1.8) 1.3 (1.2) 1.5 (1.0) 0.395 8.1 (8.4) 
Ees/Ea 0.69 (0.45) 0.69 (0.52) 0.65 (0.42) 0.59 (0.32) 0.651 0.57 (0.33) 
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5.2.3.1 Baseline characteristics of PH lung disease 
The patients with PH-lung disease had significant differences in all cardio-pulmonary 
MRI characteristics at baseline, but there was also a significant difference in mean 
pulmonary artery pressure. In order to compensate for this, baseline analysis was 
performed in the patients with severe pulmonary hypertension (mPAP ≥35mmHg). 
There were 138 patients with mPAP ≥35mmHg: 48 severe PH-COPD, 33 severe PH-
ILD, 28 severe PH-CPFE and 29 severe PH-other respiratory disease. In the ILD group 
radiological patterns of fibrosis included six patients with usual interstitial 
pneumonitis (UIP), 18 with Non-Specific Pneumonitis (NSIP), 5 with a chronic 
hypersensitivity pneumonitis (HP) pattern and 4 with an unknown radiological 
pattern of fibrosis.  
5.2.3.1.1 Demographic differences 
Baseline demographic data for the severe PH-lung patients is provided in Table 5.6. 
There was no significant difference in age or sex between the lung disease groups, 
although the severe PH-COPD and CPFE groups had a higher proportion of male 
patients, whereas the ILD group had a predominance of female patients. WHO 
functional class and walk distance were also not significantly different, although the 
walk distance was significantly lower for all PH-respiratory groups compared to 
IPAH.  
5.2.3.1.2 Haemodynamic differences 
When comparing all patients there was a significantly higher mean mPAP in the CPFE 
group with correspondingly low cardiac index. A higher proportion of patients with 
CPFE had severe PH (28/32) than COPD (48/68) and ILD (33/55).  
When comparing the severe PH-lung disease patients, although the COPD patients had 
the lowest (42mmHg) and the CPFE patients the highest mPAP (48mmHg), there was 
no significant difference in haemodynamics, although the numbers have significantly 
reduced. The PH lung and severe PH lung patients had significantly lower mPAP than 
the IPAH comparison group. Pulmonary arterial wedge pressure (PAWP) was not 
elevated in any group.  
There was no correlation between the visual severity on CT in the COPD or the ILD 
cohorts (r=0.028, p=0.818 and r=-0.39, p=0.775 respectively).  
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5.2.3.1.3 Spirometric differences 
Spirometry showed the expected differences between the severe PH-lung groups: 
COPD patients had significantly reduced forced expiratory volume in one second 
(FEV1) percent predicted (59%, sd 24) and low forced expiratory volume in second 
to forced vital capacity (FEV1/FVC) (50, sd 14), whereas ILD patients had reduced 
FVC (67%, sd 21) p-values for all spirometry were <0.0001. Transfer capacity for 
carbon monoxide (TLCO) percent predicted was similarly low in COPD, ILD and CPFE 
(24% in all, p-value 0.998). Mixed venous oxygen saturation (SvO2) was not different 
across the groups but was significantly lower in the severe PH lung patients than in 
the IPAH patients.  
 
5.2.3.2 Cardiac MRI phenotypes of severe PH-lung 
In all patients with severe PH-lung disease right ventricular volumes (end-diastolic 
and end-systolic) were moderately elevated (91ml/m2 and 60 ml/m2) with no 
significant difference between the groups (p-value 0.141 and 0.481 respectively). 
Right ventricular ejection fraction was low in all severe PH-lung groups, but with no 
significant differences between them (36% for the severe PH-lung cohort as a whole, 
p-value 0.541). Table 5.6 and Table 5.7 provide the baseline cardiac MRI metrics for 
patients with severe PH. 
Left ventricular end diastolic volume was low in all of the groups but not significantly 
different between the groups (51ml/m2). Left ventricular end systolic volume and 
ejection fraction were normal and similar across the groups (18ml/m2 and 65%, p-
values 0.481 and 0.541 respectively). Left ventricular stroke volume index was low in 
all groups, but again, not different between the groups (33ml/m2, p-value 0.315).  
Left atrial volume index was low in all of the PH-lung cases, but was significantly lower 
in the CPFE cases (mean 26 ml/m2, p-value 0.008). The interventricular septal angle 
was increased (flattened septum) in all cases but with no significant differences 
between groups (173, p-value 0.208).  
The time to peak perfusion from the pulmonary artery to the left atrium was 
significantly longer in the COPD and CPFE patients (7.9 and 8.2 secs) than in the ILD 
patients (5.1 secs, ANOVA p-value 0.016), and although the inverse of this relationship 
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was shown in pulmonary arterial average velocity, it was not found to be statistically 
significant. 
 Discussion 
The work presented in this section, discusses the baseline cardiac MRI characteristics 
in a cohort of severe PH-lung disease cohort in a tertiary referral centre (245). 
Patients with PH due to CPFE were significantly more likely to have severe PH than 
those with COPD or ILD.    
On first glance there appear to be significant differences in the baseline characteristics 
of the patients with COPD and ILD in comparison to CPFE. The most striking 
difference is with right heart catheter measured mean pulmonary artery pressure, the 
mean mPAP of COPD and ILD was 42 and 41mmHg respectively and in the CPFE 
patients was 48mmHg (p-value 0.011). A higher proportion of CPFE patients had 
severe pulmonary hypertension at baseline. In order to correct for this, comparison 
was performed in the cases who had lung disease with severe pulmonary 
hypertension (mPAP ≥35mmHg). When corrected in this way, the only significant 
differences between the groups was stroke volume and left ventricular volume index, 
both of which were lower in CPFE. It is expected that this result would be due to an 
increased PVR in the CPFE patients, but right heart catheter measured PVRI was not 
significantly different across the groups.  
It would be interesting to identify the relationship between lung disease severity on 
CT and the severity of pulmonary hypertension. Unfortunately, as the CT cans were 
performed as part of the clinical workflow, they were performed as CTPAs, to assess 
the pulmonary artery and the right ventricle. This meant that quantitative assessment 
of the pulmonary parenchyma was not possible. It is also difficult to account for the 
severity of disease between COPD, ILD and CPFE using either clinical, lung function or 
imaging criteria. In this patient cohort we found no correlation between visual score 
of CT severity and severity of PH elevation in the COPD and ILD patients, however this 
is limited by small patient numbers and differs from published literature in much 
larger numbers, but with a lower incidence of PH (103,269,270). Studies assessing the 
relationship between PH and severity of lung disease in COPD and ILD and a 
comparison of the two will require large datasets to account for the heterogeneity of 
lung disease (270). 
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This work is limited by its retrospective single centre design, although all 
quantification was performed at the time of the scan, blinded to the diagnosis. As a 
result of the study taking place in a PH referral centre, the population has a trend 
towards the presence of pulmonary hypertension. The proportion of PH and the 
severity of PH is probably more than expected for the general COPD, ILD and CPFE 
population as only patients with significant symptoms would be referred for further 
investigation (a large number of patients with COPD and ILD would be managed in 
the community or in local secondary care clinics). This also leads to a potential 
problem in the definition of baseline, as the baseline is the point at which the patient 
is referred to the PH service, rather than the point at which they develop PH.   
 Conclusion 
At baseline cardiac MRI, there were no significant differences between the pulmonary 
hypertension lung groups when allowing for differences in mean pulmonary arterial 
pressure. A higher proportion of PH-CPFE patients have mean pulmonary arterial 
pressure ≥35mmHg than the ILD and COPD groups. Future work will be required to 
assess the role of lung disease severity in the development of PH in larger numbers.   
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5.3 CARDIO-PULMONARY MRI CAN SCREEN FOR CTEPH 
 Rationale 
Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially curable 
form of pulmonary hypertension (61). The diagnosis requires a mean pulmonary 
artery pressure (mPAP) ≥25 mmHg at right heart catheterization (RHC), in the 
presence of at least one segmental defect on perfusion imaging or filling defects on 
computed tomography pulmonary angiography (CTPA), after at least 3 months of 
effective anticoagulation (62). The true incidence and prevalence of CTEPH is not 
known, but the cumulative incidence of CTEPH after survival from an acute 
pulmonary embolus is reported as 3.8% at 2 years (63). The pathological process is 
thought to be due to incomplete lysis of the acute pulmonary embolus; the subsequent 
organization of the obstructing thrombus leading to  obstruction of pulmonary 
vascular bed (64). This ultimately leads to increased pulmonary arterial pressure, 
right ventricular dysfunction and if untreated the prognosis is poor (65). 
Patients with CTEPH usually have a history of either pulmonary embolism or deep 
venous thrombosis, although a significant proportion may present with unexplained 
breathlessness or pulmonary hypertension of unknown cause (66,67). It is important 
that the diagnosis of CTEPH is made as pulmonary endarterectomy is associated with 
increased survival and a favourable functional outcome in CTEPH (61). The 2013 
World Symposium on Pulmonary Hypertension recommended single photon 
emission computed tomography (SPECT) V/Q scintigraphy as the preferred screening 
test for CTEPH (271), this entails injection of 100MBq of 99mTc labelled 
macroaggregated human albumin, resulting in exposure to ionizing radiation with an 
effective dose of 0.017mSv/MBq (87).  
Cardio-pulmonary MR imaging is emerging as an important tool for assessing the 
structure and function of the right ventricle in patients with PH (155), and  it has 
already been shown that 3D dynamic contrast enhanced (DCE) lung perfusion MRI 
has a similar sensitivity for diagnosing CTEPH when compared with planar perfusion 
scintigraphy (91). Planar scintigraphy is increasingly being replaced by SPECT in 
clinical practice, due to the higher spatial resolution and improved sensitivity in the 
detection of smaller perfusion defects (272).  
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5.3.1.1 Hypotheses 
1. Dynamic contrast enhanced perfusion MRI has high diagnostic accuracy in the 
identification of patients with chronic thrombo-emboli disease.  
2. DCE-MRI has non-inferior diagnostic accuracy to perfusion SPECT in the 
identification of chronic thrombo-embolic disease.  
 
5.3.1.2 Aims 
The aim of this study was to assess the diagnostic accuracy of perfusion MRI against 
perfusion SPECT in screening for CTEPH. 
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 Patients and Methods 
Consecutive patients with suspected CTEPH or unexplained pulmonary hypertension 
attending a pulmonary hypertension referral centre (245) underwent contrast 
enhanced lung perfusion MRI, perfusion SPECT and CTPA within 14 days  of right 
heart catheterization, from April 2013 to April 2014 were identified. A diagnosis of 
CTEPH was based upon a review of multimodality imaging, clinical correlates and 
right heart catheterisation as per standard clinical criteria (62), this was decided at a 
multi-disciplinary team meeting and was used as the reference standard. Patients 
with chronic thrombo-embolic disease, but without pulmonary hypertension were 
considered a true positive. This was decided as the current method of diagnosis of 
pulmonary hypertension is not made on imaging, but instead relies on pressure 
measurements in the pulmonary artery on right heart catheterization. The local 
research ethics committee granted ethical approval for this retrospective study, 
written consent was waived. 
5.3.2.1 Image acquisition  
MR imaging was performed on a 1.5T whole body system (HDx, GE Healthcare, 
Milwaukee, USA) using a time-resolved 3D spoiled gradient echo sequence with view-
sharing (273). An 8-channel cardiac receiver array coil was used. The sequence 
parameters were: TE=1.1 ms, TR=2.5 ms, Flip angle 30°, FOV 48 cm x 48 cm, parallel 
imaging in plane x 2, in plane resolution 200x80, bandwidth 250 kHz, slice thickness 
10 mm, approximately 32 slices, 48 time points with an overall effective 3D frame rate 
of ~ 0.5 s. Images were acquired in a coronal orientation during a single breath-hold. 
The acquired voxel size was 1.875 x 1.875 x 10 mm. Contrast injection of a 0.05ml per 
kg patient weight dose of Gd-BT-D30A (Gadovist, Schering, Berlin, Germany) was 
injected at a rate of 4 ml per second with the injection rate controlled using an 
activated pump injector (Spectris, MedRad) typically via a vein in the antecubital fossa 
using an 18G cannula, followed by a 20ml saline flush.  
SPECT imaging was performed on a General Electric Infinia SPECT system using a low 
energy general-purpose collimator. 100 MBq 99mTc MAA was administered through 
a direct intravenous injection with a needle of 21G or larger. The image acquisition 
parameters were: acquisition matrix 128x128, 60 projections per detector and 7 
seconds per projection. Images were acquired prone with the patient’s arms extended 
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above their heads, where possible. Figure 5.10 shows an example of SPECT and MRI 
perfusion imaging I a patient with and without CTEPH. 
5.3.2.2 Image analysis 
DCE perfusion images were analysed on a slice-by-slice basis by subtraction of the 
baseline pre-contrast image, this was performed on a GE Advantage workstation 
(General Electric Healthcare). The peak enhancement image in the contrast passage 
time series was independently analysed by a general radiologist (CSJ, 5 years of 
experience) and a consultant chest radiologist (AJS, 11 years of experience) blinded 
to all other imaging and clinical information. The images were reviewed on a general 
reporting workstation in the general radiology department on diagnostic quality 
Barco screens (Barco, UK). The images were qualitatively assessed as either positive 
or negative for chronic thromboembolic disease. On both DCE perfusion MRI and 
perfusion SPECT, the presence of one or more segmental or subsegmental perfusion 
defects was considered positive for pulmonary embolic disease, as per recognized 
clinical guidelines (1). The dynamic contrast enhanced perfusion images were 
typically viewed with a window of 40 and a level of 19, although this was manipulated 
if required. Subsequently the SPECT imaging was reviewed by the same radiologists, 
at a separate sitting, separated from the time of the MRI analysis by at least one week, 
blinded to all other imaging and clinical information. Any disagreements were 
resolved by consensus. The multidisciplinary decision of the presence or absence of 
chronic thrombo-embolic disease, as outlined above, was considered the reference 
standard. 
Figure 5.10: SPECT and DCE MRI perfusion 
images.  
Matched slices from 3D coronal SPECT perfusion 
images (top row) and DCE MR perfusion images 
(bottom) in a patient with normal lung perfusion 
(A) and with CTEPH (B). This shows the typical 
wedge-shaped perfusion defects (arrows) in the 
right mid, left lower, and left upper zones on the 
MR and the SPECT imaging of patient B. Note the 
images are presented on an inverse grey scale as 
reviewed clinically for SPECT. 
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5.3.2.3 Statistical analysis 
Diagnostic accuracy was assessed for SPECT and DCE perfusion MRI using a 2x2 
predictive table to calculate sensitivity, specificity, negative and positive predictive 
value. Inter-observer and inter-test agreement was assessed using kappa, with 0.60-
0.79 considered moderate agreement, 0.80-0.89 strong and above 0.90 excellent 
agreement (274). Statistical analysis was performed using SPSS 22 (IBM, Chicago) and 
GraphPad Prism 7 (GraphPad Software, San Diego). A p-value of <0.05 was considered 
statistically significant.    
5.3.2.4 Patient Demographics 
Over the 1-year period of the study, 74 patients with suspected CTEPH attended for 
perfusion MRI, SPECT and CTPA. 36 patients were diagnosed with CTEPH and 10 
patients with CTED (chronic thromboembolic disease without pulmonary 
hypertension) according to standard criteria. In the CTEPH and CTED group there 
were 20 female and 26 male patients. The mean age of both groups was 62 years 
(standard deviation 14 years).  
 Results 
DCE perfusion MRI correctly identified all CTEPH and CTED patients (sensitivity of 
100%), compared to 97% sensitivity for SPECT, p-values for all data were <0.0001 
(see table 1 for more details). The specificity of MR was 81% and SPECT 81%. The 
patient not identified by SPECT had mild, inoperable CTEPH, and was correctly 
identified on CTPA and perfusion MRI. There was one indeterminate SPECT case and 
two indeterminate MRI cases. The kappa value between SPECT and MRI was 0.88, 
indicating strong agreement. Inter-observer kappa was 0.80 and 0.88 for SPECT and 
MRI respectively indicating strong inter-observer agreement.  
Table 5.8: Summary of diagnostic performance of SPECT and MR perfusion with 95% confidence interval (CI), the 
p-values for all data were <0.0001. 
 SPECT Perfusion Perfusion MRI 
Sensitivity  97% (95% CI 88-99%) 100% (95% CI 92-100%) 
Specificity  81% (95% CI 62-94%) 81% (95% CI 62-94%) 
Positive predictive value  90% (95% CI 78-97%) 90% (95% CI 78-97%) 
Negative predictive value  96% (95% CI 78-100%) 100% (95% CI 85-100%) 
Inter-observer agreement (kappa) 0.80 0.88 
Dr CS Johns  Cardio-Pulmonary MRI in PH   148  
 Discussion  
DCE lung perfusion MRI has increased sensitivity when compared to SPECT perfusion 
scintigraphy in the detection of CTEPH. In the patients studied, a combination of 
perfusion MR and CTPA identified all patients with CTEPH and CTED. This reflects and 
updates the findings of a previous study by Rajaram et al. which compared DCE 
perfusion MRI with planar scintigraphy (91). There were two indeterminate sets of 
MRI scans, it was felt that low signal to noise ratios in these images was the underlying 
reason for an indeterminate study. Perfusion MRI can be performed in the same 
sitting as high-resolution pulmonary MR angiography and cardiac MRI scan, and has 
the potential for a “one-stop-shop” analysis of pulmonary perfusion and assessment 
of right heart and pulmonary vascular characteristics. Cardiac MR assessment of 
baseline and progression of right ventricular characteristics over time in idiopathic 
pulmonary artery hypertension (IPAH) has been previously shown to be a predictor 
of outcome (130,204). 
These results differ somewhat from the literature regarding MR in the diagnosis of 
acute pulmonary emboli (PE). The PIOPED III study assessed the efficacy of MR 
angiography, and showed a sensitivity of 78% for acute PE detection in technically 
adequate scans, 25% of patients had technically inadequate scans (275). However, 
there have been more recent reports of improving diagnostic rates, particularly when 
performed in dedicated centres (276–278). Although it should be noted that whilst 
contrast enhanced MRA and DCE perfusion images are different methods for 
assessment of the pulmonary vasculature, in that MRA focuses on structural form of 
the major vessels whilst DCE perfusion MR highlights downstream perfusion of the 
small vessels, it is likely that the main difference in the sensitivity of MR in the 
assessment of acute and chronic PE could be due to the size of thrombus detected. 
Due to improvements in technologies, modern day CTPA is able to pick up very small 
subsegmental acute PEs, which (in our opinion), are likely to be smaller than those 
that can be currently detected on MR angiography or MR perfusion imaging. These 
peripheral acute emboli are very unlikely to cause CTEPH, so the lower spatial 
resolution of MR angiography and perfusion imaging when compared to CTPA should 
not miss clinically significant chronic thrombo-embolic disease. In the present study, 
DCE-MRI had the highest sensitivity for detecting CTEPH although SPECT Q only failed 
to identify a single patient with distal thromboembolic disease. Importantly, however, 
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no modality missed surgical accessible CTEPH. The case that was missed by SPECT 
was in a patient with coexistent lung pathology which caused a defect that was not 
typical of embolic disease on the SPECT image, the anatomical information available 
on the non-subtracted MRI database meant that was less of an issue for the MR 
perfusion scan. Whilst CTPA is widely available and may give clues to other 
differential diagnoses, it should be noted that CTEPH and CTED may be missed on 
CTPA by radiologists not experienced in the assessment of pulmonary vascular 
disease leading to the recommendation in the latest international guidelines that 
SPECT Q is preferred to CTPA when screening for CTEPH (1). Given the similarities 
between the images obtained by DCE-MRI and SPECT Q, it is anticipated that DCE-MRI 
would have similar diagnostic performance in the hands of a general radiologist. In 
this study, perfusion imaging had a modest specificity of 81% (for both SPECT and 
DCE-MRI), in keeping with the known false positive rate of SPECT perfusion imaging 
(238).   
Although SPECT imaging and DCE perfusion MRI both demonstrate pulmonary 
perfusion of the small (sub-voxel size) vessels, there are fundamental differences in 
the method of acquisition and contrast enhancement. SPECT imaging represents 
deposition of radio-isotope particles in the capillaries and small arterioles in the lung 
(87), with acquisition times around ten minutes in a pseudo steady state of lung 
perfusion. DCE MR perfusion images are, however, dynamically acquired in the first 
pass of gadolinium; and a 3D dataset is acquired (here approximately every 0.5 secs) 
during a breath-hold. The initial “unenhanced” pre-bolus arrival dataset is subtracted 
from the peak enhancement dataset to give the perfusion images. As such, the MR 
images are interpreted as a snapshot of the ‘peak’ first pass perfusion signal and also 
the enhanced signal from blood in the conducting major vessels is not explicitly 
segmented from the signals from the rest of the pulmonary blood pool.  
An alternative method of analysis which might closer represent the cumulative signal 
of a SPECT scan would be to integrate the dynamic perfusion signal with time to create 
maps of regional perfused blood volume (279). An example of the quantitative 
parametric maps of pulmonary perfusion is provided on page 54 (Figure 2.18). Using 
the arterial input function and unenhanced lung T1 maps, time-contrast curves can 
be calculated for each voxel and peak contrast, mean transit time and pulmonary 
Dr CS Johns  Cardio-Pulmonary MRI in PH   150  
perfusion can be calculated, as previously described (146,280). These are calculated 
for each voxel over the time-course of the perfusion dataset and can be presented in 
a parametric map. Techniques to segment out the major vessels could also be 
employed to mask the signal from the perfused capillary bed (281), although 
background signal from the major vessels was however not felt to affect the 
radiological interpretation of the images in this study.  
This study has a number of limitations. As our study was conducted in a pulmonary 
hypertension referral centre (245) the negative and positive predictive value will only 
be valid for a population where the probability of CTEPH and CTED is high, although 
given the high sensitivity and specificity of MRI it would be expected to perform well 
in symptomatic patients following PE where the prevalence of CTEPH is increased. 
The retrospective nature of the study has the potential to introduce bias, however, 
both reviewers were blinded to each other’s observations and clinical information. A 
prospective study examining the value of MRI and SPECT VQ as a screening test for 
CTEPH will be required to address the clinical utility and diagnostic performance of 
these investigations in populations at risk. 
 Conclusion 
Dynamic contrast enhanced perfusion MRI has high sensitivity for CTEPH and does 
not use ionising radiation making it an ideal imaging screening test for patients with 
suspected CTEPH. 
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6 CARDIAC MRI CAN PROGNOSTICATE IN PULMONARY 
HYPERTENSION 
 
Once patients have been assessed for potential therapeutic options, it is important to 
identify those who are at risk of a poor outcome. The final chapter of results in this 
thesis aims to assess the role of cardiac MRI in the evaluation of mortality risk in 
patients with pulmonary hypertension.  
Previous work has shown that cardiac MRI markers of right ventricular structure and 
function can provide incremental prognostic information in patients with pulmonary 
arterial hypertension (124). In both patients with left heart and respiratory disease, 
the presence of pulmonary hypertension is known to be a marker of a poor outcome. 
There is little data available in these patient groups to identify which of the patients 
within these groups are at risk of death after the development of pulmonary 
hypertension. Work from our group, which is ongoing, has identified that the largest 
risk factor for a poor outcome in patients with CTEPH is whether the patient has 
pulmonary end-arterectomy, either due to patient choice or technical factors (282). 
Future work is concentrating on the risk factors for death in the group of patients who 
decline surgery.  
The following sections in this chapter explore the prognostic information that can be 
gained from cardiac magnetic resonance imaging in the context of respiratory disease 
(specifically COPD) and left heart diseasev.  
 
                                                        
v Each section of this chapter makes up work in separate papers. 
Cardiac MRI has Prognostic Value in PH-LHD is based upon a manuscript currently under review with the 
Journal of the American College of Cardiology: Heart Failure. 
Cardiac MRI can Identify Patients with PH-COPD Who Are At Risk Of Death is based upon a manuscript that 
has been published in European Radiology, entitled “Non-invasive methods for estimating mPAP in COPD 
using cardiovascular magnetic resonance imaging” (217). 
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6.1 CARDIAC MRI HAS PROGNOSTIC VALUE IN PH-LHD 
 Rationale 
Pulmonary hypertension is most commonly seen in patients with left heart disease 
(1,9,20,21). It is increasingly recognised (23), and is associated with a poor prognosis 
(24–27) and high levels of health care utilization. It is seen in the setting of both 
reduced and preserved left ventricular systolic function (283,284). Heart failure with 
preserved ejection fraction (HFpEF) accounts for approximately half of all patients 
with heart failure (285). In contrast to improvements in outcome following 
pharmaceutical and mechanical interventions in patients with heart failure and 
reduced left ventricular systolic function (HFrEF) there has been very limited 
progress in patients with HFpEF (23). The development of pulmonary hypertension 
and right ventricular dysfunction in these patients is associated with a worse outcome 
regardless of aetiology (286–289) Interestingly, approaches to reduce pulmonary 
artery pressure guided by implantable pulmonary artery pressure monitors (using 
primarily diuretic therapy) can improve outcomes in these patients (285,290). 
In most patients with HFpEF who develop pulmonary hypertension, elevated 
pulmonary artery pressures are thought to reflect a “passive” transmission of high left 
ventricular filling pressures through the pulmonary circulation (29). However, a 
proportion of patients develop a pre-capillary component to their pulmonary 
hypertension (combined pre-and-post capillary pulmonary hypertension, Cpc-PH), 
defined at right heart catheterization by a diastolic pulmonary gradient (>7mmHg) or 
pulmonary a vascular resistance (>3WU) (1,30,291). It has been shown that these 
patients have a worse prognosis than patients with isolated post capillary pulmonary 
hypertension (Ipc-PH) and some of these patients share histological changes with 
patients with pulmonary arterial hypertension (22,30,31). This has focussed 
attention on the potential role of pulmonary arterial vasodilator therapy (29,259). 
Although small studies have suggested benefit (266,292,293), large randomised 
controlled studies have been negative and there is concern that patients most likely 
to benefit from pulmonary vasodilator therapy were not included in these studies.   
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Whilst cardiac catheterisation is considered the gold standard to define the presence 
of pulmonary hypertension, MRI is considered the gold standard technique to assess 
right ventricular function.  
 
6.1.1.1 Hypotheses 
1. Cardiac MRI can provide a non-invasive assessment of prognosis in patients 
with PH due to left heart disease. 
 
6.1.1.2 Aims 
Given the emerging evidence that impairment of right ventricular function is an 
important determinant of outcome in HFpEF (289), the aim of this chapter was to 
examine the prognostic value of MRI metrics, haemodynamics, demographics and 
other routinely performed investigations in a comprehensively phenotyped cohort of  
patients with HFpEF using gold standard techniques to identify the presence of 
pulmonary hypertension and assess right ventricular function.  
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 Methods 
Consecutive, treatment naive patients with suspected pulmonary hypertension who 
underwent cardiac MRI at the Sheffield Pulmonary Vascular Disease Unit from April 
2012 to April 2017 were assessed for inclusion in the study. Patients underwent 
systematic evaluation including multimodality imaging and cardiac catheterisation as 
previously described in the ASPIRE Registry (4). Patients were required to have 
undergone right heart catheterisation and MRI within 30 days and inclusion criteria 
required a mean pulmonary arterial pressure ≥25mmHg, a pulmonary artery wedge 
pressure >15 mmHg,  a left ventricular ejection fraction >50% and a left atrial volume 
index >41ml/m2 (255) and no other potential cause for pulmonary hypertension, 
Figure 6.1. 
6.1.2.1 Right Heart Catheter 
Right heart catheterisation was performed using a balloon tipped 7.5Fr 
thermodilution catheter (Becton-Dickinson, Franklin Lakes, New Jersey). Pulmonary 
hypertension was defined as a resting mPAP ≥25mmHg and left heart disease was 
defined as pulmonary arterial wedge pressure >15mmHg. Cardiac output was 
calculated using the thermodilution technique. The following calculations were made:  
𝐷𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑃𝑢𝑙𝑚𝑜𝑛𝑎𝑟𝑦 𝐺𝑟𝑎𝑑𝑖𝑒𝑛𝑡 (𝐷𝑃𝐺) = 𝑑𝑃𝐴𝑃 − 𝑃𝐴𝑊𝑃 
Where dPAP is the diastolic pulmonary arterial pressure and PAWP is the mean 
pulmonary arterial wedge pressure. 
𝑆𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝑃𝑢𝑙𝑚𝑜𝑛𝑎𝑟𝑦 𝐺𝑟𝑎𝑑𝑖𝑒𝑛𝑡 (𝑆𝑃𝐺) = 𝑠𝑃𝐴𝑃 − 𝑃𝐴𝑊𝑃 
Where sPAP is the systolic pulmonary arterial pressure and PAWP is the mean 
pulmonary arterial wedge pressure. 
𝑃𝑢𝑙𝑚𝑜𝑛𝑎𝑟𝑦 𝑉𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑅𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝐼𝑛𝑑𝑒𝑥 (𝑃𝑉𝑅) =
𝑚𝑃𝐴𝑃 − 𝑃𝐴𝑊𝑃
𝐶𝐼
 
Where mPAP is the mean pulmonary arterial pressure, PAWP is the mean pulmonary 
arterial wedge pressure and CI is the cardiac index (CI = Cardiac Output/Body Surface 
Area). 
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Figure 6.1: Patient flow.  
 
RHC: right heart catheter, mPAP: 
mean pulmonary arterial pressure, 
PAWP: pulmonary arterial wedge 
pressure, PH: pulmonary 
hypertension, LA: left atrium, LVEF: 
left ventricular ejection fraction 
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6.1.2.2 MR Image Acquisition and analysis 
Cardiac MRI was performed in a pulmonary hypertension tertiary referral centre 
(245), on a GE HDx 1.5-T whole body scanner (GE Healthcare, Milwaukee, Wisconsin), 
using an 8-channel cardiac coil, with the patient supine. Four-chamber (4Ch) and 
short axis (SA) cine images were acquired, using a retrospectively cardiac gated multi-
slice steady-state free precession (SSFP) sequence. We acquired a stack of axial 
images in the SA plane, with slice thickness of 10 mm with no inter-slice gap or 8 mm 
with a 2 mm inter-slice gap, from the base to apex of both ventricles. Time resolved 
images of the pulmonary artery were performed using a retrospectively cardiac gated 
SSFP sequence with a single slice of 10mm taken perpendicular to the long axis of the 
pulmonary artery. The SSFP sequence parameters were: TR 2.8ms, TE 1.0ms, flip 
angle 50°, field of view 48x48, 256x256 matrix, 125 kHz bandwidth, and slice 
thickness 8 to 10 mm.  
Axial black blood imaging was performed using a dual inversion recovery fast spin 
echo sequence, with a stack of 8mm slices with 10mm spacing taken through the long 
axis plane of the pulmonary artery. The sequence parameters were: TR 984ms, TE 
40ms, flip angle 90˚, echo train length 32, field of view 4cm, 256x256 matrix, 31.2 kHz 
bandwidth on an 8 channel cardiac coil.  
MR images were manually analysed by DC (a cardiac MRI radiographer of 9 years 
cardiac MRI experience) on a GE Advantage Workstation 4.4 and GE Advantage 
Workstation ReportCard software, blinded to all clinical information. Left and right 
ventricular end-diastolic volume, end-systolic volumes, right and left ventricular 
stroke volume and mass were calculated (and indexed to body surface area), right and 
left ventricular ejection fractions, ventricular mass index (RV mass divided by LV 
mass) (257) and interventricular septal angle were measured as previously described 
(125,134). Right and left ventricular ejection fractions were calculated as end 
diastolic volume minus end-systolic volume divided by end diastolic volume. Maximal 
and minimal pulmonary arterial areas were manually traced, and relative area change 
was defined by the following equation: PA RAC= (maximum area-minimum 
area)/minimum area (208). Reproducibility metrics for these cardiac MRI metrics for 
DC and AJS have been previously published (124). Pulmonary arterial compliance was 
calculated as a composite metric of right heart catheter and cardiac MRI:  
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𝑃𝐶𝑎 =  
𝑠𝑃𝐴𝑃 − 𝑑𝑃𝐴𝑃
𝑃𝐴 𝑅𝐴𝐶
 
Where, PCa is the pulmonary arterial compliance, sPAP is the systolic pulmonary 
arterial pressure, dPAP is the diastolic pulmonary arterial pressure and PA RAC is the 
pulmonary arterial relative area change.  
6.1.2.3 Statistics 
Statistical analysis was performed using SPSS statistics 22 (IBM, Chicago) and all 
graphs were produced using GraphPad Prism (GraphPad, San Diego). A p-value of 
0.05 was considered statistically significant. All continuous, normally distributed 
variables are presented as mean (standard deviation).  
The interval from cardiac MRI until all cause of death or census was regarded as the 
follow-up period. The census was performed on 22nd May 2017. Log-log plots were 
inspected to ensure linearity with outcome data. Univariate and multivariate Cox 
proportional hazards regression was performed `with each variable standardised as 
the z score for the population studied, in order to allow for comparison between 
variables. Multivariate analysis was performed in a forward direction, for all variables 
with a statistically significant association with mortality on univariate analysis.   
Kaplan-Meier plots were generated using published thresholds, where available. 
Where no threshold was available, patients were dichotomised by mean value. Log 
rank χ2 was calculated for the Kaplan Meier data. ROC curve analysis was also 
performed for the prediction at death at 2 and 3 years, to balance patient numbers 
and number of deaths.  
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 Results  
6.1.3.1 Study Population 
Between April 2012 and April 2017, 2643 patients underwent cardiac MRI, Figure 
6.1 shows the flow of patients in this study. Of these 1315 were incident, treatment 
naïve and 1022 of these had RHC and MRI within 30 days of each other. 856 patients 
had pulmonary hypertension and 217 had a raised PAWP (>15mmHg). 78 cases were 
excluded due to other causes of pulmonary hypertension (38 co-existing lung disease, 
10 connective tissue disease, 27 CTEPH and 3 sarcoidosis), 12 patients were excluded 
with a LVEF <50% and 11 were excluded as they had a normal LA volume index on 
MRI (≤41ml/m2), leaving 116 patients meeting the study criteria as having HFpEF.  
Table 6.1 provides the baseline demographics of 116 patients with HFpEF. The 
average age was 73±7 years and 57% of patients  were female. Ninety-three patients 
had isolated pre capillary pulmonary hypertension (defined by DPG <7mmHg) and 24 
had combined pre and post capillary pulmonary hypertension (defined by DPG 
≥7mmHg). 105 received no PH specific treatment and 11 patients received pulmonary 
vasodilator therapy (8 sildenafil alone, 3 sildenafil in combination with bosentan, 
macitentan or ambrisentan). 
6.1.3.2 Prognostic markers 
Median follow up was 23 months, during which time there were 37 deaths. Table 6.2 
provides the univariate Cox proportional hazards analysis data for each metric, and 
Figure 6.2 provides a Forest plot of the outcome data. Male sex, hazard ratio (HR) of 
0.328 (95% CI 0.328-0.167, p=0.001) and TLCO percent predicted were strongly 
predictive of outcome, HR 0.792 (95% CI 0.314-0.770 p=0.002). 
6.1.3.2.1 Right heart catheter metrics and prognosis 
Diastolic pulmonary gradient (HR 2.862, 95% CI 1.775-4.615 p<0.001), mPAP (HR 
1.726 p=0.006), PVR (HR 1.709 p <0.001), SPG (HR 2.096 p <0.001) and TPG (HR 
2.656 p <0.001) predicted death, whilst  mean right atrial pressure (HR 1.262 p 
0.157), mean PAWP (HR 0.715 p 0.080) and cardiac index (HR 0.791 p 0.191) were 
not statistically significant predictors of death.  
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Table 6.1: Baseline patient demographics.  
  HFpEF  Ipc-PH  Cpc-PH   
  Mean sd Mean sd Mean sd p-value 
 Number 116  93  23   
Demographics        
 Age (years) 73 7 73 8 73 7 0.877 
 Sex (F/M) 66/50  55/38  11/12  0.227 
 FEV1 % predicted 71 18 72 18 69 21 0.634 
 FVC % predicted 71 17 72 17 67 19 0.314 
 FEV1/FVC 0.7 0.1 0.67 0.1 69 21 0.327 
 TLCO %Predicted 50 18 53 17 34 13 <0.001 
 ISWT (m) 149 121.0 155 123 122 123 0.306 
 Days MR to RHC 1 4 1 3 2 6 0.169 
RHC        
 mPAP (mmHg) 42 10 39 9 52 7 <0.001 
 PAWP (mmHg) 23 5 23 5 21 4 0.06 
 PVR (dyne.s) 334 236 273 187 580 253 <0.001 
 mRAP (mmHg) 15 5 15 5 18 6 0.024 
 Cardiac Index (ml/min/m
2) 2.8 1 2.9 1 2.5 0.7 0.037 
 DPG (mmHg) 1 7 -2 5 11 4 <0.001 
 SPG (mmHg) 45 18 40 15 65 12 <0.001 
 TPG (mmHg) 19 9 16 7 31 6 <0.001 
CMR        
 RV EDV index (ml/m
2) 93 34 93 37 95 23 0.847 
 RV ESV index (ml/m
2) 49 20 47 21 55 15 0.09 
 RVEF 48 10 50 10 42 8 <0.001 
 RV mass index (g/m
2) 20 10 18 9 25 11 0.006 
 LV EDV index  (ml/m
2) 71 20 74 21 59 12 0.001 
 LV ESV index (ml/m
2) 24 11 25 12 19 7 0.019 
 LVEF 67 8 67 8 68 8 0.589 
 PA RAC  12 7 13 7 8 5 0.002 
 VMI 0.35 0.16 0.31 0.13 0.48 0.21 <0.001 
 IV septal angle (˚) 150 16 145 12 168 15 <0.001 
 LA vol index (ml/m
2) 74 27 75 28 68 22 0.226 
 LV Stroke volume (ml) 88 25 91 25 77 23 0.014 
 
WHO-FC: World Health Organization-Functional Class, ISWT: incremental shuttle walk test, mPAP: mean 
pulmonary artery pressure, mRAP: mean right atrial pressure, PAWP: pulmonary arterial wedge pressure, CI: 
cardiac index, PVRI: pulmonary vascular resistance index, SvO2: Mixed venous oxygen saturations, TPG: trans 
pulmonary pressure gradient (mPAP-PAWP), SPG: systolic pressure gradient (sPAP-PAWP), MAP: mean systemic 
arterial pressure, RVEDV: right ventricular end-diastolic volume, RVESV: right ventricular end-systolic volume, 
RVEF: right ventricular ejection fraction, RV: right ventricle, LVEDV: left ventricular end-diastolic volume, LVESV: 
left ventricular end-systolic volume, LVEF: left ventricular ejection fraction, PA RAC: pulmonary artery relative area 
change, VMI: ventricular mass index, IV septum: interventricular septum  
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6.1.3.2.2 MRI metrics and prognosis 
Right ventricular ejection fraction, PA relative area change, interventricular septal 
angle and black blood artefact score were all statistically significant predictors of 
outcome on Cox proportional hazards linear regression (HR 0.499 p 0.004, HR 0.597 
p 0.009, HR 1.658 p 0.003 and HR 1.788 p 0.012 respectively) and on ROC analysis for 
death at 1, 2 and 3 years (Table 6.3). Figure 6.5 provides the Kaplan Meier analysis 
for MR metrics as predictors of survival. Pulmonary arterial compliance, based on a 
composite of cardiac MRI and right heart catheter measures, was also predictive of 
outcome (HR 0.451, p 0.006).  
6.1.3.2.3 Multivariate analysis 
Pulmonary artery RAC, TLCO percent predicted and male sex were independent 
predictors of outcome. This did not change when the right ventricular volumes and 
ejection fractions were corrected for age and sex. Figure 6.2 and Table 6.2 give the 
data from the multivariate analysis.  
  
Figure 6.2: Forrest plot analysis of survival.  
Standardized uni and multivariate hazard ratios for the prediction of all-cause mortality in patients with 
PH-HFpEF. Any statistically significant correlation is shown in red. 
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Table 6.2: Cox proportional hazards predictors of mortality from variables normalised to the z-score, HFpEF 
excluding treated patients 
  Univariate   Multivariate   
    HR 95% CI p-value HR 95% CI p-value 
Demographics         
 Age (years) 1.047 0.618 1.774 0.865     
 Sex (F/M) 0.328 0.167 0.645 0.001 0.166 0.056 0.492 0.001 
 WHO FC 1.37 0.952 1.971 0.090     
 FEV1 % predicted 0.881 0.583 1.33 0.546     
 FVC % predicted 1.013 0.677 1.515 0.950     
 FEV1/FVC 1.479 0.039 55.714 0.832     
 TLCO %Predicted 0.492 0.314 0.77 0.002 0.584 0.352 0.972 0.038 
 ISWT (m) 0.919 0.614 1.374 0.679     
RHC         
 mPAP (mmHg) 1.726 1.166 2.553 0.006     
 PAWP (mmHg) 0.715 0.492 1.041 0.080     
 
PVR (dyne.s/m2) 1.709 1.313 2.224 <0.001 
    
 mRAP (mmHg) 1.262 0.915 1.742 0.157     
 
Cardiac Index (L/min/m2) 0.791 0.556 1.125 0.191     
 DPG (mmHg) 2.862 1.775 4.615 <0.001     
 SPG (mmHg) 2.096 1.402 3.132 <0.001     
 TPG (mmHg) 2.656 1.716 4.111 <0.001     
CMR         
 
RV EDV index (ml/m2) 1.134 0.858 1.498 0.376     
 
RV ESV index (ml/m2) 1.343 0.98 1.839 0.067     
 RVEF 0.499 0.313 0.796 0.004     
 
LA vol index (ml/m2) 1.100 0.796 1.522 0.563     
 
LV EDV index  (ml/m2) 0.848 0.579 1.241 0.395     
 
LV ESV index (ml/m2) 0.812 0.484 1.362 0.430     
 LV Stroke volume (ml) 0.944 0.681 1.31 0.731     
 LVEF 1.318 0.798 2.176 0.281     
 
RV mass index (g/m2) 1.216 0.927 1.594 0.157     
 
LV mass Index (g/m2) 1.012 0.995 1.03 0.168     
 VMI 1.346 0.982 1.844 0.065     
 PA RAC (%) 0.597 0.405 0.88 0.009 0.403 0.212 0.765 0.005 
 IV septal angle (˚) 1.658 1.186 2.318 0.003     
 Black blood score 1.788 1.136 2.812 0.012     
Other         
  PA compliance 0.451 0.256 0.797 0.006         
WHO-FC: World Health Organization-Functional Class, ISWT: incremental shuttle walk test, mPAP: mean 
pulmonary artery pressure, mRAP: mean right atrial pressure, PAWP: pulmonary arterial wedge pressure, CI: 
cardiac index, PVRI: pulmonary vascular resistance index, SvO2: Mixed venous oxygen saturations, TPG: trans 
pulmonary pressure gradient (mPAP-PAWP), SPG: systolic pressure gradient (sPAP-PAWP), MAP: mean systemic 
arterial pressure,  
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Table 6.3: ROC curve analysis for survival at 1, 2 and 3 years, AUC and p-values. 
  1 Year  2 Years  3 Years 
    AUC p-value AUC p-value AUC p-value 
Survivors/Non survivors 84/16  57/27  31/35  
RHC       
 mPAP (mmHg) 0.740 0.002 0.677 0.009 0.641 0.071 
 
PVR (dyne.s/m2) 0.761 0.001 0.698 0.004 0.708 0.004 
 mRAP (mmHg) 0.556 0.482 0.581 0.233 0.569 0.337 
 DPG (mmHg) 0.739 0.003 0.709 0.002 0.762 <0.001 
 SPG (mmHg) 0.745 0.002 0.711 0.002 0.695 0.007 
 TPG (mmHg) 0.755 0.001 0.704 0.003 0.738 0.001 
 PAWP (mmHg) 0.481 0.812 0.549 0.467 0.593 0.196 
 
Cardiac Index (L/min/m2) 0.636 0.087 0.622 0.067 0.616 0.070 
Demographics       
 Age (years) 0.574 0.436 0.526 0.759 0.543 0.649 
 FEV1 % predicted 0.575 0.431 0.539 0.342 0.547 0.619 
 FVC % predicted 0.605 0.272 0.553 0.648 0.505 0.956 
 TLCO %Predicted 0.744 0.014 0.744 0.004 0.815 0.001 
 FEV1/FVC 0.618 0.089 0.622 0.154 0.635 0.264 
 ISWT (m) 0.605 0.291 0.521 0.809 0.622 0.194 
CMR       
 
RV EDV index (ml/m2) 0.555 0.488 0.501 0.992 0.519 0.792 
 
RV ESV index (ml/m2) 0.578 0.328 0.572 0.296 0.593 0.197 
 RVEF 0.805 <0.001 0.685 0.007 0.65 0.037 
 
RV mass index (g/m2) 0.700 0.011 0.66 0.020 0.604 0.073 
 
LV EDV index  (ml/m2) 0.611 0.159 0.593 0.176 0.607 0.134 
 
LV ESV index (ml/m2) 0.571 0.372 0.556 0.414 0.656 0.030 
 LVEF 0.523 0.776 0.515 0.824 0.625 0.082 
 PA RAC  0.759 0.001 0.717 0.002 0.684 0.039 
 VMI 0.683 0.021 0.703 0.003 0.614 0.113 
 IV septal angle (˚) 0.591 0.25 0.659 0.020 0.657 0.028 
 
LA vol index (ml/m2) 0.560 0.447 0.553 0.439 0.607 0.134 
 Stroke volume (ml) 0.554 0.497 0.558 0.400 0.502 0.974 
 Black blood score 0.748 0.002 0.641 0.039 0.684 0.001 
 LV mass Index       
Other       
  PA compliance 0.788 <0.001 0.718 0.06 0.67 0.017 
WHO-FC: World Health Organization-Functional Class, ISWT: incremental shuttle walk test, mPAP: mean 
pulmonary artery pressure, mRAP: mean right atrial pressure, PAWP: pulmonary arterial wedge pressure, CI: 
cardiac index, PVRI: pulmonary vascular resistance index, SvO2: Mixed venous oxygen saturations, TPG: trans 
pulmonary pressure gradient (mPAP-PAWP), SPG: systolic pressure gradient (sPAP-PAWP), MAP: mean systemic 
arterial pressure, RVEDV: right ventricular end-diastolic volume, RVESV: right ventricular end-systolic volume, 
RVEF: right ventricular ejection fraction, RV: right ventricle, LVEDV: left ventricular end-diastolic volume, LVESV: 
left ventricular end-systolic volume, LVEF: left ventricular ejection fraction, PA RAC: pulmonary artery relative area 
change, VMI: ventricular mass index, IV septum: interventricular septum   
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Figure 6.5: A) Kaplan-Meier curves for the independent predictors of mortality in PH-HFpEF. 
Figure 6.5: B) Kaplan-
Meier curves for the 
statistically significant 
MRI predictors of 
mortality in PH-
HFpEF. 
 
Figure 6.5: C) Kaplan-
Meier curves for the 
statistically significant 
right heart catheter 
predictors of mortality 
in PH-HFpEF. 
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 Discussion 
In this chapter, assessing the predictors of mortality in 116 patients with pulmonary 
hypertension due to heart failure with preserved ejection fraction, we show that 
baseline demographics, invasive measurements of haemodynamics, pulmonary 
function testing and cardiac MRI are all useful in the prediction of outcome. On 
multivariate analysis, sex, TLCO percent predicted and PA relative area change were 
all predictive of outcome.  
The results of this chapter fit with work presented in chapter 5.1 (Cardiac MRI can 
Identify and Phenotype Patients with PH in Left Heart Disease), in that the presence 
of combined pre and post capillary pulmonary hypertension is associated with 
increased risk of death. The diastolic pulmonary gradient (along with PVR, systolic 
and trans-pulmonary gradients to lesser degrees), interventricular septal angle and 
PA relative area change are all predictors of outcome, likely because they are 
predictive of the presence of pre-capillary portion to the pulmonary hypertension 
(Cpc-PH).  
Male sex, and low TLCO percent predicted and pulmonary arterial relative area 
change were independent predictors of mortality on multivariate analysis. This is 
useful in the clinical setting, as a combination of demographic information (sex), 
routine pulmonary function tests (TLCO percent predicted) and cardiac MRI 
Figure 6.6: ROC curve analysis for death at 1 and 3 years 
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sequences (PA RAC) can be used to assess prognosis, potentially reducing reliance on 
invasive tests, such as right heart catheterisation. This strengthens the previously 
presented data that identified interventricular septal angle as a potential marker for 
the presence of combined pre and post capillary pulmonary hypertension in patients 
with PH due to left heart disease. Pulmonary arterial relative area change is likely to 
be predictive of outcome as it is a marker of pulmonary arterial remodelling in 
pulmonary hypertension, and correlates with diastolic pulmonary gradient. It is 
possible to measure PA relative area change using ECG gated CT (112).  TLCO has 
previously been identified as a marker of prognosis in patients with PH-HFpEF, and 
potentially acts as a marker of capillary and post-capillary disease in PH patients 
(25,294). In our cohort of PH-HFpEF, the reduction in TLCO is not due to cardiac 
output/index (there was no correlation between TLCO percent predicted and cardiac 
output, r=0.033 and p=0.765, and neither cardiac output, nor cardiac index was 
predictive of outcome). It is also interesting that the black blood artefact score was 
predictive of outcome, whereas the cardiac output was not, supporting the idea that 
black blood score may be a marker of turbulent or vortical blood flow in the 
pulmonary artery (135).   
In this section we have demonstrated that MRI markers of the structure and function 
of the right ventricle and pulmonary artery provide prognostic information in 
patients with pulmonary hypertension due to heart failure with preserved ejection 
fraction. Cardiac MRI is considered the gold standard for the assessment of left 
ventricular function (233) and markers of RV and PA have been shown to be 
reproducible (124) and sensitive to change in PH patients (130,253,254). Access to 
cardiac MRI may be limited in certain centres, in which echocardiographic indices, 
although not assessed in these results, could be used to assess right ventricular 
function.  
This study is limited by its retrospective, single centre design. This also leads to a bias 
in the population, as it is more likely that the patients with severe pulmonary 
hypertension or those with features of pre-capillary pulmonary hypertension will be 
referred. Unfortunately due to the nature of the referral pathway, echocardiography 
was not performed at a similar time to the cardiac MRI, so comparison between the 
two was not possible in this study.  
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 Conclusion 
Low TLCO, male sex and low pulmonary arterial relative area change are the most 
significant measures of outcome in patients with pulmonary hypertension due to 
heart failure with preserved ejection fraction. The use of spirometry and cardiac MRI 
is useful for the identification of patients who are at risk, and may be helpful in 
assessment during trials for potential pulmonary arterial therapies.  
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6.2 CARDIAC MRI CAN IDENTIFY PATIENTS WITH PH DUE TO COPD WHO ARE 
AT RISK OF DEATH 
 Rationale 
Pulmonary hypertension is a predictor of death and hospitalisation (42–46) in 
patients with chronic obstructive pulmonary disease (COPD). Patients with 
pulmonary hypertension in COPD, as defined by a mean pulmonary artery pressure 
(mPAP) of ≥25mmHg have a 5 year survival rate of 36% (47). A number of studies in 
patients with severe COPD have shown that mild pulmonary hypertension is 
common: a recent study in patients with severe COPD referred for lung volume 
reduction surgery demonstrating pulmonary hypertension at right heart catheter in 
50% (295,296). More recently, with the advent of therapies for other forms of 
pulmonary hypertension there has been increasing interest in the subset of lung 
disease patients with severe (previously called “out of proportion”) pulmonary 
hypertension, defined as an mPAP ≥35mmHg or mPAP ≥35mmHg with cardiac index 
≤2.0 (50), where a cardiovascular limitation to exercise, rather than respiratory 
limitation exists (297). This raises the possibility that pulmonary vascular therapies 
may improve symptoms and outcome in this patient group (298).  
The gold standard for diagnosis of pulmonary hypertension is right heart catheter 
(RHC), however, this is an invasive test (8). As such, patients are screened for 
pulmonary hypertension with echocardiography, but unfortunately, this is less 
accurate in COPD where pulmonary artery pressure, when able to be measured is 
often overestimated (244,250). A non-invasive method for estimating mPAP in COPD 
patients would therefore be useful to help diagnose PH, in prognostication and for 
possible assessment of treatment response or follow up in clinical trials.  
Several predictive cardiac magnetic resonance (CMR) imaging models have been 
proposed for estimation of pulmonary artery pressure (125,235,249,299). The 
predictive value of these MR derived imaging models in a population of patients with 
suspected pulmonary hypertension in COPD remains unknown.  
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6.2.1.1 Hypotheses  
1. Models of mean pulmonary arterial pressure prediction from cardiac MRI can be 
used to identify patients with PH due to COPD. 
2. Cardiac MRI is able to assess the risk of death in patients with COPD and suspected 
PH.  
 
6.2.1.2 Aims  
The aim of this section was to assess the diagnostic accuracy and the prognostic value 
of these published models of non-invasive mPAP prediction using cardiovascular MRI.  
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 Materials and Methods 
All consecutive patients who underwent MRI at a pulmonary hypertension referral 
centre (245) from April 2012 to October 2015 with suspected pulmonary 
hypertension were assessed for inclusion. Inclusion criteria were a formal diagnosis 
of COPD (according to standard criteria), as per the ASPIRE (Assessing the Spectrum 
of Pulmonary hypertension Identified at a REferral centre) registry (245). Patients 
were assessed for either obstructive spirometry (defined as FEV1/FVC ratio of ≤0.70) 
or qualitative CT evidence of emphysema, as per standard radiological practice (268). 
Any patients without RHC and MRI within 90 days were excluded. Ethical approval 
was granted from a local ethics committee for this retrospective study, written 
consent was waived (ref c06/Q2308/8).  
6.2.2.1 Image Acquisition  
Cardiac MRI was performed in a pulmonary hypertension tertiary referral centre 
(245), on a GE HDx 1.5-T whole body scanner (GE Healthcare, Milwaukee, Wisconsin), 
using an 8-channel cardiac coil, with the patient supine. Four-chamber (4Ch) and 
short axis (SA) cine images were acquired using a retrospectively cardiac gated multi-
slice steady-state free precession (SSFP) sequence. A stack of axial images in the SA 
plane with slice thickness of 8 mm with a 2 mm inter-slice gap or 10 mm with no inter-
slice gap were acquired, covering both ventricles from base to apex. The SSFP 
sequence parameters were: TR 2.8ms, TE 1.0ms, flip angle 50°, field of view 48x43.2, 
256x256 matrix, 125 kHz bandwidth, and slice thickness 8 to 10 mm. This cardiac MRI 
scan protocol takes approximately 40 minutes to perform.   
6.2.2.2 Image Analysis and Metrics 
MR images were manually analysed by DC (a cardiac MRI radiographer of 9 years 
cardiac MRI experience) on a GE Advantage Workstation 4.4 and GE Advantage 
Workstation ReportCard software, with the observer blinded to all clinical 
information and other investigations. Left and right ventricular end-diastolic volume, 
end-systolic volume, right and left ventricular stroke volume and mass were 
calculated (all indexed to body surface area), right and left ventricular ejection 
fraction, ventricular mass index (RV mass divided by LV mass) (133) and 
interventricular septal angle were measured as previously described (125). Right and 
left ventricular ejection fractions were calculated as (end diastolic volume minus end-
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systolic volume) divided by end diastolic volume. Maximal and minimal PA areas were 
manually traced, and relative area change was defined by the following equation: 
RAC= (maximum area-minimum area)/minimum area (208). Reproducibility metrics 
for these cardiac MRI metrics for DC and AJS have been previously published (124). 
Please see Figure 6.7 for a diagram of the key imaging metrics that were measured. 
6.2.2.3 CMR image based models  
Previously published parametric models, developed for diagnostic and prognostic 
assessment in PH, were derived from Cardiac MRI metrics: 
1. The RVCMR model; is based on ventricular mass index and interventricular 
septal angle: mPAP = –4.6 + (interventricular septal angle x 0.23) + 
(ventricular mass index x 16.3), see Figure 1 (A and B). This model was 
developed in a cohort of 64 treatment naïve patients with suspected 
pulmonary hypertension in a tertiary referral centre. In a derivation cohort of 
64 patients with suspected pulmonary hypertension, this showed good 
correlation with right heart catheter measured mPAP and strong diagnostic 
accuracy. The published threshold of ≥32 mmHg had 87% sensitivity and 90% 
specificity for the presence of all causes of pulmonary hypertension (125). 
2. The PARVCMR model; is similar to the CMR-RV model (above), with the addition 
of basic function metrics of the pulmonary artery: CMR-PA/RV = -21.806 + 
(inter-ventricular septal angle x 0.31) + (ventricular mass index x 11.5) + 
(Diastolic pulmonary artery area x 0.01) – (PA relative area change x 0.22), see 
Figure 1 (A, B, C and D). This model was derived in 247 patients with suspected 
pulmonary hypertension patients and was predictive of pulmonary 
hypertension in a separate prospective cohort of 115 patients, with an area 
under the receiver operator curve of 0.92 (299).  
3. The alpha index; comprises both functional and structural information, 
utilising right ventricular function along with pulmonary artery size: Alpha 
index = minimum PA area/RV ejection fraction. This model was assessed in a 
cohort of 185 patients, with an area under ROC curve of 0.95 (249).  
The diagnostic cut-off for pulmonary hypertension for RVCMR was ≥32 and alpha index 
≥7.2, as published in the literature (125,249,299). PA/RVCMR does not have a 
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published threshold, so we used a threshold of ≥25, as this mirrors the threshold of 
invasively-measured mPAP at right heart catheterisation.  
 
6.2.2.4 Right Heart Catheterisation 
Right heart catheterisation was performed using a balloon tipped 7.5Fr 
thermodilution catheter (Becton-Dickinson, Franklin Lakes, New Jersey). Pulmonary 
hypertension was defined as a resting mPAP ≥25mmHg and severe pulmonary 
hypertension as a resting mPAP ≥35mmHg. Cardiac output was calculated using 
thermodilution.  
6.2.2.5 Statistics 
Pearson’s correlation between CMR models and RHC-mPAP were calculated. The 
relative accuracy of the models was assessed using Bland-Altman plots. Diagnostic 
accuracy was calculated from the 2x2 contingency table to calculate sensitivity, 
specificity, negative predictive value and positive predictive value. Receiver operating 
characteristic (ROC) curves were constructed and the area under the ROC curve 
(AUC) recorded.  
The interval from CMR until all cause death or census was regarded as the follow-up 
period. The census was performed on 25/02/2016. Log-log plots were visually 
inspected to ensure linearity with outcome data. Survival analysis was performed 
using univariate and multivariate Cox proportional hazards regression. In order to 
Figure 6.7: Cardiac MRI metrics. 
Pulmonary artery relative area 
change (A) taken from cine images 
taken at the level of the pulmonary 
trunk, perpendicular to the main 
pulmonary artery; septal angle (B) 
taken as the angle made between 
the insertion points of the RV to the 
mid septum on the end-systolic 
image from the short axis stack; and 
(C) ventricular mass index taken by 
segmentation of the muscle mass of 
the left and right ventricle on the 
stack of images taken in the short 
axis plane.  
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allow for comparison between each metric, this was performed with each variable 
standardised as the z score for the population studied. Multivariate analysis was 
performed in a forward direction, for all variables with a statistically significant 
association with mortality on univariate analysis.   
Kaplan-Meier plots were generated for each model and RHC measured mPAP, 
dichotomised by a value of 35, and Chi square values were calculated using the Log 
rank test, as this is the threshold value for severe pulmonary hypertension (50). 
Statistical analysis was made using SPSS 22 (IBM, Chicago) and graphs were created 
using GraphPad Prism 7 (GraphPad Software, San Diego). A p-value of <0.05 was 
considered statistically significant. 
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 Results 
A total of 1864 patients were referred to the pulmonary hypertension centre during 
the period studied and underwent right heart catheterisation: of these 145 had a 
documented diagnosis of COPD from a respiratory specialist. 102 had MRI and RHC 
within 90 days, so were included in the study. There were 87 patients with pulmonary 
hypertension (69 of these had severe pulmonary hypertension) and 15 patients 
without pulmonary hypertension (please see Figure 6.8 for the patient selection 
pathway).  
 
 
There were 24 with Gold severity 1, 40 with GOLD severity 2, 18 with GOLD severity 
3 and 7 with GOLD severity 4, 13 patients did not have spirometry results available 
for analysis. Of the 102 cases of COPD included in the study, 75 had spirometric 
evidence of airflow limitation (FEV1/FVC ratio <0.7), and the remaining 17 had 
evidence of emphysema on CT.  
Table 6.4 shows the patient demographics and clinical characteristics for the whole 
group and split into no PH (mPAP <25mmHg), PH (mPAP 25≥35mmHg) and severe 
PH (mPAP ≥35mmHg).  
  
Figure 6.8: Patient 
flow 
Dr CS Johns  Cardio-Pulmonary MRI in PH   174  
Table 6.4: Patient demographics, mean with standard deviation with ANOVA p-value.  
    All patients No PH PH Severe PH P-value (ANOVA) 
 Number 102 15 18 69  
Clinical Demographics     
 Age (years) 67 (12) 59 (17) 67 (12) 69 (9) 0.012 
 Sex (F/M)      
 WHO functional class (II,III,IV)     
 ISWT (m) 174 (169) 432 (264) 141 (101) 121 (87) <0.001 
Baseline catheter data     
 mPAP (mmHg) 40 (12) 21 (3) 31 (3) 47 (8) <0.001 
 mRAP (mmHg) 11 (6) 6 (2) 8 (3) 11 (7) 0.056 
 PAWP (mmHg) 12 (4) 10 (3) 12 (3) 13 (4) 0.013 
 CI (Litre/m
2) 2.8 (0.9) 3.1 (0.7) 3.2 (0.9) 2.6 (0.9) 0.005 
 PVRI (WU) 3.7 (2.7) 1.1 (0.6) 2.0 (0.5) 4.37 (2.7) <0.001 
 SvO2 (%) 65 (9) 72 (8) 69 (5) 62 (9) <0.001 
 Days RHC to MR 5 (15) 5 (19) 5 (13) 5 (14) 0.989 
Spirometry  n=89 n=9 n=17 n=63  
 FEV1 (% Pred) 66 (24) 76 (24) 58 (15) 66 (25) 0.165 
 FVC (% Pred) 85 (22) 92 (20) 77 (15) 87 (24) 0.155 
 FEV1/FVC 0.55 (0.15) 0.63 (0.20) 0.51 (0.10) 0.55 (0.15) 0.179 
 TLCO (% Pred) 30 (22) 80 (31) 33 (15) 21 (9) <0.001 
Cardiac MRI      
 RV EDV index 89 (35) 72 (30) 70 (32) 97 (34) 0.002 
 RV ESV index 56 (31) 36 (18) 37 (26) 66 (30) <0.001 
 RVEF 40 (14) 51 (8) 51 (11) 35 (12) <0.001 
 RV mass index      
 
LV EDV index 55 (18) 62 (10) 63 (18) 52 (19) 0.026 
 LV ESV index 20 (18) 19 (6) 20 (10) 20 (12) 0.921 
 LVEF 64 (12) 69 (10) 69 (9) 61 (12) 0.014 
 PA RAC 10 (8) 16 (14) 12 (8) 8 (6) 0.008 
 VMI 0.43 (0.28) 0.28 (0.11) 0.28 (0.17) 0.51 (0.31) 0.001 
 IVS angle 165 (24) 134 (10) 152 (14) 174 (20) <0.001 
 Black blood score 3 (1) 1 (1) 2 (1) 3 (1) <0.001 
 Alpha-index 25 (14) 13 (6) 16 (6) 30 (14) <0.001 
 RVCMR 41 (9) 33 (4) 35 (5) 44 (9) <0.001 
  PARVCMR 35 (9) 23 (5) 30 (5) 39 (7) <0.001 
PH: pulmonary hypertension, WHO: World Health Organisation, ISWT: Incremental shuttle walk test, FEV1: Forced 
expiratory volume in 1 second, RVC-mPAP: right heart catheter measured mean pulmonary artery pressure, mRAP: 
mean right atrial pressure, PAWP: pulmonary arterial wedge pressure, CI: cardiac index, PVRI: pulmonary vascular 
resistance index, SvO2: mixed venous oxygen saturation, FVC: forced vital capacity, TLCO: transfer factor for carbon 
monoxide, RHC: right heart catheter, MRI: magnetic resonance imaging. 
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6.2.3.1 Diagnostic accuracy 
Table 6.5 shows the univariate correlations of CMR imaging metrics: RV end diastolic 
volume index, RV end systolic volume index, RV ejection fraction, RV mass, PA 
diastolic area and relative area change, ventricular mass index, interventricular septal 
angle septal angle, average velocity and black blood score all showed statistically 
significant correlations with mPAP. All of the models showed strong correlations with 
RHC measured mPAP, with p-values <0.0001. The PARVCMR model showed stronger 
correlation with mPAP than the individual quantitative measurements alone. A 
scatter plot of the MRI models against mPAP is given in Figure 6.9. The models all 
showed a stronger correlation with mPAP in the patients with mPAP <35mmHg (r 
and p-values for RVCMR were 0.550 and 0.001, PARVCMR 0.653 and <0.001 and alpha 
0.341 and 0.052) than in the patients with mPAP ≥35mmHg (r and p-value for RVCMR 
were 0.431 and <0.001, PARVCMR 0.407 and 0.001 and alpha 0.210 and 0.083).  
 
Table 6.5: CMR imaging metrics and MRI model correlations with mPAP 
 Correlation with mPAP 
R p-value 
RVEDV index 0.377 <0.0001 
RVESV index 0.482 <0.0001 
RVEF -0.585 <0.0001 
RV mass 0.372 <0.0001 
LVEDV index -0.304 0.002 
LVESV index -0.029 0.772 
LVEF -0.221 0.026 
PA diastolic area 0.401 <0.0001 
PA RAC -0.344 <0.0001 
VMI 0.470 <0.0001 
IVS angle 0.710 <0.0001 
Average PA velocity -0.428 <0.0001 
Black blood score 0.603 <0.0001 
RVCMR 0.689 <0.0001 
PARVCMR 0.732 <0.0001 
Alpha index 0.527 <0.0001 
RVEDV: right ventricular end-diastolic volume, RVESV: right ventricular end-systolic volume, RVEF: right 
ventricular ejection fraction, RV: right ventricle, LVEDV: left ventricular end-diastolic volume, LVESV: left 
ventricular end-systolic volume, LVEF: left ventricular ejection fraction, PA: pulmonary artery, PA RAC: pulmonary 
artery relative area change, VMI: ventricular mass index, IVS: interventricular septum 
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Bland-Altman plots were also created to assess the accuracy of the models against 
RHC-mPAP (Figure 6.10), this was not performed for alpha index as it was not 
designed to directly assess mPAP. Bland-Altman analysis showed modest accuracy for 
RVCMR (bias -5.2%, limits of agreement -51.2 to 40.8%) and PA/RVCMR models (bias 
12.2% and limits of agreement -30.7 to 55.0%). Table 6.5 shows the correlation of 
the CMR models against RHC mPAP. Figure 6.11 shows the ROC curves for the three 
CMR models. PARVCMR and RVCMR had the largest AUC values, 0.93 (95% confidence 
interval 0.86-1.0) and 0.91 (95% confidence interval 0.84-0.97) respectively, and 
alpha index also showed good diagnostic accuracy with AUC 0.837 (95% confidence 
interval 0.74-0.94). The sensitivity and specificity of the PA/RVCMR model was 92% 
and 80%, CMR-RV model 90% and 79%, and the alpha index 100% and 13% 
respectively (as shown in Table 6.6).  
 
 
Figure 6.9: Scatter plots showing correlations of each MRI model with right heart catheter measured mPAP. 
Figure 6.10: 
Bland-Altman plots 
showing the 
accuracy of each 
model against RHC-
mPAP. 
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Table 6.6: Diagnostic accuracy for pulmonary hypertension.  
 Sensitivity Specificity PPV NPV ROC AUC  P-value 
RVCMR  
(≥32) 
90% (95% CI 
82-95) 
79% (95% CI 
52-92) 
96% (95% CI 
89-99) 
58% (95% CI 
36-77%) 
0.908 (95% CI 
0.84-0.97) 
<0.0001 
PARVCMR  
(≥25) 
92% (95% CI 
84-96%) 
80% (95% CI 
55-93%) 
96% (95% CI 
90-93%) 
63% (95% CI 
41-81%) 
0.931 (95% CI 
0.86-1.00) 
<0.0001 
Alpha Index 
(≥7.2) 
100% (95%CI 
96-100) 
13% (95% CI 
0-38) 
87% (95% CI 
79-92% 
100% (95% CI 
18-100%) 
0.837 (95% CI 
0.73-0.94) 
0.020 
PPV: positive predictive value, NPV: negative predictive value. 
 
6.2.3.2 Outcome 
During a mean follow up period of 1.5 years (standard deviation 0.9) there were 33 
deaths. Table 6.7 gives the scaled univariate Cox proportional hazards regression 
results for patient demographics, RHC and CMR measurements. Age, sex, walk 
distance FEV1 percent predicted, FVC percent predicted and FEV1/FVC ratio were not 
univariate predictors of mortality. PA relative area change, right ventricular mass 
index, ventricular mass index, interventricular septal angle and RV end-diastolic 
volume index were univariate predictors of mortality (p=0.009, p=<0.001, p=0.002 
and p=0.023 respectively). RHC measured mPAP was a strong predictor of mortality 
(p=0.004), as were the RVCMR and PARVCMR models (p=0.002 and p=0.012 
respectively). There was a statistically significant difference in survival when the 
population was split by a threshold of 35mmHg for RHC-mPAP, RVCMR and PARVCMR 
models, with a log rank chi squared of 5.03, 5.47 and 7.10 respectively (see figure 6). 
Figure 6.11: ROC curve for the 
diagnosis of pulmonary 
hypertension. 
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On multivariate analysis (performed on all univariate predictors of outcome for 
demographics, right heart catheter and cardiac MRI), right ventricular mass index and 
PA relative area change were statistically significant, with scaled Cox multivariate 
hazard ratios 1.549 (95% CI 1.172-2.047, p=0.002) and 0.561 (95% CI 0.333-0.946, 
p=0.030) respectively.   
  
Figure 6.12: Kaplan-Meier survival tables, all dichotomised by 35. 
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Table 6.7: Univariate Cox proportional hazards regression analysis for survival. 
   Hazard ratio 95% confidence interval p-value 
Demographics     
 Age 1.424 0.936 2.166 0.098 
 Sex 0.781 0.388 1.57 0.487 
 
WHO functional 
status 
1.45 1.031 2.039 0.033 
 Walk distance 0.475 0.167 1.354 0.164 
 FVC % pred 1.221 0.835 1.785 0.304 
 FEV1 % pred 1.399 0.928 2.108 0.109 
 FEV1/FVC 1.244 0.85 1.82 0.262 
 TLCO % pred 0.593 0.19 1.852 0.369 
Right heart catheter    
 mPAP 1.74 1.198 2.526 0.004 
 mRAP 1.297 0.873 1.927 0.199 
 PAWP 0.933 0.651 1.338 0.707 
 CI 0.847 0.566 1.268 0.421 
 PVRI 1.384 1.034 1.853 0.029 
 SvO2 0.857 0.59 1.245 0.418 
Cardiac MRI     
 RV EDV index 1.381 1.013 1.882 0.041 
 RV ESV index 1.338 0.981 1.824 0.066 
 RVEF 0.784 0.548 1.122 0.183 
 RV mass index 1.673 1.303 2.148 <0.001 
 LV EDV index 0.759 0.494 1.166 0.209 
 LV ESV index 0.766 0.478 1.228 0.269 
 LVEF 1.077 0.756 1.535 0.681 
 PA RAC 0.543 0.343 0.859 0.009 
 VMI 1.417 1.135 1.768 0.002 
 IVS angle 1.48 1.055 2.075 0.023 
 
Black blood 
score 
1.377 0.925 2.05 0.115 
 
Average PA 
velocity 
1.018 0.697 1.484 0.928 
 Alpha-index 1.19 0.858 1.65 0.297 
 RVCMR 1.565 1.175 2.083 0.002 
  PARVCMR 1.59 1.108 2.282 0.012 
WHO: World Health Organisation, FEV1: Forced expiratory volume in 1 second, FVC: Forced vital capacity, RHC: 
right heart catheter, mPAP: right heart catheter measured mean pulmonary artery pressure, mRAP: mean right 
atrial pressure, PAWP: pulmonary artery wedge pressure, CI: cardiac index, PVRI: pulmonary vascular resistance 
index, SvO2: mixed venous oxygen saturation, CMR: cardiopulmonary magnetic resonance, RVEDV: right ventricular 
end-diastolic volume, RVESV: right ventricular end-systolic volume, RVEF: right ventricular ejection fraction, RV: 
right ventricle, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end-systolic volume, LVEF: left 
ventricular ejection fraction, PA RAC: pulmonary artery relative area change, VMI: ventricular mass index, IVS: 
interventricular septum, RVCMR: right ventricle based cardiopulmonary magnetic 
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 Discussion  
This study demonstrates that CMR models can be used to assess for the presence of 
pulmonary hypertension in COPD with good diagnostic accuracy, whilst also 
providing prognostic information similar to right heart catheterisation. This data 
supports the potential use of CMR in the non-invasive assessment of suspected 
pulmonary hypertension in patients with COPD. We have shown that single 
measurements from cardiac MRI (most notably septal angle) correlate strongly with 
right heart catheter measured mPAP. A model which includes measurements from the 
right ventricle, the diagnostic accuracy is slightly reduced, but inclusion of basic 
measurements of pulmonary arterial structure and function increases the accuracy of 
predicted mPAP and therefore the presence of pulmonary hypertension. Therefore, 
we recommend the use of PARVCMR model in the diagnosis of pulmonary hypertension 
in patients with COPD. In the presence of COPD, right ventricular mass index and PA 
relative area change are the strongest predictors of outcome, but further work to 
develop prognostic thresholds is required.  
Studies performed primarily in patients with pulmonary arterial hypertension have 
shown that structural and functional indices of the right ventricle (RV end diastolic 
volume index, RV end-systolic volume index, RV ejection fraction, RV mass, 
interventricular septal angle) and pulmonary artery (PA area, PA relative area change 
and black blood score) correlate with RHC measured mPAP. Inter and intra-observer 
reproducibility data for these cardiac MRI metrics for DC and AJS have been 
previously published. RV end-diastolic and systolic measurements had excellent 
inter-observer reproducibility (ICC 0.959 and 0.991) and pulmonary artery relative 
area change had high inter-observer reproducibility (ICC 0.891). Right ventricular 
ejection fraction also had high inter-observer reproducibility (ICC 0.957) (124). We 
and others, have shown that we can further develop predictive equations using MR 
metrics to estimate measurements made at cardiac catheterisation. However, to date 
there is very little data on the use of MR imaging as a diagnostic and prognostic tool 
in patients with COPD and suspected pulmonary hypertension. In this study we have 
shown that these structural and functional indices of the right ventricle and 
pulmonary artery correlate with right heart catheter measured mean pulmonary 
arterial pressure: with pulmonary artery relative area change, ventricular mass index 
and interventricular septal angle having the strongest correlations. We have shown 
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that the use of PARVCMR and RVCMR models, improve the prediction of mPAP and also 
the diagnostic accuracy of quantitative CMR measures.  
The alpha model showed good correlation with mPAP, but had a low diagnostic 
accuracy: this model suffered from a diagnostic threshold that was too low for this 
cohort, significantly reducing its specificity. Changing the threshold of the alpha index 
to 16 increased the diagnostic accuracy of this model to 77% sensitivity and 80% 
specificity. This inaccuracy may be related to the measurement of right ventricular 
ejection fraction, particularly the reproducibility between different centres. In the 
original paper, it was not described how the right ventricular endocardial contours 
were measured, specifically, whether the papillary muscles and RV trabeculations 
were included, which may potentially add a bias into the calculation.  
Pulmonary hypertension, confirmed by right heart catheter, has been recognised for 
many years as a marker of disease severity in COPD. In this study we have shown that 
cardiac MRI measured right ventricular mass and therefore ventricular mass index, 
along with pulmonary artery relative area change are significant predictors of 
mortality on univariate analysis. However, by using CMR derived parametric models, 
particularly the RVCMR model which combine these CMRI derived measures, we can 
improve the prediction of outcome in COPD patients on multivariate analysis. These 
models may be further improved with novel imaging biomarkers in pulmonary 
hypertension assessment. One such marker is the 4D flow assessment of the life of 
vortices within the pulmonary artery,  which has been shown to have a very high 
correlation with mPAP (r2 0.95) (141). 
A potential source of error arises from the use of MR models, which were developed 
for use in a cohort of all causes of pulmonary hypertension, and not validated in 
specific sub-groups, such as PH-COPD in this case. We feel that it is likely that the 
findings of a raised interventricular septal angle and ventricular mass index are likely 
to occur most subgroups of pulmonary hypertension (with the exception of left heart 
disease) as they are related to the pressure differential between the left and right 
ventricles. The measures of pulmonary arterial structure and function (size and 
relative area change) are likely to be transferable across subgroups, as they are 
markers of pulmonary vascular compliance and remodelling. We therefore feel that it 
reasonable to use these models in specific sub-groups of pulmonary hypertension, 
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although validation, such as in this chapter, would be useful.  The models that are used 
in this chapter use parameters that are stated with a degree of precision (for example 
an offset of 21.806 for PARVCMR), likely more than is required for this purpose. We 
have maintained the equations in the published form to reduce any bias in the 
calculations, but it is likely that less decimal places could be used for these parameters 
for the prediction of outcome and the presence of pulmonary hypertension in COPD.  
Currently, RHC is the gold standard test for the assessment of pulmonary 
hypertension, and is used to assess prognosis in suspected COPD-PH cases. The ability 
to use non-invasive CMR models in this patient group may avoid the need for RHC, as 
we have shown CMR to be as good in the assessment of prognosis. The strong 
correlation of CMR imaging models with RHC mPAP suggest it may also have a role in 
follow up, and also in assessment of treatment response in possible future trials 
assessing vasodilator response in COPD-PH. The role of cardiac MRI in COPD is further 
strengthened as this is a cohort of patients in which echocardiography is challenging. 
In the presence of COPD echocardiography has a relatively high rate of non-diagnostic 
quality studies. It has a good negative predictive value but a poorer positive predictive 
value (244). In patients with a normal right ventricle and predicted systolic 
pulmonary artery pressure (estimated from the tricuspid regurgitant jet velocity 
using the Bernoulli equation) pulmonary hypertension is highly unlikely. The main 
role for cardiac MRI in patients with COPD, therefore, probably lies in the group of 
patients with high estimated systolic pulmonary artery pressures or non-diagnostic 
scans. This may be at diagnosis, as studied, or potentially at follow up.   
The non-invasive estimation of mPAP has multiple other potential uses, beyond 
prognosis in COPD, although these have not been addressed in this thesis. In advanced 
COPD patients considered for lung volume reduction surgery (LVRS), severe 
pulmonary hypertension is considered a contraindication (300), so the non-invasive 
assessment of mPAP on MR would be a useful tool in patient selection. Furthermore, 
left or right ventricular dysfunction is considered a relative contraindication to LVRS 
(300), and can be assessed at the same CMR sitting. In COPD patients with pulmonary 
hypertension there is evidence that outcome may be improved if treated with lung 
transplantation over LVRS (301), assessment of mPAP could be performed in the 
same sitting as a ventilation study in the preoperative assessment of LVRS or 
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transplant candidates (162,302), allowing for the assessment of the best surgical 
option and the best target in the lung. 
This study is limited by its single centre, retrospective design, at a tertiary pulmonary 
hypertension referral centre where the severity of pulmonary hypertension is more 
severe. The results, therefore represent a biased population as the patients have been 
screened by echocardiography and excessive symptoms for the presence of 
pulmonary hypertension before referral (the vast majority of patients with COPD are 
managed in primary care). This has resulted in a smaller proportion of non-
pulmonary hypertension patients than would be present in a general population of 
COPD, however in the absence of a prospective trial, this is difficult to overcome. 
Furthermore, the assessment of the presence of COPD in the population relied upon 
the accurate documentation of a clinical diagnosis of COPD. This likely resulted in a 
lower proportion of patients being identified, but is likely to be more robust than 
using either spirometry or CT defined emphysema alone. Furthermore, the end-point 
was defined as all-cause mortality, which doesn’t take into account other causes of 
death in patients with COPD, such as coronary heart disease (60) and COPD 
exacerbation (59). 
Despite this, we feel that these tools are valid for the assessment of patients who are 
referred to a pulmonary hypertension centre regarding the presence of pulmonary 
hypertension and prognosis, as this is the population that was studied. It may be that 
more specific diagnostic thresholds would be suitable for use in the general COPD 
population. 
 
 Conclusion 
The use of the PARVCMR model, derived from cardiovascular magnetic resonance 
imaging in the assessment of COPD allows for accurate, non-invasive estimation of 
pulmonary artery pressure and the presence of pulmonary hypertension. Right 
ventricular mass index and pulmonary artery relative area change are most predictive 
of outcome.  
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7 DISCUSSION AND FUTURE DIRECTIONS 
Cardiac MRI is considered the gold standard for the assessment of left ventricular 
structure and function. It also provides similar information on the right ventricle and 
pulmonary artery, which are useful in the diagnosis and assessment of suspected 
pulmonary hypertension.  
7.1 DIAGNOSIS 
In a large cohort of incident patients referred to a tertiary referral centre with 
suspected pulmonary hypertension, the data presented in this thesis shows that 
cardio-pulmonary MRI has high diagnostic accuracy. A model comprising simple, 
reproducible and easy to obtain metrics (interventricular septal angle, ventricular 
mass index and black blood score) can identify patients with pulmonary hypertension 
with 100% specificity and 62% sensitivity. A more sensitive threshold has also been 
identified with 93% sensitivity and 79% specificity, which may be useful to screen for 
patients with pulmonary hypertension, although this would need to be validated in a 
screening population.  
Whilst this highly specific measurement is useful in the identification of patients with 
pulmonary hypertension, there is still a requirement for assessment of response to 
nitric oxide in patients with suspected pulmonary arterial hypertension to assess for 
optimal therapeutic strategies. This work can be further improved with inclusion of 
an assessment of vasodilator response on cardiac MRI.  
Patients with dilated left atria were excluded from the analysis, as it is expected that 
these patients will not be correctly identified using the proposed model 
(interventricular septal angle and ventricular mass index will be normalised due to 
high left ventricular filling pressures). Further work is required to identify a method 
of mPAP prediction in those patients with dilated left atria to accurately identify 
pulmonary hypertension. Although currently this is only performed to provide 
prognostic information and the use of septal angle can identify patients who may have 
a precapillary component to their PH-LHD and therefore should be assessed for the 
potential of PAH.  
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Figure 7.1: A proposed flow chart for investigation of PH using cardiac MRI based upon the data presented in this 
thesis 
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7.2 PHENOTYPING 
Once the presence of pulmonary hypertension has been identified, it is important to 
assess the underlying cause to correctly initiate treatment. The most important 
groups to correctly identify are pulmonary arterial hypertension (which can be 
difficult to differentiate from left heart disease) and chronic thrombo-embolic 
pulmonary hypertension, as these are the groups of patients who respond to 
treatments directed at the pulmonary vasculature.  
 PH-Left Heart Disease 
As previously discussed, further is work required in the differentiation of patients 
with pulmonary arterial hypertension from those with PH due to left heart disease. 
Left atrial volume index is considered the non-invasive assessment of choice for the 
presence of PH due to left heart disease, however in an unselected cohort of patients 
with suspected PH there is only a relatively modest prediction of raised pulmonary 
arterial wedge pressure using left atrial volume index alone. Cardiac MRI is able to 
assess structure of the cardiac chambers, as with left atrial volume index, but is also 
able to assess the function.  
The left ventricle left atrium (LVLA) cine view provides a useful overview of left atrial 
area. When measured at each phase of the cardiac cycle, this gives a temporally 
resolved assessment of the function of the left atrium, and can be performed at the 
same time as an assessment of changes in left ventricular volume (Figure 7.3). In a 
similar methodology to atrial function on echocardiography, the relative proportions 
of reservoir, conduit and pump functions to the overall LA function can be calculated, 
in a similar methodology to with echocardiography.  
Figure 7.2: Measurements of reservoir, conduit 
and pump function from the left atrial area 
curve. 
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Using phase contrast flow imaging, with the slice selected just below the level of the 
mitral and tricuspid valves, the flow through the tricuspid and mitral valves can be 
assessed, with a lower Venc, the through plane motion (longitudinal) of the 
myocardium can also be calculated. This data can be analysed to provide the velocities 
of E, A and e’ and a’ velocities, in a similar methodology to echocardiography and likely 
to be useful in the assessment of the diastolic function of the left and right ventricles.  
Figure 7.3: Example left atrial volume curves  
A typical LA area and LV volume change in a patient with PAH and in a patient with PH-HFpEF. 
 
Figure 7.4: Trans-mitral and 
tissue flow. 
The E and A waves can be 
identified from the trans mitral 
flow curve (black), along with 
the e’ and a’ waves from the 
tissue flow curve (grey). These 
represent passive filling and 
active filling of the left ventricle, 
respectively and are useful for 
the assessment of the left 
ventricular diastolic function.  
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A further group of patients who may benefit from selected therapy and have 
significant interest in the context of clinical trials are those patents with combined pre 
and post capillary pulmonary hypertension. Cardiac MRI derived interventricular 
septal angle can be used to non-invasively predict the presence of an elevated 
diastolic pressure gradient in suspected pulmonary hypertension patients with 
elevated pulmonary arterial wedge pressures with reasonable diagnostic accuracy 
(AUC 0.911). To date, trials assessing pulmonary hypertension specific therapies in 
patients with PH-LHD have assessed an unselected cohort of patients. The 
interventricular septal angle may offer the potential to identify patients for targeted 
therapy. 
 CTEPH 
In a cohort of 74 patients referred to this centre with suspected CTEPH, DCE lung 
perfusion MRI has at least equivalent sensitivity when compared to SPECT perfusion 
scintigraphy in the detection of CTEPH. In the patients studied, a combination of 
perfusion MR and CTPA identified all patients with CTEPH and CTED. This reflects and 
updates the findings of a previous study by Smitha Rajaram, which compared DCE 
perfusion MRI with planar scintigraphy (91). Perfusion MRI can be performed in the 
same sitting as high-resolution pulmonary MR angiography and cardiac MRI scan, and 
has the potential for a “one-stop-shop” analysis of pulmonary perfusion and 
assessment of right heart and pulmonary vascular characteristics, as explored in the 
chapter on the diagnosis of pulmonary hypertension.  
In the 1-year cohort of 74 patients studied for a comparison of DCE-MRI and SPECT, 
significant improvements in the diagnostic pathway could be made. DCE-MRI was 
able to correctly identify the presence of CTEPH, with only two indeterminate DCE-
MRI scans, which would require screening with SPECT. In all of the other cases, we 
could replace nuclear medicine SPECT imaging with MRI. CTPA is also useful in this 
regard, however it has been shown to have reduced sensitivity in comparison to 
SPECT perfusion, particularly in non-specialist centres, so is not recommended as a 
screening tool for CTEPH (1,101). The increasing use of perfusion imaging and iodine 
mapping may help in this regard (108,109). Using a cut-off of MR-predicted mPAP ≥38 
mmHg we would be able to avoid right heart catheterisation 39 patients of the 73 
total, as MRI confirms that they have PH. This would represent a significant reduction 
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in the workload of the PH department, with its associated potential money saving. 
From a patient perspective a reduction in the need for multiple tests, one of which is 
invasive, and radiation exposure is valuable.   
7.3 ASSESSMENT OF PROGNOSIS 
The final theme of this thesis is the assessment of prognosis. Previous work has shown 
that cardiac MRI derived metrics are useful in the prognostic assessment of patients 
with pulmonary arterial hypertension (124) and surgery is the best predictor of 
survival in CTEPH (282). In a cohort of patients with pulmonary hypertension due to 
COPD, the use of the cardiac MRI multi-parametric models provides an accurate, non-
invasive estimation of pulmonary artery pressure and the presence of pulmonary 
hypertension. In this group of patients, there is no PH specific therapy, so the 
diagnosis of PH is made for prognostic reasons. At the same sitting, the right 
ventricular mass index and pulmonary artery relative area change can be measured 
and are predictive of mortality, with no incremental benefit from the addition of right 
heart catheter based pressure measurements.  
In patients with PH due to heart failure with preserved ejection fraction, low TLCO, 
male sex and low pulmonary arterial relative area change were the most significant 
measures of outcome. The use of pulmonary function testing and cardiac MRI can 
identify patients who are at risk, with no incremental benefit from right heart 
catheterisation.  
7.4 ANALYSIS OF VESSEL ABNORMALITIES 
Current methods of imaging in pulmonary hypertension concentrate on indirect 
consequences of raised pulmonary vascular resistance: the right ventricle and 
proximal pulmonary artery (cardiac MRI and CTPA) or the “end-organ” capillary level 
perfusion (perfusion SPECT and DCE-MRI). In pre-capillary pulmonary hypertension, 
the main pathophysiological drive is from pulmonary vascular remodelling. It seems 
logical, therefore, that there is an important role being played by the pulmonary 
vasculature causing increased pulmonary vascular resistance, driving the 
abnormalities of the right ventricle and main pulmonary artery, and leading to 
abnormal tissue perfusion. Although, the most important vessels in increased PVR are 
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likely to be too small to be visualised on CT. My future aim is to improve the methods 
of analysis of the pulmonary vascular tree from CTPA and assess its role in the 
development of pulmonary hypertension. Particularly in the assessment of the 
similarities between those patients with pre-capillary remodelling in PH-LHD and 
COPD and patients with PAH. Using third party software (VIDA Diagnostics, 
Coralville,, Iowa), it is possible to produce detailed maps of the pulmonary vascular 
tree, which can be interrogated to assess the underlying abnormalities (Figure 7.5). 
Figure 7.5: A surface rendering of a model of the pulmonary vasculature taken from CTPA.  
The blue represents the proximal pulmonary vasculature and the red represents the distal vasculature, 
comprising arterial and venous structures. A semi-automated separation of the pulmonary arterial system 
from the pulmonary venous system is shown inlayed, as is the frequency distribution data for the cross 
sectional area of each vessel. 
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Work from other centres has been published in the assessment of the pulmonary 
vasculature in patients with COPD and pulmonary hypertension, mainly using 
increasingly large unenhanced CT datasets (303,304). Initially, three slices were 
analysed for each patient at the level of the aortic arch, 1cm below the carina and 1cm 
below the right inferior pulmonary vein. A particle analysis segments any circular 
structures and assumes them to be vessels, then the cross-sectional areas are 
measured (305). Using this methodology, it has been shown that small vessel loss 
(measured as the percentage of vessels <5mm2 cross-sectional area - %CSA<5) 
significantly correlates with CT densitometry measures of emphysema (percentage of 
lung volume with HU <-950 - %LAA-950), r=−0.83, p<0.0001, and weak correlations 
with FEV1 percent predicted and FEV1/FVC (r=0.29, p<0.0001 and r=0.45, p<0.0001 
respectively) in 191 cases in the National Lung Screening Trial (306). Further work in 
79 patients with severe COPD on the National Emphysema Treatment Trial (NETT), 
showed that this loss of small vessels (%CSA<5) significantly correlates with mPAP 
(305) and in 81 cases with stable COPD small vessel loss was associated with an 
increased risk of acute exacerbation of COPD (307), which fits with data showing that 
main PA size is associated with exacerbation risk and therefore morbidity and 
mortality (59).  
More recently, 3D analysis of the pulmonary vessels has been employed, confirming 
that with increasing emphysema on CT there is “pruning of the small blood vessels” 
(vessels with cross-sectional area of <5mm2) (308), which in a small cohort of patients 
was shown to reverse with lung volume reduction surgery (309). The small vessel loss 
is associated with disease severity on CT (308), and also with reduced left ventricular 
filling in smokers without evidence of lung disease (310). More sophisticated methods 
of assessment of parenchymal disease also increase the ability to phenotype lung 
disease (311). 
A study assessing the difference in quantitative pulmonary parenchymal 
abnormalities and vessel loss in patients with COPD-PH showed a significant 
difference between patients in the <35mmHg (non-severe PH) and ≥35mmHg (Severe 
PH). In severe PH, the strongest correlator with increasing mPAP was increasing small 
pulmonary vessel volumes (%CSA<5), whereas in the non-severe PH group the 
strongest correlator with increasing mPAP was bronchial wall thickness. Moreover, 
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in the non-severe PH patients an increase in mPAP was actually associated with a 
reduction in small vessel volumes (312). Hence, probing abnormalities in the small 
vessels in PH-lung disease has the potential to increase our understanding of the 
interaction between phenotypes of lung disease and pulmonary hypertension.  
7.5 ASSESSMENT OF FOLLOW UP AND TREATMENT RESPONSE 
As discussed in the introductory sections of this thesis, the final part of clinical 
assessment in patients with PH is to identify those patients who respond and those 
patients who do not respond to therapy. MRI is sensitive to change and is reproducible 
and therefore represents a strong marker for the assessment of disease progression, 
non-invasively.  
From the cohort of patients scanned in Sheffield there are a large number of patients 
with repeat scans, which would be interesting data to analyse for the best predictors 
of outcome and response to treatment.  
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AWARDS RELATED TO THIS THESIS 
A talk regarding the work in Chapter 4 (“Improving the Non-invasive Identification of 
Pulmonary Hypertension”) was awarded “best oral presentation” at the 2016 Insigneo 
Annual Scientific Meeting.  
Two talks generated from data in Chapters 4 and 5 (“Improving the Non-invasive 
Identification of Pulmonary Hypertension” and “Using Cardiac MRI to Differentiate 
Pre and Post Capillary PH in Left Heart Disease”) were awarded Magna cum Laude 
awards at the 2017 ISMRM in Honolulu, Hawaii.  
Two talks generated from data in Chapters 4 and 5 (“Improving the Non-invasive 
Identification of Pulmonary Hypertension” and “Using Cardiac MRI to Differentiate 
Pre and Post Capillary PH in Left Heart Disease”) were awarded 1st place in the 
Grainger Prize in 2016 and 2017 respectively.  
A poster generated from Chapter 4 (“Improving the Non-invasive Identification of 
Pulmonary Hypertension”) was awarded 2nd place in the Vera Ansell poster 
competition at RCR2017 in Liverpool.  
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